Powrót do strony głownej << Powrót do listy zbiorów wartości

# Zbiór wartości Substancja czynna wg klasyfikacji WHO ATC 2024‑07‑01

ID | 2.16.840.1.113883.3.4424.13.11.321 | Data obowiązywania | obowiązuje od 2024‑07‑01
Status | Draft | Etykieta wersji | 1.3.2
Nazwa | SubstancjaCzynnaATC | Nazwa wyświetlana | Substancja czynna wg klasyfikacji WHO ATC
Opis | Zbiór wartości służy do określenia kodu substancji czynnej wg klasyfikacji WHO ATC
Żródłowy system kodowania | 2.16.840.1.113883.6.73 - WHO Anatomical Therapeutic Chemical classification
Poziom/ Typ | Kod | Nazwa wyświetlana | System kodowania
--- | --- | --- | ---
0‑L | A | PRZEWÓD POKARMOWY I METABOLIZM | WHO Anatomical Therapeutic Chemical classification
0‑L | A01 | PREPARATY STOMATOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | A01A | PREPARATY STOMATOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA | Preparaty zapobiegające próchnicy | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA01 | sodu fluorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA02 | sodu monofluorofosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA03 | olaflur | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA04 | cyny(II) fluorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AA51 | sodu fluorek, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB | Leki przeciwinfekcyjne i antyseptyki do stosowania w jamie ustnej | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB02 | wodoru nadtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB03 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB04 | amfoterycyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB05 | polinoksylina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB06 | domifen | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB07 | oksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB08 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB09 | mikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB10 | natamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB11 | różne | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB12 | heksetydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB13 | tetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB14 | benzoksoniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB15 | tibezoniowy jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB16 | mepartrycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB17 | metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB18 | klotrimazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB19 | sodu peroksoboran | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB21 | chlortetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB22 | doksycyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB23 | minocyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB24 | oktenidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB25 | oksytetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AB53 | chlorheksydyna i cetylopirydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC | Kortykosteroidy do stosowania miejscowego w jamie ustnej | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC01 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC02 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC03 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC04 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AC54 | prednizolon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD | Inne leki do stosowania miejscowego w jamie ustnej | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD01 | epinefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD02 | benzydamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD05 | kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD06 | adrenalon | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD07 | amleksanoks | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD08 | bekaplermin | WHO Anatomical Therapeutic Chemical classification
0‑L | A01AD11 | różne | WHO Anatomical Therapeutic Chemical classification
0‑L | A02 | LEKI STOSOWANE W ZABURZENIACH WYDZIELANIA SOKU ŻOŁĄDKOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A02A | LEKI ZOBOJĘTNIAJĄCE SOK ŻOŁĄDKOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA | Związki magnezu | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA01 | magnezu węglan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA02 | magnezu tlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA03 | magnezu nadtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA04 | magnezu wodorotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA05 | magnezu krzemian | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AA10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB | Związki glinu | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB01 | glinu wodorotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB02 | algeldrat | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB03 | glinu fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB04 | glinu węglan zasadowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB05 | glinu acetooctan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB06 | aloglutamol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB07 | glinu glicynian | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AB10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC | Związki wapnia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC01 | wapnia węglan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC02 | wapnia krzemian | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AC10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD | Połączenia i kompleksy glinu, wpania i magnezu | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD01 | połączenia soli | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD02 | magaldrat | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD03 | almagat | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD04 | hydrotalcyt | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AD05 | almasylat | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF | Leki zobojętniające sok żółądkowy z lekami przeciw wzdęciom | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF01 | magaldrat i leki przeciw wzdęciom | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AF02 | połączenia soli i leki przeciw wzdęciom | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AG | Leki zobojętniające sok żołądkowy z lekami przeciwskurczowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AH | Leki zobojętniające sok żołądkowy z sodu wodorowęglanem | WHO Anatomical Therapeutic Chemical classification
0‑L | A02AX | Leki zobojętniające sok żołądkowy, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02B | LEKI STOSOWANE W CHOROBIE WRZODOWEJ I REFLUKSIE ŻOŁĄDKOWO-PRZEŁYKOWYM | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA | Antagoniści receptora H2 | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA01 | cymetydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA02 | ranitydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA03 | famotydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA04 | nizatydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA05 | niperotydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA06 | roksatydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA07 | ranitydyna z bizmutu cytrynianem | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA08 | lafutydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA51 | cymetydyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BA53 | famotydyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB | Prostaglandyny | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB01 | mizoprostol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BB02 | enprostil | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC | Inhibitory pompy protonowej | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC01 | omeprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC02 | pantoprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC03 | lanzoprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC04 | rabeprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC05 | ezomeprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC06 | dekslanzoprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC07 | deksrabeprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC08 | wonoprazan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC09 | tegoprazan | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC51 | omeprazol, kombinacje | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC53 | lanzoprazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BC54 | rabeprazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD | Połączenia stosowane w eradykacji Helicobacter pylori | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD01 | omeprazol, amoksycylina i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD02 | lanzoprazol, tetracyklina i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD03 | lanzoprazol, amoksycylina i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD04 | pantoprazol, amoksycylina i klarytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD05 | omeprazol, amoksycylina i klarytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD06 | ezomeprazol, amoksycylina i klarytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD07 | lanzoprazol, amoksycylina i klarytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD08 | bizmutu(III) cytrynian zasadowy, tetracyklina i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD09 | lanzoprazol, klarytromycyna i tinidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD10 | lanzoprazol, amoksycylina i lewofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD11 | pantoprazol, amoksycylina, klarytromycyna i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD12 | rabeprazol, amoksycylina i klarytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD13 | rabeprazol, amoksycylina i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD14 | wonoprazan, amoksycylina i klarytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD15 | wonoprazan, amoksycylina i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD16 | omeprazol, amoksycylina i rifabutyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BD17 | wonoprazan i amoksycylina | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX | Inne leki stosowane w chorobie wrzodowej i refluksie żołądkowo-przełykowym | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX01 | karbenoksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX02 | sukralfat | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX03 | pirenzepina | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX04 | metiosulfoniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX05 | bizmutu(III) cytrynian zasadowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX06 | proglumid | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX07 | gefarnat | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX08 | sulglikotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX09 | acetoksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX10 | zolimidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX11 | troksypid | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX12 | bizmutu(III) azotan zasadowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX13 | kwas algi | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX14 | rebamipid | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX15 | teprenon | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX16 | irsogladyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX51 | karbenoksolon, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX71 | karbenoksolon, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | A02BX77 | gefarnat, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | A02X | INNE LEKI STOSOWANE W ZABURZENIACH WYDZIELANIA SOKU ŻOŁĄDKOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A03 | LEKI STOSOWANE W CZYNNOŚCIOWYCH ZABURZENIACH PRZEWODU POKARMOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A03A | LEKI STOSOWANE W CZYNNOŚCIOWYCH ZABURZENIACH PRZEWODU POKARMOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA | Syntetyczne leki cholinolityczne, estry trzeciorzędowych amin | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA01 | oksyfencyklimina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA03 | kamilofin | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA04 | mebeweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA05 | trimebutyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA06 | rocyweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA07 | dicykloweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA08 | diheksyweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA09 | difemeryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AA30 | piperidolat | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB | Syntetyczne leki cholinolityczne, czwartorzędowe związki amoniowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB01 | benzylon | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB02 | glikopironiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB03 | oksyfenonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB04 | pentienat | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB05 | propantelina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB06 | otyloniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB07 | metantelina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB08 | tridiheksetyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB09 | izopropamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB10 | heksocyklium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB11 | poldyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB12 | mepenzolat | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB13 | bewonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB14 | pipenzolat | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB15 | difemanil | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB16 | (2-benzohydryloksyetylo)dietylometyloamoniowy jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB17 | tiemoniowy jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB18 | prifiniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB19 | timepidiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB21 | fenpiweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AB53 | oksyfenonium, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC | Syntetyczne leki przeciwskurczowe, amidy z trzeciorzędowymi aminami | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC02 | dimetyloaminopropionylofenotiazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC04 | nikofetamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AC05 | tyropramid | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD | Papaweryna i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD01 | papaweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD02 | drotaweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AD30 | moksaweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE | Antagoniści receptorów serotonich | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE01 | alosetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AE03 | cylansetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX | Inne leki stosowane w czynnościowych zaburzeniach przewodu pokarmowego | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX01 | fenpipran | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX02 | diizopromina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX03 | chlorbenzoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX04 | pinaweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX05 | fenoweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX06 | idanpramina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX07 | proksazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX08 | alweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX09 | trepibuton | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX10 | izometepten | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX11 | karoweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX12 | floroglucynol | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX13 | silikony | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX14 | waletamat | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX15 | olejek eteryczny miętowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX30 | trimetylodifenylopropylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03AX58 | alweryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A03B | ALKALOIDY POKRZYKU WILCZA JAGODA I POCHODNE, BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA | Alkaloidy pokrzyku wilcza jagoda, aminy trzeciorzędowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA01 | atropina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA03 | hioscyjamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BA04 | wszystkie alkaloidy pokrzyku wilcza jagoda | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB | Alkaloidy pokrzyku wilcza jagoda półsyntetyczne, czwartorzędowe związki amoniowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB01 | hioscyny butylobromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB02 | metyloatropina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB03 | metyloskopolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB04 | fentonium | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB05 | cymetropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03BB06 | homatropiny metylobromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A03C | LEKI PRZECIWSKURCZOWE W POŁĄCZENIU Z PSYCHOLEPTYKAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA | Syntetyczne leki cholinolityczne w połączeniu z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA01 | izopropamid i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA02 | klidynium i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA03 | oksyfencyklimina i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA04 | otyloniowy bromek i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA05 | glikopironiowy bromek i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA06 | bewonium i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA07 | ambutonium i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA08 | difemanil i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA09 | pipenzolat i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA30 | emepronium i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CA34 | propantelina i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB | Alkaloidy pokrzyku wilcza jagoda i pochodne w połączeniu z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB01 | metyloskopolamina i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB02 | wszystkie alkaloidy pokrzyku wilcza jagoda i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB03 | atropina i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB04 | homatropiny metylobromek i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CB31 | hioscyjamina i psycholeptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A03CC | Inne leki przeciwskurczowe w połączeniu z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | A03D | LEKI PRZECIWSKURCZOWE W POŁĄCZENIU Z LEKAMI PRZECIWBÓLOWYMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA | Syntetyczne leki cholinolityczne w połączeniu z lekami przeciwbólowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA01 | tropenzilon i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA02 | pitofenon i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA03 | bewonium i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA04 | cyklonium i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA05 | kamylofina i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA06 | trospium i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DA07 | tiemoniowy jodek i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DB | Alkaloidy pokrzyku wilcza jagoda i pochodne w połączeniu z lekami przeciwbólowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DB04 | skopolaminy butylobromek i leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A03DC | Inne leki przeciwskurczowe w połączeniu z lekami przeciwbólowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A03E | LEKI PRZECIWSKURCZOWE I LEKI CHOLINOLITYCZNE W POŁĄCZENIU Z INNYMI LEKAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A03EA | Leki przeciwskurczowe, psycholeptyki i leki przeciwbólowe w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | A03ED | Leki przeciwskurczowe w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | A03F | LEKI POBUDZAJĄCE PERYSTALTYKĘ | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA | Leki pobudzające perystaltykę | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA01 | metoklopramid | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA02 | cyzapryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA03 | domperydon | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA04 | bromopryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA05 | alizapryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA06 | klebopryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA07 | itopryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA08 | cynitapryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA09 | mozapryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A03FA10 | akotiamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A04 | LEKI PRZECIWWYMIOTNE I PRZECIW NUDNOŚCIOM | WHO Anatomical Therapeutic Chemical classification
0‑L | A04A | LEKI PRZECIWWYMIOTNE I PRZECIW NUDNOŚCIOM | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA | Antagoniści receptorów serotonich 5-HT3 | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA01 | ondansetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA02 | granisetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA03 | tropisetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA04 | dolasetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA05 | palonosetron | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AA55 | palonosetron, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD | Inne leki przeciwwymiotne | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD01 | skopolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD02 | ceru(IV) szczawian | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD04 | chlorobutanol | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD05 | metopimazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD10 | dronabinol | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD11 | nabilon | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD12 | aprepitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD13 | kazopitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD14 | rolapitant | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD51 | skopolamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A04AD54 | chlorobutanol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A05 | LEKI STOSOWANE W CHOROBACH DRÓG ŻÓŁCIOWYCH I WĄTROBY | WHO Anatomical Therapeutic Chemical classification
0‑L | A05A | LEKI STOSOWANE W CHOROBACH DRÓG ŻÓŁCIOWYCH | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA | Kwasy żółciowe i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA01 | kwas chenodeoksycholowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA02 | kwas ursodeoksycholowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA03 | kwas cholowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA04 | kwas obetycholowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AA05 | ursodoksykoltauryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AB | Leki stosowane w chorobach dróg żółciowych | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AB01 | nikotynylu metyloamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX | Inne leki stosowane w chorobach dróg żółciowych | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX01 | piprozolina | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX02 | hymekromon | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX03 | cyklobutyrol | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX04 | chlorek maraliksybatu | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX05 | odewiksybat | WHO Anatomical Therapeutic Chemical classification
0‑L | A05AX06 | elafibranor | WHO Anatomical Therapeutic Chemical classification
0‑L | A05B | LEKI STOSOWANE W CHOROBACH WĄTROBY, LEKI LIPOTROPOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA | Leki stosowane w chorobach wątroby | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA01 | argininy glutaminian | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA03 | sylimaryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA04 | cytiolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA05 | epomediol | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA06 | ornityny oksyglukuronian | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA07 | tidiacyk z argininą | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA08 | kwas glicyryzy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA09 | metadoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A05BA10 | fosfolipidy | WHO Anatomical Therapeutic Chemical classification
0‑L | A05C | LEKI STOSOWANE W CHOROBACH DRÓG ŻÓŁCIOWYCH I LEKI LIPOTROPOWE W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | A06 | LEKI PRZECZYSZCZAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | A06A | LEKI PRZECZYSZCZAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA | Leki zmiękczające masy kałowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA01 | parafina ciekła | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA02 | sodu dokuzynian | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AA51 | parafina ciekła, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB | Kontaktowe leki przeczyszczające | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB01 | oksyfenizatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB02 | bisakodyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB03 | dantron | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB04 | fenoloftaleina | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB05 | olej rycy | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB06 | sennozydy | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB07 | kora szakłaku amerykańskiego | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB08 | sodu pikosiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB09 | bisoksatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB20 | kontaktowe leki przeczyszczające w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB30 | kontaktowe leki przeczyszczające w połączeniu z alkaloidami pokrzyku wilcza jagoda | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB52 | bisakodyl, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB53 | dantron, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB56 | sennozydy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB57 | kora szakłaku amerykańskiego, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AB58 | pikosiarczan sodu, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC | Leki przeczyszczające zwiększające objętość mas kałowych | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC01 | nasienie płesznika | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC02 | etuloza | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC03 | ziele zatwaru | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC05 | nasienie lnu | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC06 | metyloceluloza | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC07 | pszenica (włókna) | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC08 | polikarobofil wapniowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC51 | nasienie płesznika, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC53 | ziele zatwaru, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AC55 | nasienie lnu, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD | Osmotyczne leki przeczyszczające | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD01 | magnezu węglan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD02 | magnezu tlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD03 | magnezu nadtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD04 | magnezu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD10 | sole mineralne w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD11 | laktuloza | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD12 | laktytol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD13 | sodu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD14 | pentaerytrytyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD15 | makrogol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD16 | mannitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD17 | sodu fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD18 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD19 | magnezu cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD21 | sodu winian | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD61 | laktuloza, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AD65 | makrogol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG | Wlewki doodbytnicze | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG01 | sodu fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG02 | bisakodyl | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG03 | dantron, włącznie z połączeniami | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG04 | glicerol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG06 | oleje | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG07 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG10 | sodu dokuzynian, włącznie z połączeniami | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG11 | sodu laurylosiarczan, włącznie z połączeniami | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AG20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH | Antagoniści obwodowych receptorów opioidowych | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH01 | metylonaltreksonu bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH02 | alwimopan | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH03 | naloksegol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH04 | nalokson | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AH05 | naldemedyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX | Inne leki przeczyszczające | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX01 | glicerol | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX02 | leki wytwarzające dwutlenek węgla | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX03 | lubiproston | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX04 | linaklotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX05 | prukalopryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX06 | tegaserod | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX07 | plekanatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX08 | tenapanor | WHO Anatomical Therapeutic Chemical classification
0‑L | A06AX09 | elobiksybat | WHO Anatomical Therapeutic Chemical classification
0‑L | A07 | LEKI PRZECIWBIEGUNKOWE, PRZECIWZAPALNE/PRZECIWINFEKCYJNE, STOSOWANE W CHOROBACH PRZEWODU POKARMOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A07A | LEKI PRZECIWINFEKCYJNE STOSOWANE W CHOROBACH PRZEWODU POKARMOWGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA01 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA02 | nystatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA03 | natamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA04 | streptomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA05 | polimiksyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA06 | paromomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA07 | amfoterycyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA08 | kanamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA09 | wankomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA10 | kolistyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA11 | ryfaksymina | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA12 | fidaksomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA13 | ryfamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA51 | neomycyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AA54 | streptomycyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB | Sulfonamidy | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB02 | ftalilosulfatiazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB03 | sulfaguanidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AB04 | sukcynylosulfatiazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AC | Pochodne imidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AC01 | mikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX | Inne leki przeciwinfekcyjne stosowane w chorobach przewodu pokarmowgo | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX01 | broksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX02 | acetarsol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX03 | nifuroksazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A07AX04 | nifurzyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A07B | ADSORBENTY | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA | Preparaty węgla | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA01 | węgiel aktywny | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BA51 | węgiel aktywny, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BB | Związki bizmutu | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC | Inne adsorbenty | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC01 | pektyny | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC02 | kaolin | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC03 | krospowidon | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC04 | atapulgit | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC05 | diosmektyt | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07BC54 | atapulgit, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07C | ELEKTROLITY Z WĘGLOWODANAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A07CA | Doustne sole nawadniające | WHO Anatomical Therapeutic Chemical classification
0‑L | A07D | LEKI HAMUJĄCE PERYSTALTYKĘ JELIT | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA | Leki hamujące perystaltykę jelit | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA01 | difenoksylat | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA02 | opium | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA03 | loperamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA04 | difenoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA05 | loperamidu tlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA06 | eluksadolina | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA52 | morfina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07DA53 | loperamid, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07E | LEKI PRZECIWZAPALNE STOSOWANE W CHOROBACH PRZEWODU POKARMOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA | Kortykosteroidy o działaniu miejscowym | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA01 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA02 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA03 | prednizon | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA04 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA05 | tiksokortol | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA06 | budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EA07 | beklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EB | Leki przeciwalergiczne, z wyłączeniem kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EB01 | kwas kromoglika | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC | Kwas aminosalicylowy i leki podobne | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC01 | sulfasalazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC02 | mesalazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC03 | olsalazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A07EC04 | balsalazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A07F | LEKI PRZYWRACAJĄCE PRAWIDŁOWĄ FLORĘ JELITOWĄ, HAMUJĄCE BIEGUNKĘ | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA | Leki przywracające prawidłową florę jelitową, hamujące biegunkę | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA01 | bakterie wytwarzające kwas mlekowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA02 | saccharomyces boulardii | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA03 | Escherichia coli | WHO Anatomical Therapeutic Chemical classification
0‑L | A07FA51 | bakterie wytwarzające kwas mlekowy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07X | INNE LEKI PRZECIWBIEGUNKOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA | Inne leki przeciwbiegunkowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA01 | taniny białczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA02 | ceratonia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA03 | związki wapnia | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA04 | racekadotryl | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA06 | krofelemer | WHO Anatomical Therapeutic Chemical classification
0‑L | A07XA51 | białczan taniny, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A08 | LEKI PRZECIW OTYŁOŚCI Z WYŁĄCZENIEM PRODUKTÓW DIETETYCZNYCH | WHO Anatomical Therapeutic Chemical classification
0‑L | A08A | LEKI PRZECIW OTYŁOŚCI Z WYŁĄCZENIEM PRODUKTÓW DIETETYCZNYCH | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA | Leki przeciw otyłości działające ośrodkowo | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA01 | fentermina | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA02 | fenfluramina | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA03 | amfepramon | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA04 | deksfenfluramina | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA05 | mazindol | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA06 | etylamfetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA07 | katyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA08 | klobenzoreks | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA09 | mefenoreks | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA10 | sybutramina | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA11 | lorkaseryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA12 | setmelanotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA51 | fentermina i topiramat | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA56 | efedryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AA62 | bupropion i naltrekson | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AB | Leki przeciw otyłości działające obwodowo | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AB01 | orlistat | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AX | Inne leki przeciw otyłości | WHO Anatomical Therapeutic Chemical classification
0‑L | A08AX01 | rymonabant | WHO Anatomical Therapeutic Chemical classification
0‑L | A09 | LEKI POPRAWIAJĄCE TRAWIENIE, WŁĄCZNIE Z ENZYMAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A09A | LEKI POPRAWIAJĄCE TRAWIENIE, WŁĄCZNIE Z ENZYMAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA | Enzymy | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA01 | diastaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA02 | połączenia enzymów (lipaza, proteaza itp.) | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA03 | pepsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AA04 | tylaktaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB | Leki zawierające kwasy | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB01 | kwasu glutaminowego chlorowodorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB02 | betainy chlorowodorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB03 | kwas solny | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AB04 | kwas cytry | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AC | Enzymy i leki zawierające kwasy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AC01 | pepsyna i leki zawierające kwasy | WHO Anatomical Therapeutic Chemical classification
0‑L | A09AC02 | mieszanina enzymów i leki zawierające kwasy | WHO Anatomical Therapeutic Chemical classification
0‑L | A10 | LEKI STOSOWANE W CUKRZYCY | WHO Anatomical Therapeutic Chemical classification
0‑L | A10A | INSULINY I ANALOGI | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB | Insuliny i analogi krótko działające, do wstrzykiwań | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB01 | insulina ludzka | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB02 | insulina wołowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB03 | insulina wieprzowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB04 | insulina lispro | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB05 | insulina aspart | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB06 | insulina glulizynowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AB30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AC | Insuliny i analogi o średnim czasie działania, do wstrzykiwań | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AC01 | insulina ludzka | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AC02 | insulin wołowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AC03 | insulina wieprzowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AC04 | insulina lispro | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AC30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD | Insuliny i analogi o średnim lub długim czasie działania w połączeniu z krótko działającymi, do wstrzykiwań | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD01 | insulina ludzka | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD02 | insulina wołowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD03 | insulina wieprzowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD04 | insulina lispro | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD05 | insulina aspart | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD06 | insulina degludec i insulina aspart | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AD30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE | Insuliny i analogi długo działąjące, do wstrzykiwań | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE01 | insulina ludzka | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE02 | insulina wołowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE03 | insulina wieprzowa | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE04 | insulina glargina | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE05 | insulina detemir | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE06 | insulina degludek | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE07 | ikodek insuliny | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE54 | insulina glargina i liksysenatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AE56 | insulina degludek i liraglutyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AF | Insuliny i analogi, do inhalacji | WHO Anatomical Therapeutic Chemical classification
0‑L | A10AF01 | insulina ludzka | WHO Anatomical Therapeutic Chemical classification
0‑L | A10B | LEKI HIPOGLIKEMIZUJĄCE, Z WYŁĄCZENIEM INSULIN | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BA | Biguanidy | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BA01 | fenformina | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BA02 | metformina | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BA03 | buformina | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB | Pochodne sulfonylomocznika | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB01 | glibenklamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB02 | chloropropamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB03 | tolbutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB04 | glibornurid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB05 | tolazamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB06 | karbutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB07 | glipizyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB08 | glikwidon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB09 | gliklazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB10 | metaheksamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB11 | glizoksepid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB12 | glimepiryd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BB31 | acetoheksamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BC | Sulfonamidy (heterocykliczne) | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BC01 | glimidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD | Połączenia doustnych leków hipoglikemizujących | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD01 | fenformina i pochodne sulfonylomocznika | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD02 | metformina i pochodne sulfonylomocznika | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD03 | metformina i rozyglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD04 | glimepiryd i rozyglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD05 | metformina i pioglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD06 | glimepiryd i pioglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD07 | metformina i sytagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD08 | metformina i wildagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD09 | pioglitazon i alogliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD10 | metformina i saksagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD11 | metformina i linagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD12 | pioglitazon i sytagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD13 | metformina i alogliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD14 | metformina i repaglinid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD15 | metformina i dapagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD16 | metformina i kanagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD17 | metformina i akarboza | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD18 | metformina i gemigliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD19 | linagliptyna i empagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD20 | metformina i empagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD21 | saksagliptyna i dapagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD22 | metformina i ewogliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD23 | metformina i ertugliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD24 | sytagliptyna i ertugliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD25 | metformina, saksagliptyna i dapagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD26 | metformina i lobeglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD27 | metformina, linagliptyna i empagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD28 | metformina i teneliligliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BD29 | sitagliptyna i dapagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BF | Inhibitory alfa-glukozydazy | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BF01 | akarboza | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BF02 | miglitol | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BF03 | wogliboza | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BG | Pochodne tiazolidynodionu | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BG01 | troglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BG02 | rozyglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BG03 | pioglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BG04 | lobeglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH | Inhibitory dipeptydylopeptydazy 4 (DPP-4) | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH01 | sytagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH02 | wildagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH03 | saksagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH04 | alogliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH05 | linagliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH06 | gemigliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH07 | ewogliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH08 | teneligliptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH51 | sytagliptyna i symwastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BH52 | gemigliptyna i rozuwastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ | Analogi glukagonopodobnego peptydu 1 (GLP-1) | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ01 | eksenatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ02 | liraglutyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ03 | liksysenatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ04 | albiglutyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ05 | dulaglutyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ06 | semaglutyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BJ07 | beinaglutyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK | Inhibitory kotransportera glukozowo-sodowego 2 (SGLT2) | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK01 | dapagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK02 | kanagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK03 | empagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK04 | ertugliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK05 | ipragliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK06 | sotagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK07 | luzeogliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BK08 | beksagliflozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX | Inne doustne leki hipoglikemizujące, z wyłączeniem insulin | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX01 | guma guar | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX02 | repaglinid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX03 | nateglinid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX05 | pramlintyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX06 | benfluoreks | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX08 | mitiglinid | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX15 | imeglimina | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX16 | tyrzepatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX17 | karfloglitazar | WHO Anatomical Therapeutic Chemical classification
0‑L | A10BX18 | dorzagliatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A10X | INNE LEKI STOSOWANE W CUKRZYCY | WHO Anatomical Therapeutic Chemical classification
0‑L | A10XA | Inhibitory reduktazy aldozy | WHO Anatomical Therapeutic Chemical classification
0‑L | A10XA01 | tolrestat | WHO Anatomical Therapeutic Chemical classification
0‑L | A10XX | Inne leki stosowane w cukrzycy | WHO Anatomical Therapeutic Chemical classification
0‑L | A10XX01 | teplizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | A11 | Witaminy | WHO Anatomical Therapeutic Chemical classification
0‑L | A11A | PREPARATY WIELOWITAMINOWE, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | A11AA | Preparaty wielowitaminowe ze związkami mineralnymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A11AA01 | preparaty wielowitaminowe i żelazo | WHO Anatomical Therapeutic Chemical classification
0‑L | A11AA02 | preparaty wielowitaminowe i wapń | WHO Anatomical Therapeutic Chemical classification
0‑L | A11AA03 | preparaty wielowitaminowe i inne związki mineralne, włącznie z połączeniami | WHO Anatomical Therapeutic Chemical classification
0‑L | A11AA04 | preparaty wielowitaminowe i pierwiastki śladowe | WHO Anatomical Therapeutic Chemical classification
0‑L | A11AB | preparaty wielowitaminowe, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A11B | PREPARATY WIELOWITAMINOWE, BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | A11BA | Preparaty wielowitaminowe, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | A11C | WITAMINA A I D, WŁĄCZNIE Z POŁĄCZENIAMI OBYDWU WITAMIN | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CA | Witamina A, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CA01 | retynol (witamina A) | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CA02 | betakaroten | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CB | Witamina A i D w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC | Witamina D i analogi | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC01 | ergokalcyferol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC02 | dihydrotachysterol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC03 | alfakalcydol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC04 | kalcytriol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC05 | cholekalcyferol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC06 | kalcyfediol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A11CC55 | cholekalcyferol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A11D | WITAMINA B1, BEZ DODATKÓW I W POŁĄCZENIU Z WITAMINĄ B6 I B12 | WHO Anatomical Therapeutic Chemical classification
0‑L | A11DA | Witamina B1, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | A11DA01 | tiamina (witamina B1) | WHO Anatomical Therapeutic Chemical classification
0‑L | A11DA02 | sulbutiamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A11DA03 | benfotiamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A11DB | Witamian B1 w połączeniu z witaminą B6 i/lub witaminą B12 | WHO Anatomical Therapeutic Chemical classification
0‑L | A11E | KOMPLEKS WITAMIN GRUPY B, WŁĄCZENIE Z POŁĄCZENIAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A11EA | Kompleks witamin grupy B, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | A11EB | Kompleks witamin grupy B z witaminą C | WHO Anatomical Therapeutic Chemical classification
0‑L | A11EC | Kompleks witamin grupy B ze związkami mineralnymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A11ED | Kompleks witamin grupy B ze steroidami anabolicznymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A11EX | Kompleks witamin grupy B, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A11G | KWAS ASKORBOWY (WITAMINA C), WŁĄCZNIE Z POŁĄCZENIAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | A11GA | Kwas askorbowy (witamina C), bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | A11GA01 | kwas askorbowy (witamina C) | WHO Anatomical Therapeutic Chemical classification
0‑L | A11GB | kwas askorbowy (witamina C), połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A11GB01 | kwas askorbowy (witamina C) i wapń | WHO Anatomical Therapeutic Chemical classification
0‑L | A11H | PREPARATY INNYCH WITAMIN BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA | Preparaty innych witamin bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA01 | nikotynamid | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA02 | pirydoksyna (witamina B6) | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA03 | tokoferol (witamina E) | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA04 | ryboflawina (witamina B2) | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA05 | biotyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA06 | pirydoksalu fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA07 | inozytol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA08 | tokofersolan | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA30 | dekspantenol | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA31 | wapnia pantotenian | WHO Anatomical Therapeutic Chemical classification
0‑L | A11HA32 | pantetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A11J | PREPARATY INNYCH WITAMIN, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | A11JA | Połączenia witamin | WHO Anatomical Therapeutic Chemical classification
0‑L | A11JB | Witaminy ze związkami mineralnymi | WHO Anatomical Therapeutic Chemical classification
0‑L | A11JC | Witaminy, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A12 | ZWIĄZKI MINERALNE | WHO Anatomical Therapeutic Chemical classification
0‑L | A12A | WAPŃ | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA | Wapń | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA01 | wapnia fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA02 | wapnia glubionian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA03 | wapnia glukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA04 | wapnia węglan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA05 | wapnia mleczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA06 | wapnia laktoglukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA07 | wapnia chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA08 | wapnia glicerofosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA09 | kompleks lizyny z wapnia cytrynianem | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA10 | wapnia glukoheptonian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA11 | wapnia pangamanian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA13 | wapnia cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA20 | wapń (różne sole w połączeniu) | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AA30 | wapnia lewulinian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12AX | Wapń, połączenia z witaminą D i/lub innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | A12B | POTAS | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA | Potas | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA01 | potasu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA02 | potasu cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA03 | potasu wodorowinian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA04 | potasu wodorowęglan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA05 | potasu glukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA30 | potas (różne sole w połączeniu) | WHO Anatomical Therapeutic Chemical classification
0‑L | A12BA51 | potasu chlorek, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A12C | INNE ZWIĄZKI MINERALNE | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CA | Sód | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CA01 | sodu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CA02 | sodu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CB | Cynk | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CB01 | cynku siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CB02 | cynku glukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CB03 | kompleks białkowy cynku | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC | Magnez | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC01 | magnezu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC02 | magnezu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC03 | magnezu glukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC04 | magnezu cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC05 | magnezu asparaginian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC06 | magnezu mleczan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC07 | magnezu lewulinian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC08 | magnezu pidolan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC09 | magnezu orotan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC10 | magnezu tlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CC30 | magnez (różne sole w połączeniu) | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CD | Fluor | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CD01 | sodu fluorek | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CD02 | sodu monofluorofosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CD51 | fluor, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CE | Selen | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CE01 | sodu selenian | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CE02 | sodu selenin | WHO Anatomical Therapeutic Chemical classification
0‑L | A12CX | Preparaty innych związków mineralnych | WHO Anatomical Therapeutic Chemical classification
0‑L | A13 | LEKI WZMACNIAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | A13A | LEKI WZMACNIAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | A14 | LEKI ANABOLICZNE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | A14A | STEROIDY ANABOLICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA | Pochodne androstanu | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA01 | androstanolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA02 | stanozolol | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA03 | metandienon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA04 | metenolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA05 | oksymetolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA06 | kwinbolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA07 | prasteron | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA08 | oksandrolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AA09 | noretandrolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AB | Pochodne estrenu | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AB01 | nandrolon | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AB02 | etyloestrenol | WHO Anatomical Therapeutic Chemical classification
0‑L | A14AB03 | oksabolonu cypionian | WHO Anatomical Therapeutic Chemical classification
0‑L | A14B | INNE LEKI ANABOLICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | A15 | LEKI POPRAWIAJĄCE APETYT | WHO Anatomical Therapeutic Chemical classification
0‑L | A16 | INNE LEKI DZIAŁAJĄCE NA PRZEWÓD POKARMOWY I METABOLIZM | WHO Anatomical Therapeutic Chemical classification
0‑L | A16A | INNE LEKI DZIAŁAJĄCE NA PRZEWÓD POKARMOWY I METABOLIZM | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA | Aminokwasy i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA01 | lewokarnityna | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA02 | ademetionina | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA03 | glutamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA04 | merkaptamina | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA05 | kwas karglumi | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA06 | betaina | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AA07 | metreleptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB | Enzymy | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB01 | algluceraza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB02 | imigluceraza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB03 | agalzydaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB04 | agalzydaza beta | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB05 | laronidaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB06 | sakrozydaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB07 | alglukozydaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB08 | galsulfaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB09 | idursulfaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB10 | welagluceraza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB11 | taligluceraza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB12 | elosulfaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB13 | asfotaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB14 | sebelipaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB15 | welmanaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB16 | idursulfaza beta | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB17 | cerliponaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB18 | westronidaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB19 | pegwaliaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB20 | pegunigalzydaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB21 | atidarsagen autotemcel | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB22 | awalglukozydaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB23 | cypaglukozydaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB24 | pegzilarginaza | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB25 | olipudaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB26 | eladokagen eksuparwowek | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AB27 | pabinafusp alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX | Różne leki działające na przewód pokarmowy i metabolizm | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX01 | kwas tiokty | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX02 | anetolotrition | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX03 | sodu fenylomaślan | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX04 | nityzynon | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX05 | cynku octan | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX06 | miglustat | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX07 | sapropteryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX08 | teduglutyd | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX09 | glicerolu fenylomaślan | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX10 | eliglustat | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX11 | sodu benzoesan | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX12 | trientyna | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX13 | urydyny trioctan | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX14 | migalastat | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX15 | telotristat | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX16 | giwosyran | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX17 | triheptanoina | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX18 | lumasiran | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX19 | fosdenopteryna | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX20 | lonafarnib | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX21 | eliwaldogen autotemcel | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX22 | kwas tiomolibdenowy | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX23 | leryglitazon | WHO Anatomical Therapeutic Chemical classification
0‑L | A16AX30 | benzoesan sodu i fenylooctan sodu | WHO Anatomical Therapeutic Chemical classification
0‑L | B | KREW I UKŁAD KRWIOTWÓRCZY | WHO Anatomical Therapeutic Chemical classification
0‑L | B01 | LEKI PRZECIWZAKRZEPOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | B01A | LEKI PRZECIWZAKRZEPOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA | Antagoniści witaminy K | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA01 | dikumarol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA02 | fenindion | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA03 | warfaryna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA04 | fenprokumon | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA07 | acenokumarol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA08 | etylu biskumoctan | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA09 | kloryndion | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA10 | difenadion | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA11 | tioklomarol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AA12 | fluindion | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB | Grupa heparyn | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB01 | heparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB02 | antytrombina III | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB04 | dalteparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB05 | enoksaparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB06 | nadroparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB07 | parnaparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB08 | rewiparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB09 | danaparoid | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB10 | tynazaparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB11 | sulodeksyd | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB12 | bemiparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AB51 | heparyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC | Leki hamujące agregację płytek z wyłączeniem heparyny | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC01 | ditazol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC02 | klorykromen | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC03 | pikotamid | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC04 | klopidogrel | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC05 | tyklopidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC06 | kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC07 | dipirydamol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC08 | karbazalat wapniowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC09 | epoprostenol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC10 | indobufen | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC11 | iloprost | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC13 | abcyksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC15 | aloksypryn | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC16 | eptyfibatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC17 | tyrofiban | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC18 | triflusal | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC19 | beraprost | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC21 | treprostynil | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC22 | prasugrel | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC23 | cylostazol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC24 | tykagrelol | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC25 | kangrelor | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC26 | worapaksar | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC27 | seleksypag | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC28 | limaprost | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AC56 | kwas acetylosalicylowy, połączenia z inhibitorami pompy protonowej | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD | Enzymy | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD01 | streptokinaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD02 | alteplaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD03 | anistreplaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD04 | urokinaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD05 | fibrynolizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD06 | brinaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD07 | reteplaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD08 | saruplaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD09 | ankrod | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD10 | drotrekogina alfa (aktywowana) | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD11 | tenekteplaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD12 | białko C | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AD13 | apadamtaza alfa i cinaksadamtaza alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE | Bezpośrednie inhibitory trombiny | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE01 | dezyrudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE02 | lepirudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE03 | argatroban | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE04 | melagatran | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE05 | ksymelagatran | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE06 | biwalirudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AE07 | dabigatran eteksylat | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AF | Bezpośrednie inhibitory czynnika Xa | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AF01 | rywaroksaban | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AF02 | apiksaban | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AF03 | edoksaban | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AF04 | betriksaban | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AF51 | rywaroksaban i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AX | Inne leki przeciwzakrzepowe | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AX01 | defibrotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AX04 | dermatanu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AX05 | fondaparynuks | WHO Anatomical Therapeutic Chemical classification
0‑L | B01AX07 | kaplacyzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | B02 | LEKI PRZECIWKRWOTOCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | B02A | LEKI PRZECIWFIBRYNOLITYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AA | Aminokwasy | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AA01 | kwas aminokapro | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AA02 | kwas traneksamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AA03 | kwas aminometylobenzoesowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AB | Inhibitory proteinazy | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AB01 | aprotynina | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AB02 | alfa1-antytrypsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AB04 | kamostat | WHO Anatomical Therapeutic Chemical classification
0‑L | B02AB05 | ulinastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B02B | WITAMINA K I INNE LEKI HEMOSTATYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BA | Witamina K | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BA01 | fitomenadion | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BA02 | menadion | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BB | Fibrynogen | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BB01 | fibrynogen, ludzki | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC | Leki hemostatyczne do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC01 | gąbka żelatynowa absorbująca | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC02 | utleniona celuloza | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC03 | ester hydroksymetylowy kwasu tetragalakturonowego | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC05 | adrenalon | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC06 | trombina | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC07 | kolagen | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC08 | wapnia alginian | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC09 | epinefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BC30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD | Czynniki krzepnięcia krwi | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD01 | czynnik krzepnięcia IX, II, VII i X w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD02 | czynnik krzepnięcia VIII | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD03 | zespół czynników krzepnięcia przeciw inhibitorowi czynnika VIII | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD04 | czynnik krzepnięcia IX | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD05 | czynnik krzepnięcia VII | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD06 | czynnik von Willebranda i czynnik krzepnięcia VIII w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD07 | czynnik krzepnięcia XIII | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD08 | czynnik krzepnięcia VIIa | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD10 | czynnik von Willebranda | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD11 | katrydekakog | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD13 | czynnik krzepnięcia X | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD14 | susoktokog alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD15 | waloktokogen roksaparwowek | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD16 | etranakogen dezaparwowek | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BD30 | trombina | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX | Inne leki hemostatyczne działające ogólnie | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX01 | etamsylat | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX02 | karbazochrom | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX03 | batroksobin | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX04 | romiplostym | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX05 | eltrombopag | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX06 | emicyzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX07 | luzutrombopag | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX08 | awatrombopag | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX09 | fostamatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | B02BX10 | koncyzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | B03 | LEKI STOSOWANE W NIEDOKRWISTOŚCI | WHO Anatomical Therapeutic Chemical classification
0‑L | B03A | PREPARATY ŻELAZA | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA | Związki żelaza dwuwartościowego, preparaty doustne | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA01 | żelaza(II) glicynosiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA02 | żelaza(II) fumaran | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA03 | żelaza(II) glukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA04 | żelaza(II) węglan | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA05 | żelaza(II) chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA06 | żelaza(II) bursztynian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA07 | żelaza(II) siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA08 | żelaza(II) winian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA09 | żelaza(II) asparaginian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA10 | żelaza(II) askorbinian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA11 | żelaza(II) jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AA12 | żelaza(II) sodu cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB | Związki żelaza trójwartościowego, preparaty doustne | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB01 | żelaza(III) sodu cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB02 | żelaza(III) tlenek z sacharozą | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB03 | sodu feredenian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB04 | żelaza(III) wodorotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB05 | kompleksy żelaza(III) tlenku z polimaltozą | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB07 | kompleks chondroityny siarczanu i żelaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB08 | żelazo(III) z acetylowaną transferyną | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB09 | żelaza(III) proteinianobursztynian | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AB10 | żelaza(III) maltol | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AC | Żelazo, preparaty pozajelitowe | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AD | Żelazo w połączeniu z kwasem foliowym | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AD01 | kompleks aminokwasów żelaza i kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AD02 | fumaran żelazawy i kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AD03 | siarczan żelazawy i kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AD04 | kompleksy polimaltozy tlenku żelaza i kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AD05 | glukonian żelazawy i kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AE | Żelazo w innych połączeniach | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AE01 | żelazo, witamina B12 i kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AE02 | żelazo, preparaty wielowitaminowe i kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AE03 | żelazo i preparaty wielowitaminowe | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AE04 | żelazo, preparaty wielowitaminowe i związki mineralne | WHO Anatomical Therapeutic Chemical classification
0‑L | B03AE10 | różne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B03B | WITAMINA B12 I KWAS FOLIOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA | Witamina B12 (cyjanokobalamina i analogi) | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA01 | cyjanokobalamina | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA02 | kompleks cyjanokobalaminy z taniną | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA03 | hydroksokobalamina | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA04 | kobamamid | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA05 | mekobalamina | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA51 | cyjanokobalamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BA53 | hydroksokobalamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BB | Kwas foliowy i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BB01 | kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B03BB51 | kwas foliowy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B03X | INNE LEKI STOSOWANE W NIEDOKRWISTOŚCI | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA | Inne leki stosowane w niedokrwistości | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA01 | erytropoetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA02 | darbepoetyna alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA03 | glikol metoksypolietyle-epoetyna beta | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA04 | peginezatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA05 | roksadustat | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA06 | luspatercept | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA07 | daprodustat | WHO Anatomical Therapeutic Chemical classification
0‑L | B03XA08 | wadadustat | WHO Anatomical Therapeutic Chemical classification
0‑L | B05 | PREPARATY KRWIOZASTĘPCZE I ROZTWORY DO WLEWÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | B05A | KREW I PREPARATY KRWIOPOCHODNE | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA | Preparaty krwiozastępcze i frakcje białkowe osocza | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA01 | albumina | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA02 | inne frakcje białkowe osocza | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA03 | fluorowęglowe substytuty krwi | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA05 | dekstran | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA06 | preparaty żelatyny | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA07 | hydroksyetyloskrobia | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA08 | hemoglobiny krosfumaryl | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA09 | hemoglobiny rafimer | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AA10 | hemoglobiny glutamer (bydlęcy) | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AX | Inne produkty krwiopochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AX01 | erytrocyty | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AX02 | trombocyty | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AX03 | osocze krwi | WHO Anatomical Therapeutic Chemical classification
0‑L | B05AX04 | komórki macierzyste z krwi pępowinowej | WHO Anatomical Therapeutic Chemical classification
0‑L | B05B | Roztwory do wlewów dożylnych | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BA | Roztwory do żywienia pozajelitowego | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BA01 | aminokwasy | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BA02 | emulsje tłuszczowe | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BA03 | węglowodany | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BA04 | hydrolizaty białkowe | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BA10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BB | Roztwory wpływające na równowagę elektrolitową | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BB01 | elektrolity | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BB02 | elektrolity z węglowodanami | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BB03 | trometamol | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BB04 | elektrolity w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BC | Roztwory wywołujące diurezę osmotyczną | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BC01 | mannitol | WHO Anatomical Therapeutic Chemical classification
0‑L | B05BC02 | mocznik | WHO Anatomical Therapeutic Chemical classification
0‑L | B05C | ROZTWORY DO IRYGACJI | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA | Leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA01 | cetylopirydynium | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA02 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA03 | nitrofural | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA04 | sulfametizol | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA05 | taurolidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA06 | kwas migdałowy | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA07 | noksytiolina | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA08 | etakrydyny mleczan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA09 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CA10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CB | Roztwory soli | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CB01 | sodu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CB02 | sodu cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CB03 | magnezu cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CB04 | sodu wodorowęglan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CB10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CX | Inne roztwory do irygacji | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CX01 | glukoza | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CX02 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CX03 | glicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CX04 | mannitol | WHO Anatomical Therapeutic Chemical classification
0‑L | B05CX10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B05D | ROZTWORY DO DIALIZY OTRZEWNOWEJ | WHO Anatomical Therapeutic Chemical classification
0‑L | B05DA | Roztwory izotoniczne | WHO Anatomical Therapeutic Chemical classification
0‑L | B05DB | Roztwory hipertoniczne | WHO Anatomical Therapeutic Chemical classification
0‑L | B05X | Dożylne roztwory uzupełniające | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA | roztwory elektrolitów | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA01 | potasu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA02 | sodu wodorowęglan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA03 | sodu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA04 | amo chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA05 | magnezu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA06 | potasu fosforan, włącznie z połączeniami z innymi solami potasu | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA07 | wapnia chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA08 | sodu octan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA09 | sodu fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA10 | magnezu fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA11 | magnezu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA12 | cynku chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA13 | kwas solny | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA14 | sodu glicerofosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA15 | potasu mleczan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA16 | roztwory kardioplegiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA17 | potasu octan | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA18 | siarczan cynku | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA19 | glukonian wapnia | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA20 | selenit sodu | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA30 | połączenia elektrolitów | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XA31 | elektrolity w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XB | Aminokwasy | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XB01 | argininy chlorowodorek | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XB02 | alanyloglutamina | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XB03 | lizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XC | Witaminy | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XX | Inne dożylne roztwory uzupełniające | WHO Anatomical Therapeutic Chemical classification
0‑L | B05XX02 | trometamol | WHO Anatomical Therapeutic Chemical classification
0‑L | B05Z | ROZTWORY DO HEMODIALIZY I HEMOFILTRACJI | WHO Anatomical Therapeutic Chemical classification
0‑L | B05ZA | Roztwory do hemodializy, koncentraty | WHO Anatomical Therapeutic Chemical classification
0‑L | B05ZB | Roztwory do hemofiltracji | WHO Anatomical Therapeutic Chemical classification
0‑L | B06 | INNE LEKI HEMATOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | B06A | INNE LEKI HEMATOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AA | Enzymy | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AA02 | fibrynolizyna i deoksyrybonukleaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AA03 | hialuronidaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AA04 | chymotrypsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AA07 | trypsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AA10 | deoksyrybonukleaza | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AA55 | streptokinaza, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AB | Produkty zawierające hem | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AB01 | hemina | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AC | Leki stosowane w dziedzicznym obrzęku naczynioruchowym | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AC01 | inhibitor C1, pochodzący z osocza | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AC02 | ikatybant | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AC03 | ekalantyd | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AC04 | konestat alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AC05 | lanadelumab | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AC06 | berotralstat | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AX | Inne czynniki hematologiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AX01 | kryzanlizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AX02 | betibeglogene autotemcel | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AX03 | wokselotor | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AX04 | mitapwat | WHO Anatomical Therapeutic Chemical classification
0‑L | B06AX05 | autotemcel eksagamglogenu | WHO Anatomical Therapeutic Chemical classification
0‑L | C | UKŁAD SERCOWO-NACZYNIOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | C01 | Leki nasercowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C01A | Glikozydy nasercowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA | Glikozydy naparstnicy | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA01 | acetylodigitoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA02 | acetylodigoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA03 | liście naparstnicy | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA04 | digitoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA05 | digoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA06 | lanatozyd C | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA07 | deslanozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA08 | metylodigoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA09 | gitoformat | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AA52 | acetylodigoksyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AB | Glikozydy cebuli morskiej | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AB01 | proscylarydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AB51 | proscylarydyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AC | Glikozydy strofantusa | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AC01 | strofantyna G | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AC03 | cymaryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AX | Inne glikozydy nasercowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C01AX02 | peruwozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C01B | LEKI PRZECIWARYTMICZNE, KLASA I i III | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA | Leki przeciwarytmiczne, klasa Ia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA01 | chinidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA02 | prokainamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA03 | dyzopiramid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA04 | sparteina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA05 | ajmalina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA08 | prajmalina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA12 | lorajmina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA13 | hydrochinidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA51 | chinidyna, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BA71 | chinidyna, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BB | Leki przeciwarytmiczne, klasa Ib | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BB01 | lidokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BB02 | meksyletyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BB03 | tokainid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BB04 | apryndyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BC | Leki przeciwarytmiczne, klasa Ic | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BC03 | propafenon | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BC04 | flekainid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BC07 | lorkainid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BC08 | enkainid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BC09 | etacyzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD | Leki przeciwarytmiczne, klasa III | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD01 | amiodaron | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD02 | bretyliowy tozylan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD03 | bunaftyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD04 | dofetylid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD05 | ibutylid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD06 | tedysamil | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BD07 | dronedaron | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BG | Inne leki przeciwarytmiczne, klasa I i III | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BG01 | moracyzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BG07 | cybenzolina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01BG11 | wernakalant | WHO Anatomical Therapeutic Chemical classification
0‑L | C01C | LEKI POBUDZAJĄCE PRACĘ SERCA Z WYŁĄCZENIEM GLIKOZYDÓW NASERCOWYCH | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA | Leki adrenergiczne i dopaminergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA01 | etylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA02 | izoprenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA03 | norepinefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA04 | dopamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA05 | norfenefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA06 | fenylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA07 | dobutamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA08 | oksedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA09 | metaraminol | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA10 | metoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA11 | mefentermina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA12 | dimetofryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA13 | prenalterol | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA14 | dopeksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA15 | gepefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA16 | ibopamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA17 | midodryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA18 | oktopamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA19 | fenoldopam | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA21 | kafedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA22 | arbutamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA23 | teodrenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA24 | epinefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA25 | amezyniowy metylosiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA26 | efedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA27 | droksydopa | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA28 | centachina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CA51 | etylefryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CE | Inhibitory fosfodiesterazy | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CE01 | amrynon | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CE02 | milrynon | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CE03 | enoksymon | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CE04 | bukladezyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CX | Inne leki pobudzające pracę serca | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CX06 | angiotensynamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CX07 | ksamoterol | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CX08 | lewosymendan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CX09 | angiotensyna II | WHO Anatomical Therapeutic Chemical classification
0‑L | C01CX10 | omekamtyw mekarbyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C01D | LEKI ROZSZERZAJĄCE NACZYNIA STOSOWANE W CHOROBACH SERCA | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA | Organiczne azotany | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA02 | glicerolu triazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA04 | metylopropylopropanodiolu diazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA05 | pentaerytrytylu tetraazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA07 | propatyloazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA08 | izosorbidu diazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA09 | trolnitrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA13 | erytrytylu tetraazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA14 | izosorbidu monoazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA20 | organiczne azotany w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA38 | tenitramina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA52 | glicerolu triazotan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA54 | metylopropylopropanodiolu diazotan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA55 | pentaerytrytylu tetraazotan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA57 | propatyloazotan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA58 | izosorbidu diazotan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA59 | trolnitrat, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA63 | erytrytylu tetraazotan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DA70 | organiczne azotany w połączeniu z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DB | Pochodne chinolonu rozszerzające naczynia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DB01 | flosechina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX | Inne leki rozszerzające naczynia stosowane w chorobach serca | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX01 | itraminy tozylan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX02 | prenylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX03 | oksyfedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX04 | benzjodaron | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX05 | karbokromen | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX06 | heksobendyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX07 | etafenon | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX08 | heptaminol | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX09 | imolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX10 | dilazep | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX11 | trapidyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX12 | molsydomina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX13 | efloksat | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX14 | cynepazet | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX15 | klorydalol | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX16 | nikorandyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX18 | linsydomina | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX19 | nezyrytyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX21 | serelaksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX22 | werycyguat | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX51 | itraminy tozylan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX52 | prenylamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX53 | oksyfedryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01DX54 | benzjodaron, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C01E | INNE LEKI NASERCOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EA | Prostaglandyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EA01 | alprostadyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB | Inne leki nasercowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB02 | kamfora | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB03 | indometacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB04 | glikozydy głogu | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB05 | kreatynolofosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB06 | fosfokreatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB07 | fruktozo-1,6-bisfosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB09 | ubidekarenon | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB10 | adenozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB11 | tyracyzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB13 | akadezyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB15 | trimetazydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB16 | ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB17 | iwabradyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB18 | ranolazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB21 | regadenozon | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB22 | meldonium | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB23 | kwas tiazotowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EB24 | mawacamten | WHO Anatomical Therapeutic Chemical classification
0‑L | C01EX | Inne połączenia leków nasercowych | WHO Anatomical Therapeutic Chemical classification
0‑L | C02 | LEKI PRZECIWNADCIŚNIENIOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | C02A | LEKI PRZECIWADRENERGICZNE O DZIAŁANIU OŚRODKOWYM | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA | Alkaloidy rauwolfii | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA01 | rescynamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA02 | rezerpina | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA03 | połączenia alkaloidów rauwolfii | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA04 | alkaloidy rauwolfii, korzeń | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA05 | dezerpidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA06 | metozerpidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA07 | bietazerpina | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA52 | rezerpina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA53 | połączenia alkaloidów rauwolfii, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AA57 | bietazerpina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AB | Metylodopa | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AB01 | metylodopa (lewoskrętna) | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AB02 | metylodopa (racemiczna) | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AC | Agoniści receptora imidazolowego | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AC01 | klonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AC02 | guanfacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AC04 | tolonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AC05 | moksonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02AC06 | rylmenidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02B | LEKI PRZECIWADRENERGICZNE BLOKUJĄCE ZWOJE NERWOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | C02BA | Pochodne sulfoniowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C02BA01 | trimetafan | WHO Anatomical Therapeutic Chemical classification
0‑L | C02BB | Aminy drugo- i trzeciorzędowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C02BB01 | mekamylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C02BC | Bis-czwartorzędowe związki amoniowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C02C | LEKI PRZECIWADRENERGICZNE O DZIAŁANIU OBWODOWYM | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CA | Antagoniści receptora alfa-adrenergicznego | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CA01 | prazosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CA02 | indoramina | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CA03 | trimazosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CA04 | doksazosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CA06 | urapidyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC | Pochodne guanidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC01 | betanidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC02 | guanetydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC03 | guanoksan | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC04 | debryzochina | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC05 | guanoklor | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC06 | guanazodyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02CC07 | guanoksabenz | WHO Anatomical Therapeutic Chemical classification
0‑L | C02D | LEKI DZIAŁAJĄCE NA MIĘŚNIE GŁADKIE TĘTNICZEK | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DA | Pochodne tiazydowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DA01 | diazoksyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DB | Pochodne hydrazynoftalazyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DB01 | dihydralazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DB02 | hydralazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DB03 | endralazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DB04 | kadralazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DC | Pochodne pirymidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DC01 | minoksydyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DD | Pochodne nitroprusydku | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DD01 | nitroprusydek | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DG | Pochodne guanidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C02DG01 | pinacydyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C02K | INNE LEKI PRZECIWNADCIŚNIENIOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KA | Alkaloidy, z wyłączeniem alkaloidów rauwolfii | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KA01 | ciemiężyca | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KB | Inhibitory hydroksylazy tyrozynowej | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KB01 | metyrozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KC | Inhibitory MAO | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KC01 | pargilina | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KD | Antagoniści serotoniny | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KD01 | ketanseryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KN | Inne leki antyhipertensyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KN01 | aprocytentan | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX | Leki przeciwnadciśnieniowe stosowane w tętniczym nadciśnieniu płucnym | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX01 | bozentan | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX02 | ambryzentan | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX03 | sytaksentan | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX04 | macitentan | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX05 | riocyguat | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX52 | ambryzentan i tadalafil | WHO Anatomical Therapeutic Chemical classification
0‑L | C02KX54 | macytentan i tadalafil | WHO Anatomical Therapeutic Chemical classification
0‑L | C02L | LEKI PRZECIWNADCIŚNIENIOWE I DIURETYKI W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA | Alkaloidy rauwolfii i diuretyki w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA01 | rezerpina i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA02 | rescynamina i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA03 | dezerpidyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA04 | metozerpidyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA07 | bietazerpina i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA08 | alkaloidy rauwolfii i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA09 | syrosyngopina i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA50 | połączenie alkaloidów rauwolfii i diuretyków włącznie z innymi połączeniami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA51 | rezerpina i diuretyki, połączenia z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA52 | rescynamina i diuretyki, połączenia z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LA71 | rezerpina i diuretyki, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LB | Metylodopa i diuretyki w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LB01 | metylodopa (lewoskrętna) i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LC | Agoniści receptora imidazolowego w połączeniu z diuretykami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LC01 | klonidyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LC05 | moksonidyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LC51 | klonidyna i diuretyki, połączenia z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LE | Antagoniści receptora alfa-adrenergicznego i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LE01 | prazosyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LF | Pochodne guanidyny i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LF01 | guanetydyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LG | Pochodne hydrazynoftalazyny i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LG01 | dihydralazyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LG02 | hydralazyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LG03 | pikodralazyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LG51 | dihydralazyna i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LG73 | pikodralazyna i diuretyki, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LK | Alkaloidy, z wyłączeniem alkaloidów rauwolfii, w połączeniach z diuretykami | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LK01 | ciemiężyca i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LL | inhibitory MAO i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LL01 | pargilina i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LN | Antagoniści serotoniny i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LX | Inne leki przeciwnadciśnieniowe i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02LX01 | pinacydyl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C02N | POŁĄCZENIA LEKÓW PRZECIWNADCIŚNIENIOWYCH Z GRUPY ATC C02 | WHO Anatomical Therapeutic Chemical classification
0‑L | C03 | DIURETYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | C03A | DIURETYKI O UMIARKOWANYM DZIAŁANIU, TIAZYDY | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA | Tiazydy, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA01 | bendroflumetiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA02 | hydroflumetiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA03 | hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA04 | chlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA05 | politiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA06 | trichlorometiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA07 | cyklopentiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA08 | metyklotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA09 | cyklotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AA13 | mebutyzyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB | Tiazydy i potas w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB01 | bendroflumetiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB02 | hydroflumetiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB03 | hydrochlorotiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB04 | chlorotiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB05 | politiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB06 | trichlorometiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB07 | cyklopentiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB08 | metyklotiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AB09 | cyklotiazyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AH | Tiazydy, połączenia z psycholeptykami i/lub z lekami przeciwbólowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AH01 | chlorotiazyd, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AH02 | hydroflumetiazyd, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AX | Tiazydy, połączenia z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | C03AX01 | hydrochlorotiazyd, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C03B | DIURETYKI O UMIARKOWANYM DZIAŁANIU, Z WYŁĄCZENIEM TIAZYDÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA | Sulfonamidy, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA02 | kwinetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA03 | klopamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA04 | chlorotalidon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA05 | mefruzyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA07 | klofenamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA08 | metolazon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA09 | metykran | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA10 | ksypamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA11 | indapamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA12 | kloreksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA13 | fenkwizon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BA82 | kloreksolon, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BB | Sulfonamidy i potas w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BB02 | kwinetazon i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BB03 | klopamid i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BB04 | chlortalidon i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BB05 | mefruzyd i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BB07 | klofenamid i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BC | Diuretyki zawierające rtęć | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BC01 | mersalil | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BD | Pochodne ksantyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BD01 | teobromina | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BK | Sulfonamidy, połączenia z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BX | Inne diuretyki o umiarkowanym działaniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C03BX03 | cykletanina | WHO Anatomical Therapeutic Chemical classification
0‑L | C03C | DIURETYKI O SILNYM DZIAŁANIU | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CA | Sulfonamidy, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CA01 | furosemid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CA02 | bumetanid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CA03 | piretanid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CA04 | torasemid | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CB | Sulfonamidy i potas w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CB01 | furosemid i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CB02 | bumetanid i potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CC | pochodne kwasu aryloksyoctowego | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CC01 | kwas etakry | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CC02 | kwas tienylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CD | Pochodne pirazolonu | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CD01 | muzolimina | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CX | Inne diuretyki o silnym działaniu | WHO Anatomical Therapeutic Chemical classification
0‑L | C03CX01 | etozolina | WHO Anatomical Therapeutic Chemical classification
0‑L | C03D | ANTAGONIŚCI ALDOSTERONU I INNE DIURETYKI OSZCZĘDZAJĄCE POTAS | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DA | Antagoniści aldosteronu | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DA01 | spironolakton | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DA02 | potasu kanrenoinian | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DA03 | kanrenon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DA04 | eplerenon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DA05 | finerenon | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DB | Inne diuretyki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DB01 | amiloryd | WHO Anatomical Therapeutic Chemical classification
0‑L | C03DB02 | triamteren | WHO Anatomical Therapeutic Chemical classification
0‑L | C03E | DIURETYKI I LEKI OSZCZĘDZAJĄCE POTAS W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA | Diuretyki o umiarkowanym działaniu i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA01 | hydrochlorotiazyd i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA02 | trichlorometiazyd i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA03 | epityzyd i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA04 | altyzyd i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA05 | mebutyzyd i leki oszczędzjące potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA06 | chlortalidon i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA07 | cyklopentiazyd i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA12 | metolazon i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA13 | bendroflumetiazyd i związki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EA14 | butyzyd i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EB | Diuretyki o silnym działaniu i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EB01 | furosemid i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03EB02 | bumetanid i leki oszczędzające potas | WHO Anatomical Therapeutic Chemical classification
0‑L | C03X | INNE DIURETYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | C03XA | Inhibitory wazopresyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C03XA01 | tolwaptan | WHO Anatomical Therapeutic Chemical classification
0‑L | C03XA02 | koniwaptan | WHO Anatomical Therapeutic Chemical classification
0‑L | C04 | LEKI ROZSZERZAJĄCE NACZYNIA OBWODOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | C04A | LEKI ROZSZERZAJĄCE NACZYNIA OBWODOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AA | Pochodne 2-amino-1-fenyloetanolu | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AA01 | izoksupryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AA02 | bufenina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AA31 | bametan | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AB | Pochodne imidazoliny | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AB01 | fentolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AB02 | tolazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AC | Kwas nikoty i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AC01 | kwas nikoty | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AC02 | alkohol nikotynylowy (pirydylokarbinol) | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AC03 | nikotynian inozytolu | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AC07 | cyklonikat | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AD | Pochodne puryny | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AD01 | pentyfilina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AD02 | nikotynian ksantynolu | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AD03 | pentoksyfilina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AD04 | nikotynian etofiliny | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AE | Alkaloidy sporyszu | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AE01 | ergoloidu mezylany | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AE02 | nicergolina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AE04 | dihydroergokrystyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AE51 | ergoloidu mezylany, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AE54 | dihydroergokrystyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AF | Enzymy | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AF01 | kalidynogenaza | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX | Inne leki rozszerzające naczynia obwodowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX01 | cyklandelat | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX02 | fenoksybenzamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX07 | winkamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX10 | moksysylit | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX11 | bencyklan | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX17 | winburnina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX19 | suloktydyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX20 | buflomedil | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX21 | naftydrofuryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX23 | butalamina | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX24 | wisnadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX26 | cetiedyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX27 | cynepazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX28 | ifenprodyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX30 | azapetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX32 | fasudyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C04AX33 | klazosentan | WHO Anatomical Therapeutic Chemical classification
0‑L | C05 | LEKI DZIAŁAJĄCE OSŁANIAJĄCO NA NACZYNIA KRWIONOŚNE | WHO Anatomical Therapeutic Chemical classification
0‑L | C05A | LEKI STOSOWANE W LECZENIU HEMOROIDÓW I SZCZELINY ODBYTU DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA | Kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA01 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA04 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA05 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA06 | fluorometolon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA08 | fluokortolon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA09 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA10 | fluocynolonu acetonid | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA11 | fluocynonid | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AA12 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AB | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD | Leki miejscowo znieczulające | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD01 | lidokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD02 | tetrakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD03 | benzokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD04 | cynchokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD05 | prokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD06 | oksetakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AD07 | pramokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AE | Leki zmniejszające napięcie mięśni | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AE01 | glicerolu triazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AE02 | izosorbidu diazotan | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AE03 | diltiazem | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AX | Inne leki stosowane w leczeniu hemoroidów i szczeliny odbytu do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AX01 | preparaty glinu | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AX02 | preparaty bizmutu, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AX03 | inne preparaty, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AX04 | preparaty cynku | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AX05 | tribenozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C05AX06 | fenylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | C05B | LEKI STOSOWANE W LECZENIU ŻYLAKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BA | Heparyna lub heparynoidy do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BA01 | organo-heparynoid | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BA02 | sodu apolan | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BA03 | heparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BA04 | sodu pentozanu polisiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BA51 | heparynoid, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BA53 | heparyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BB | Leki obliterujące naczynia do wstrzykiwań domiejscowych | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BB01 | monoetanoloaminy oleinian | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BB02 | polidokanol | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BB03 | cukier inwertowany | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BB04 | sodu tetradecylu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BB05 | fenol | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BB56 | glukoza, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BX | Inne leki obliterujące naczynia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BX01 | wapnia dobezylan | WHO Anatomical Therapeutic Chemical classification
0‑L | C05BX51 | wapnia dobezylan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05C | LEKI WZMACNIAJĄCE NACZYNIA WŁOSOWATE | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA | Bioflawonoidy | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA01 | rutozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA02 | monokserutyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA03 | diosmina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA04 | trokserutyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA05 | hidrosmina | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA51 | rutozyd, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA53 | diosmina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CA54 | trokserutyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CX | Inne leki wzmacniające naczynia włosowate | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CX01 | tribenozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CX02 | naftazon | WHO Anatomical Therapeutic Chemical classification
0‑L | C05CX03 | nasienie kasztanowca | WHO Anatomical Therapeutic Chemical classification
0‑L | C05X | INNE ŚRODKI WAZOPROTEKCYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | C05XX | Inne środki wazoprotekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | C05XX01 | beperminogen perplazmid | WHO Anatomical Therapeutic Chemical classification
0‑L | C07 | BETA-ADRENOLITYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | C07A | BETA-ADRENOLITYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA | Beta-adrenolityki, nieselektywne | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA01 | alprenolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA02 | oksprenolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA03 | pindolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA05 | propranolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA06 | tymolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA07 | sotalol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA12 | nadolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA14 | mepindolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA15 | karteolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA16 | tertatolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA17 | bopindolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA19 | bupranolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA23 | penbutolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AA27 | kloranolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB | Beta-adrenolityki, selektywne | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB01 | praktolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB02 | metoprolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB03 | atenolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB04 | acebutolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB05 | betaksolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB06 | bewantolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB07 | bisoprolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB08 | celiprolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB09 | esmolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB10 | epanolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB11 | esatenolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB12 | nebiwolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB13 | talinolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AB14 | landiolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AG | Alfa- i beta-adrenolityki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AG01 | labetalol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07AG02 | karwedylol | WHO Anatomical Therapeutic Chemical classification
0‑L | C07B | BETA-ADRENOLITYKI I TIAZYDY | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BA | Beta-adrenolityki nieselektywne i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BA02 | oksprenolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BA05 | propranolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BA06 | tymolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BA07 | sotalol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BA12 | nadolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BA68 | metypranolol i tiazydy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB | Beta-adrenolityki selektywne i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB02 | metoprolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB03 | atenolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB04 | acebutolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB06 | bewantolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB07 | bisoprolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB12 | nebiwolol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BB52 | metoprolol i tiazydy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BG | Alfa- i beta-adrenolityki i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07BG01 | labetalol i tiazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07C | BETA-ADRENOLITYKI I INNE DIURETYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CA | Beta-adrenolityki nieselektywne i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CA02 | oksprenolol i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CA03 | pindolol i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CA17 | bopindolol i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CA23 | penbutolol i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CB | Beta-adrenolityki selektywne i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CB02 | metoprolol i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CB03 | atenolol i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CB53 | atenolol i inne diuretyki, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CG | Alfa- i beta-adrenolityki i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07CG01 | labetalol i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07D | BETA-ADRENOLITYKI, TIAZYDY I INNE DIURETYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | C07DA | Beta-adrenolityki nieselektywne, tiazydy i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07DA06 | tymolol, tiazydy i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07DB | Beta-adrenolityki selektywne, tiazydy i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07DB01 | atenolol, tiazydy i inne diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C07E | BETA-ADRENOLITYKI I LEKI ROZSZERZAJĄCE NACZYNIA OBWODOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | C07EA | Beta-adrenolityki nieselektywne i leki rozszerzajace naczynia obwodowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C07EB | Beta-adrenolityki selektywne i leki rozszerzajace naczynia obwodowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C07F | BETA-ADRENOLITYKI, INNE POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FB | Beta-adrenolityki i blokery kanału wapniowego | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FB02 | metoprolol i felodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FB03 | atenolol i nifedypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FB07 | bisoprolol i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FB12 | nebiwolol i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FB13 | metoprolol i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FX | Beta-adrenolityki, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FX01 | propranolol i inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FX02 | sotalol i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FX03 | metoprolol i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FX04 | bisoprolol i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FX05 | metoprolol i iwabradyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C07FX06 | karwedylol i iwabradyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C08 | BLOKERY KANAŁU WAPNIOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | C08C | SELEKTYWNE BLOKERY KANAŁU WAPNIOWEGO O DOMINUJĄCYM DZIAŁANIU NACZYNIOWYM | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA | Pochodne dihydropirydyny | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA01 | amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA02 | felodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA03 | izradypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA04 | nikardypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA05 | nifedypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA06 | nimodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA07 | nizoldypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA08 | nitrendypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA09 | lacydypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA10 | nilwadypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA11 | manidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA12 | barnidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA13 | lerkanidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA14 | cylnidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA15 | benidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA16 | klewidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA17 | lewamlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA51 | amlodypina i celekoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CA55 | nifedypina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CX | Inne selektywne blokery kanału wapniowego o dominującym działaniu naczyniowym | WHO Anatomical Therapeutic Chemical classification
0‑L | C08CX01 | mibefradyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C08D | SELEKTYWNE BLOKERY KANAŁU WAPNIOWEGO O BEZPOŚREDNIM DZIAŁANIU NASERCOWYM | WHO Anatomical Therapeutic Chemical classification
0‑L | C08DA | Pochodne fenyloalkiloaminy | WHO Anatomical Therapeutic Chemical classification
0‑L | C08DA01 | werapamil | WHO Anatomical Therapeutic Chemical classification
0‑L | C08DA02 | gallopamil | WHO Anatomical Therapeutic Chemical classification
0‑L | C08DA51 | werapamil, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C08DB | Pochodne benzotiazepiny | WHO Anatomical Therapeutic Chemical classification
0‑L | C08DB01 | diltiazem | WHO Anatomical Therapeutic Chemical classification
0‑L | C08E | NIESELEKTYWNE BLOKERY KANAŁU WAPNIOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | C08EA | Pochodne fenyloalkiloaminy | WHO Anatomical Therapeutic Chemical classification
0‑L | C08EA01 | fendylina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08EA02 | beprydyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C08EX | Inne nieselektywne blokery kanału wapniowego | WHO Anatomical Therapeutic Chemical classification
0‑L | C08EX01 | lidoflazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C08EX02 | perheksylina | WHO Anatomical Therapeutic Chemical classification
0‑L | C08G | BLOKERY KANAŁU WAPNIOWEGO I DIURETYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | C08GA | Blokery kanału wapniowego i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C08GA01 | nifedypina i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C08GA02 | amlodypina i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09 | LEKI DZIAŁAJĄCE NA UKŁAD RENINA-ANGIOTENSYNA | WHO Anatomical Therapeutic Chemical classification
0‑L | C09A | INHIBITORY KONWERTAZY ANGIOTENSYNY (ACE), BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA | Inhibitory konwertazy angiotensyny (ACE), bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA01 | kaptopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA02 | enalapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA03 | lizynopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA04 | peryndopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA05 | ramipryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA06 | chinapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA07 | benazepryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA08 | cylazapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA09 | fozynopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA10 | trandolapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA11 | spirapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA12 | delapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA13 | moeksypryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA14 | temokapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA15 | zofenopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09AA16 | imidapryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09B | INHIBITORY KONWERTAZY ANGIOTENSYNY (ACE), POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA | Inhibitory konwertazy angiotensyny (ACE) i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA01 | kaptopryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA02 | enalapryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA03 | lizynopryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA04 | peryndopryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA05 | ramipryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA06 | chinapryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA07 | benazepryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA08 | cylazapryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA09 | fozynopryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA12 | delapryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA13 | moeksypryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BA15 | zofenopryl i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB | INHIBITORY KONWERTAZY ANGIOTENSYNY (ACE) I BLOKERY KANAŁU WAPNIOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB02 | enalapryl i lerkanidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB03 | lizynopryl i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB04 | peryndopryl i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB05 | ramipryl i felodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB06 | enalapryl i nitrendypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB07 | ramipryl i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB10 | trandolapryl i werapamil | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB12 | delapryl i manidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BB13 | benazepryl i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX | Inhibitory konwertazy angiotensyny (ACE), inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX01 | peryndopryl, amlodypina i indapamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX02 | peryndopryl i bisoprolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX03 | ramipryl, amlodypina i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX04 | peryndopryl, bisoprolol i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX05 | ramipryl i bisoprolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX06 | peryndopryl, bisoprolol, amlodypina i indapamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C09BX07 | zofenopril i nebiwolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C09C | ANTAGONIŚCI RECEPTORA ANGIOTENSYNY II, BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA | Antagoniści receptora angiotensyny II, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA01 | losartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA02 | eprosartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA03 | walsartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA04 | irbesartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA05 | tazosartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA06 | kandesartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA07 | telmisartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA08 | olmesartan medoksomil | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA09 | azylsartan medoksomil | WHO Anatomical Therapeutic Chemical classification
0‑L | C09CA10 | fimasartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C09D | ANTAGONIŚCI RECEPTORA ANGIOTENSYNY II, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA | Antagoniści receptora angiotensyny II i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA01 | losartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA02 | eprosartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA03 | walsartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA04 | irbesartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA06 | kandesartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA07 | temisartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA08 | olmesartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA09 | azylsartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DA10 | fimasartan i diuretyki | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB | Antagoniści receptora angiotensyny II i blokery kanału wapniowego | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB01 | walsartan i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB02 | olmesartan i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB04 | telmisartan i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB05 | irbesartan i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB06 | losartan i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB07 | kandesartan i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB08 | walsartan i lerkanidypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DB09 | fimasartan i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX | Antagoniści receptora angiotensyny II, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX01 | walsartan, amlodypina i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX02 | walsartan i aliskiren | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX03 | olmesartan, amlodypina i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX04 | walsartan i sakubitryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX05 | walsartan i nebiwolol | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX06 | kandesartan, amlodypina i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX07 | irbesartan, amlodypina i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C09DX08 | telmisartan, amlodypina i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C09X | INNE LEKI DZIAŁAJĄCE NA UKŁAD RENINA-ANGIOTENSYNA | WHO Anatomical Therapeutic Chemical classification
0‑L | C09XA | Inhibitory reniny | WHO Anatomical Therapeutic Chemical classification
0‑L | C09XA01 | remikiren | WHO Anatomical Therapeutic Chemical classification
0‑L | C09XA02 | aliskiren | WHO Anatomical Therapeutic Chemical classification
0‑L | C09XA52 | aliskiren i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C09XA53 | aliskiren i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C09XA54 | aliskiren, amlodypina i hydrochlorotiazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | C10 | LEKI ZMNIEJSZAJĄCE STĘŻENIE LIPIDÓW W SUROWICY | WHO Anatomical Therapeutic Chemical classification
0‑L | C10A | LEKI ZMNIEJSZAJĄCE STĘŻENIE LIPIDÓW W SUROWICY, BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA | Inhibitory reduktazy HMG-CoA | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA01 | symwastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA02 | lowastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA03 | prawastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA04 | fluwastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA05 | atorwastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA06 | ceriwastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA07 | rozuwastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AA08 | pitawastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB | Fibraty | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB01 | klofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB02 | bezafibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB03 | glinu klofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB04 | gemfibrozyl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB05 | fenofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB06 | symfibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB07 | ronifibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB08 | cyprofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB09 | etofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB10 | klofibryd | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB11 | fenofibrat choliny | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AB12 | pemafibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AC | Leki wiążące kwasy żółciowe | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AC01 | kolestyramina | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AC02 | kolestypol | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AC03 | kolekstran | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AC04 | kolesewelam | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD | Kwas nikoty i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD01 | nicerytrol | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD02 | kwas nikoty | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD03 | nikofuranoza | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD04 | glinu nikotynian | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD05 | alkohol nikotynylowy (pirydylokarbinol) | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD06 | acypimoks | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AD52 | kwas nikoty, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX | Inne leki zmniejszające stężenie lipidów w surowicy | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX01 | dekstrotyroksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX02 | probukol | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX03 | tiadenol | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX05 | meglutol | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX06 | triglicerydy omega-3 włącznie z innymi estrami i kwasami | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX07 | magnezu pirydoksalu 5-fosforanu glutaminian | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX08 | polikozanol | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX09 | ezetymib | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX10 | alipogen typarwowek | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX11 | mipomersen | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX12 | lomitapid | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX13 | ewolokumab | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX14 | alirokumab | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX15 | kwas bempediowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX16 | inklisiran | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX17 | ewinakumab | WHO Anatomical Therapeutic Chemical classification
0‑L | C10AX18 | wolanesorsen | WHO Anatomical Therapeutic Chemical classification
0‑L | C10B | LEKI ZMNIEJSZAJĄCE STĘŻENIE LIPIDÓW W SUROWICY, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA | Połaczenia różnych leków zmniejszających stężenie lipidów w surowicy | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA01 | lowastatyna i kwas nikoty | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA02 | symwastatyna i ezetymib | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA03 | prawastatyna i fenofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA04 | symwastatyna i fenofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA05 | atorwastatyna i ezetymib | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA06 | rozuwastatyna i ezetymib | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA07 | rosuwastatyna i kwasy tłuszczowe omega-3 | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA08 | atorwastatyna i kwasy tłuszczowe omega-3 | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA09 | rozuwastatyna i fenofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA10 | kwas bempediowy i ezetymib | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA11 | prawastatyna i ezetymib | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BA12 | prawastatyna, ezetymib i fenofibrat | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX | Leki zmniejszające stężenie lipidów w surowicy w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX01 | symwastatyna i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX02 | prawastatyna i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX03 | atorwastatyna i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX04 | symwastatyna, kwas acetylosalicylowy i ramipryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX05 | rozuwastatyna i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX06 | atorwastatyna, kwas acetylosalicylowy i ramipryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX07 | rozuwastatyna, amlodypina i lizynopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX08 | atorwastatyna i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX09 | rozuwastatyna i amlodypina | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX10 | rozuwastatyna i walsartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX11 | atorwastatyna, amlodypina i peryndopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX12 | atorwastatyna, kwas acetylosalicylowy i peryndopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX13 | rozuwastatyna, peryndopryl i indapamid | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX14 | rozuwastatyna, amlodypina i peryndopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX15 | atorwastatyna i peryndopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX16 | rozuwastatyna i fimasartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX17 | rozuwastatyna i ramipryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX18 | atorwastatyna, amlodypina i ramipryl | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX19 | atorwastatyna, amlodypina i kandesartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX20 | rozuwastatyna i telmisartan | WHO Anatomical Therapeutic Chemical classification
0‑L | C10BX21 | rosuwastatyna i peryndopryl | WHO Anatomical Therapeutic Chemical classification
0‑L | D | LEKI STOSOWANE W DERMATOLOGII | WHO Anatomical Therapeutic Chemical classification
0‑L | D01 | LEKI PRZECIWGRZYBICZE STOSOWANE W DERMATOLOGII | WHO Anatomical Therapeutic Chemical classification
0‑L | D01A | LEKI PRZECIWGRZYBICZE DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA01 | nystatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA02 | natamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA03 | hachimycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA04 | pecylocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA06 | mepartrycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA07 | pirolnitryna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA08 | gryzeofulwina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AA20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC | Pochodne imidazolu i triazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC01 | klotrymazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC02 | mikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC03 | ekonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC04 | chlormidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC05 | izokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC06 | tiabendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC07 | tiokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC08 | ketokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC09 | sulkonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC10 | bifonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC11 | oksykonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC12 | fentykonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC13 | omokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC14 | sertakonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC15 | flukonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC16 | flutrimazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC17 | eberkonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC18 | lulikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC19 | efinakonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC20 | imidazole/triazole w połączeniu z kortykosteroidami | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC21 | netikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC22 | lanokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC52 | mikonazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AC60 | bifonazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE | Inne leki przeciwgrzybicze do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE01 | bromochlorosalicylanilid | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE02 | metylorozanilina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE03 | tribromometakrezol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE04 | kwas undecyle | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE05 | polinoksylina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE06 | 2-(4-chlorofenoksy)etanol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE07 | chlorofenezyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE08 | tyklaton | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE09 | sulbentyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE10 | etylu hydroksybenzoesan | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE11 | haloprogina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE12 | kwas salicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE13 | selenu siarczek | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE14 | cyklopiroks | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE15 | terbinafina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE16 | amorolfina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE17 | dimazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE18 | tolnaftat | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE19 | tolcyklat | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE21 | flucytozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE22 | naftyfina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE23 | butenafina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE24 | tawaborol | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE25 | liranaftat | WHO Anatomical Therapeutic Chemical classification
0‑L | D01AE54 | kwas undecyle, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D01B | LEKI PRZECIWGRZYBICZE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D01BA | Leki przeciwgrzybicze do stosowania ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | D01BA01 | gryzeofulwina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01BA02 | terbinafina | WHO Anatomical Therapeutic Chemical classification
0‑L | D01BA03 | fosrawukonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D02 | LEKI KERATOLITYCZNE I OSŁANIAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | D02A | LEKI KERATOLITYCZNE I OSŁANIAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AA | Preparaty silikonowe | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AB | Preparaty cynku | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AC | Preparaty zawierające wazelinę i tłuszcze | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AD | Plastry w płynie | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AE | Preparaty zawierające mocznik | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AE01 | mocznik | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AE51 | mocznik, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AF | Preparaty zawierające kwas salicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D02AX | Inne leki keratolityczne i osłaniające | WHO Anatomical Therapeutic Chemical classification
0‑L | D02B | LEKI OSŁANIAJĄCE PRZED PROMIENIOWANIEM UV | WHO Anatomical Therapeutic Chemical classification
0‑L | D02BA | Leki osłaniające przed promieniowaniem UV do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D02BA01 | kwas aminobenzoesowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D02BA02 | oktynoksat | WHO Anatomical Therapeutic Chemical classification
0‑L | D02BB | Preparaty osłaniające przed promieniowaniem UV do stosowania ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | D02BB01 | betakaroten | WHO Anatomical Therapeutic Chemical classification
0‑L | D02BB02 | afamelanotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | D03 | PREPARATY DO LECZENIA RAN I OWRZODZEŃ | WHO Anatomical Therapeutic Chemical classification
0‑L | D03A | LEKI ZABLIŹNIAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AA | Maści zawierające tran z wątroby dorsza | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX | Inne leki zabliźniające | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX01 | kadeksomer z jodem | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX02 | dekstranomer | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX03 | deksopantenol | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX04 | wapnia pantotenian | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX05 | kwas hialuro | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX06 | bekaplermina | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX09 | krylanomer | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX10 | enoksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX11 | sodu chloryn | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX12 | trolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX13 | kora brzozy | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX14 | Centella asiatica herba, w tym kombinacje | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX15 | trafermin | WHO Anatomical Therapeutic Chemical classification
0‑L | D03AX16 | beremagen geperpawek | WHO Anatomical Therapeutic Chemical classification
0‑L | D03B | ENZYMY | WHO Anatomical Therapeutic Chemical classification
0‑L | D03BA | Enzymy proteolityczne | WHO Anatomical Therapeutic Chemical classification
0‑L | D03BA01 | trypsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D03BA02 | kolagenaza | WHO Anatomical Therapeutic Chemical classification
0‑L | D03BA03 | bromelainy | WHO Anatomical Therapeutic Chemical classification
0‑L | D03BA52 | kolagenaza, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D04 | LEKI PRZECIWŚWIĄDOWE WŁĄCZNIE Z PRZECIWHISTAMIMI, ZNIECZULAJĄCYMI ITP. | WHO Anatomical Therapeutic Chemical classification
0‑L | D04A | LEKI PRZECIWŚWIĄDOWE WŁĄCZNIE Z PRZECIWHISTAMIMI, ZNIECZULAJĄCYMI ITP. | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA | Leki przeciwhistaminowe do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA01 | tonzylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA02 | mepiramina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA03 | tenalidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA04 | tripelenamina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA09 | chloropiramina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA10 | prometazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA12 | tolpropamina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA13 | dimetynden | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA14 | klemastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA15 | bamipina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA16 | feniramina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA22 | izotypendil | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA32 | difenhydramina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA33 | difenhydraminy metylobromek | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AA34 | chlorfenoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB | Leki znieczulające do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB01 | lidokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB02 | cynchokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB03 | oksybuprokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB04 | benzokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB05 | kwinizokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB06 | tetrakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AB07 | pramokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AX | Inne leki przeciwświądowe | WHO Anatomical Therapeutic Chemical classification
0‑L | D04AX01 | doksepina | WHO Anatomical Therapeutic Chemical classification
0‑L | D05 | LEKI PRZECIWŁUSZCZYCOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | D05A | LEKI PRZECIWŁUSZCZYCOWE DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AA | Preparaty dziegciowe | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AC | Pochodne antracenu | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AC01 | ditranol | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AC51 | ditranol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AD | Psoraleny do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AD01 | trioksysalen | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AD02 | metoksalen | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX | Inne leki przeciwłuszczycowe do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX01 | kwas fumarowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX02 | kalcypotriol | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX03 | kalcytriol | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX04 | takalcytol | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX05 | tazaroten | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX06 | roflumilast | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX07 | tapinarof | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX52 | kalcypotriol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D05AX55 | tazaroten i ulobetasol | WHO Anatomical Therapeutic Chemical classification
0‑L | D05B | LEKI PRZECIWŁUSZCZYCOWE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BA | Psoraleny do stosowania ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BA01 | trioksysalen | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BA02 | metoksalen | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BA03 | bergapten | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BB | Retynoidy o działaniu przeciwłuszczycowym | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BB01 | etretynat | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BB02 | acytretyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BX | Inne leki przeciwłuszczycowe do stosowania ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | D05BX51 | pochodne kwasu fumarowego, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D06 | ANTYBIOTYKI I CHEMIOTERAPEUTYKI STOSOWANE W DERMATOLOGII | WHO Anatomical Therapeutic Chemical classification
0‑L | D06A | ANTYBIOTYKI DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AA | Tetracyklina i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AA01 | demeklocyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AA02 | chlorotetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AA03 | oksytetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AA04 | tetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX | Inne antybiotyki do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX01 | kwas fusydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX02 | chloramfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX04 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX05 | bacytracyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX07 | gentamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX08 | tyrotrycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX09 | mupirocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX10 | wirginiamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX11 | ryfaksymina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX12 | amikacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX13 | retapamulina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX14 | ozenoksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06AX15 | ryfamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06B | CHEMIOTERAPEUTYKI DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA | Sulfonamidy | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA01 | sulfadiazyna srebrowa | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA02 | sulfatiazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA03 | mafenid | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA04 | sulfametyzol | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA05 | sulfanilamid | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA06 | sulfamerazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BA51 | sulfadiazyna srebrowa, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB | Leki przeciwwirusowe | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB01 | idoksurydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB02 | tromantadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB03 | acyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB04 | podofilotoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB05 | inozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB06 | pencyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB07 | lizozym | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB08 | ibacytabina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB09 | edoksudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB10 | imikwimod | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB11 | dokozanol | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB12 | sinekatechiny | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BB53 | acyklowir, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BX | Inne chemioterapeutyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BX01 | metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BX02 | ingenolu mebutynian | WHO Anatomical Therapeutic Chemical classification
0‑L | D06BX03 | tyrbanibulina | WHO Anatomical Therapeutic Chemical classification
0‑L | D06C | ANTYBIOTYKI I CHEMIOTERAPEUTYKI, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | D07 | KORTYKOSTEROIDY, LEKI DERMATOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | D07A | KORTYKOSTEROIDY, BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AA | Kortykosteroidy o słabym działaniu (grupa I) | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AA01 | metyloprednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AA02 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AA03 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB | Kortykosteroidy o umiarkowanie silnym działaniu (grupa II) | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB01 | klobetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB02 | hydrokortyzonu maślan | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB03 | flumetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB04 | fluokortyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB05 | fluperolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB06 | fluorometolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB07 | flupredniden | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB08 | dezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB09 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB10 | alklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB11 | hydrokortyzonu butepran | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB19 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB21 | klokortolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AB30 | połączenia kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC | Kortykosteroidy o silnym działaniu (grupa III) | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC01 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC02 | flukrolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC03 | dezoksymetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC04 | fluocynolonu acetonid | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC05 | fluokortolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC06 | diflukortolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC07 | fludroksykortyd | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC08 | fluocynonid | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC09 | budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC10 | diflorazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC11 | amcynonid | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC12 | halometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC13 | mometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC14 | metyloprednizolonu aceponian | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC15 | beklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC16 | hydrokortyzonu aceponian | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC17 | flutykazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC18 | prednikarbat | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC19 | difluprednat | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AC21 | ulobetazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AD | Kortykosteroidy o bardzo silnym działaniu (grupa IV) | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AD01 | klobetazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D07AD02 | halcynonid | WHO Anatomical Therapeutic Chemical classification
0‑L | D07B | KORTYKOSTEROIDY, POŁĄCZENIA Z ANTYSEPTYKAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BA | Kortykosteroidy o słabym działaniu, połączenia z antyseptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BA01 | prednizolon i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BA04 | hydrokortyzon i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BB | Kortykosteroidy o umiarkowanie silnym działaniu, połączenia z antyseptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BB01 | flumetazon i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BB02 | dezonid i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BB03 | triamcynolon i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BB04 | hydrokortyzonu maślan i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BC | Kortykosteroidy o silnym działaniu, połączenia z antyseptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BC01 | betametazon i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BC02 | fluocynolonu acetonid i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BC03 | fluokortolon i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BC04 | diflukortolon i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07BD | Kortykosteroidy o bardzo silnym działaniu, połączenia z antyseptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07C | KORTYKOSTERIDY, POŁĄCZENIA Z ANTYBIOTYKAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CA | kortykosteroidy o słabym działaniu, połączenia z antybiotykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CA01 | hydrokortyzon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CA02 | metyloprednizolon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CA03 | prednizolon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CB | Kortykosteroidy o umiarkowanie silnym działaniu, połączenia z antybiotykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CB01 | triamcynolon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CB02 | flupredniden i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CB03 | fluorometolon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CB04 | deksametazon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CB05 | flumetazon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CC | Kortykosteroidy o silnym działaniu, połączenia z antybiotykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CC01 | betametazon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CC02 | fluocynolonu acetonid i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CC03 | fludroksykortyd i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CC04 | beklometazon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CC05 | fluocynonid i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CC06 | fluokortolon i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CD | Kortykosteroidy o bardzo silnym działaniu, połączenia z antybiotykami | WHO Anatomical Therapeutic Chemical classification
0‑L | D07CD01 | klobetazol i antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | D07X | KORTYKOSTEROIDY, INNE POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XA | Kortykosteroidy o słabym działaniu, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XA01 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XA02 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XB | Kortykosteroidy o umiarkowanie silnym działaniu, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XB01 | flumetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XB02 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XB03 | flupredniden | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XB04 | fluorometolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XB05 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XB30 | połączenia kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XC | Kortykosteroidy o silnym działaniu, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XC01 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XC02 | dezoksymetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XC03 | mometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XC04 | diflukortolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XC05 | fluokortolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D07XD | Kortykosteroidy o bardzo silnym działaniu, inne połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D08 | ANTYSEPTYKI I PREPARATY DEZYNFEKUJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | D08A | ANTYSEPTYKI I PREPARATY DEZYNFEKUJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AA | Pochodne akrydyny | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AA01 | etakrydyny mleczan | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AA02 | aminoakrydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AA03 | euflawina | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AB | Związki glinu | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AC | Biguanidy i amidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AC01 | dibromopropamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AC02 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AC03 | propamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AC04 | heksamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AC05 | poliheksanid | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AC52 | chloroheksydyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AD | Kwasu borowego produkty | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AE | Fenol i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AE01 | heksachlorofen | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AE02 | polikrezulen | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AE03 | fenol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AE04 | triklosan | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AE05 | chloroksylenol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AE06 | bifenylol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AF | Pochodne nitrofuranu | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AF01 | nitrofural | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AG | Związki zawierające jod | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AG01 | jod/eter oktylofenoksypoliglikolowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AG02 | powidon jodowany | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AG03 | jod | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AG04 | dijodohydroksypropan | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AH | Pochodne chinoliny | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AH01 | dekwalinium | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AH02 | chlorchinaldol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AH03 | oksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AH30 | kliochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ | Czwartorzędowe związki amoniowe | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ01 | benzalkonium | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ02 | cetrymonium | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ03 | cetylopirydynium | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ04 | cetrymid | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ05 | benzoksoniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ06 | didecylodimetyloamoniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ08 | benzetoniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ10 | dekametoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ57 | oktenidyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ58 | benzetoniowy chlorek, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AJ59 | dodekloniowy bromek, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK | Związki zawierające rtęć | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK01 | rtęci(II) amidochlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK02 | fenylortęci(II) boran | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK03 | rtęci(II) chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK04 | merbromina | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK05 | rtęć metaliczna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK06 | tiomersal | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AK30 | rtęci (II) jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AL | Związki srebra | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AL01 | srebra azotan | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AL30 | srebro | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX | Inne antyseptyki i preparaty dezynfekujące | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX01 | wodoru nadtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX02 | eozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX03 | propanol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX04 | tozylochloramid sodowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX05 | izopropanol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX06 | potasu nadmanganian | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX07 | sodu podchloryn | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX08 | Etanol | WHO Anatomical Therapeutic Chemical classification
0‑L | D08AX53 | propanol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D09 | OPATRUNKI LECZNICZE | WHO Anatomical Therapeutic Chemical classification
0‑L | D09A | OPATRUNKI LECZNICZE | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA | Opatrunki z lekami przeciwinfekcyjnymi | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA01 | framycetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA02 | kwas fusydy | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA03 | nitrofural | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA04 | fenylortęci (II) azotan | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA05 | benzododecynium | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA06 | triklosan | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA07 | cetylopirydinium | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA08 | glinu chlorowodorotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA09 | powidon jodowany | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA10 | kliochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA11 | benzalkonium | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA12 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AA13 | jodoform | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AB | Opatrunki cynkowe | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AB01 | Opatrunki cynkowe bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AB02 | Opatrunki cynkowe z dodatkami | WHO Anatomical Therapeutic Chemical classification
0‑L | D09AX | Opatrunki z wazeliną | WHO Anatomical Therapeutic Chemical classification
0‑L | D10 | LEKI PRZECIWTRĄDZIKOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | D10A | LEKI PRZECIWTRĄDZIKOWE DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AA | Kortykosteroidy, połączenia stosowane w leczeniu trądziku | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AA01 | fluorometolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AA02 | metyloprednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AA03 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AB | Preparaty zawierające siarkę | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AB01 | bitionol | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AB02 | siarka | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AB03 | tioksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AB05 | mesulfen | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD | Retynoidy do stosowania miejscowego w trądziku | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD01 | tretynoina | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD02 | retinol | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD03 | adapalen | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD04 | izotretynoina | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD05 | motretynid | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD06 | trifaroten | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD51 | tretynoina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD53 | adapalen, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AD54 | izotretynoina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AE | Nadtlenki | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AE01 | benzoilu nadtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AE51 | benzoilu nadtlenek, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF | Leki przeciwinfekcyjne stosowane w trądziku | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF01 | klindamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF02 | erytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF03 | chloramfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF04 | meklocyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF05 | nadifloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF06 | sulfacetamid | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF07 | minocyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF51 | klindamycyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AF52 | erytromycyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX | Inne leki przeciwtrądzikowe do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX01 | glinu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX02 | rezorcynol | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX03 | kwas azelai | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX04 | glinu tlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX05 | dapson | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX06 | klaskoteron | WHO Anatomical Therapeutic Chemical classification
0‑L | D10AX30 | różne kombinacje | WHO Anatomical Therapeutic Chemical classification
0‑L | D10B | LEKI PRZECIWTRĄDZIKOWE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | D10BA | Retynoidy stosowane w trądziku | WHO Anatomical Therapeutic Chemical classification
0‑L | D10BA01 | izotretynoina | WHO Anatomical Therapeutic Chemical classification
0‑L | D10BX | Inne leki przeciwtrądzikowe do stosowania ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | D10BX01 | ichtazol | WHO Anatomical Therapeutic Chemical classification
0‑L | D11 | INNE LEKI DERMATOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | D11A | INNE LEKI DERMATOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AA | Leki hamujące pocenie | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AA01 | glikopironium | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC | Szampony lecznicze | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC01 | cetrymid | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC02 | związki kadmu | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC03 | związki selenu | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC06 | powidon jodowany | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC08 | związki siarki | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC09 | ksenysalat | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AC30 | inne | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AE | Androgeny do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AE01 | metandienon | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AF | Preparaty przeciw brodawkom i odciskom | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH | Leki stosowane w leczeniu zapalenia skóry, z wyłączeniem kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH01 | takrolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH02 | pimekrolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH03 | kwas kromoglika | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH04 | alitretynoina | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH05 | dupilumab | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH06 | krysaborol | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH07 | tralokinumab | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH08 | abrocytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH09 | ruksolitynib | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH10 | lebrikizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH11 | delgocytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AH12 | nemolizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX | Inne leki dermatologiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX01 | minoksydyl | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX02 | kwas gamole | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX03 | wapnia glukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX04 | litu bursztynian | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX05 | magnezu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX06 | mechinol | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX08 | tyratrikol | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX09 | oksaceprol | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX10 | finasteryd | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX11 | hydrochinon | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX12 | cynku pirytionian | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX13 | monobenzon | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX16 | eflornityna | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX18 | diklofenak | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX21 | brymonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX22 | iwermektyna | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX23 | potasu aminobenzoesan | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX24 | kwas deoksycholowy | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX25 | wodoru nadtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX26 | kofeina | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX27 | oksymetazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX52 | kwas gamole, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | D11AX57 | kolagen, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G | UKŁAD MOCZOWO-PŁCIOWY I HORMONY PŁCIOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | G01 | LEKI PRZECIWINFEKCYJNE I ANTYSEPTYKI STOSOWANE W GINEKOLOGII | WHO Anatomical Therapeutic Chemical classification
0‑L | G01A | LEKI PRZECIWINFEKCYJNE I ANTYSEPTYKI, Z WYŁĄCZENIEM POŁĄCZEŃ Z KORTYKOSTEROIDAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA01 | nystatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA02 | natamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA03 | amfoterycyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA04 | kandycydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA05 | chloramfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA06 | hachimycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA07 | oksytetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA08 | karfecylina | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA09 | mepartrycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA10 | klindamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA11 | pentamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AA51 | nystatyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AB | Związki arsenu | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AB01 | acetarsol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AC | Pochodne chinoliny | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AC01 | dijodohydroksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AC02 | kliochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AC03 | chlorchinaldol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AC05 | dekwalinium | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AC06 | broksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AC30 | oksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AD | Kwasy organiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AD01 | kwas mlekowy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AD02 | kwas octowy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AD03 | kwas askorbowy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AE | Sulfonamidy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AE01 | sulfatolamid | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AE10 | połączenia sulfonamidów | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF | Pochodne imidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF01 | metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF02 | klotrymazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF04 | mikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF05 | ekonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF06 | ornidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF07 | izokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF08 | tiokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF11 | ketokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF12 | fentikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF13 | azanidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF14 | propenidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF15 | butokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF16 | omokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF17 | oksykonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF18 | flutrimazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF19 | sertakonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF20 | połączenia pochodnych imidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF21 | tinidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AF55 | ekonazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AG | Pochodne triazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AG02 | terkonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX | Inne leki przeciwinfekcyjne i antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX01 | klodantoina | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX02 | inozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX03 | polikrezulen | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX05 | nifuratel | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX06 | furazolidon | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX09 | metylorozanilina | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX11 | powidon jodowany | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX12 | cyklopiroks | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX13 | protiofat | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX14 | lactobacillus | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX15 | miedzi usninian | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX16 | heksetydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX17 | dapiwiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | G01AX66 | oktenidyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G01B | LEKI PRZECIWINFEKCYJNE I ANTYSEPTYKI W POŁĄCZENIU Z KORTYKOSTEROIDAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | G01BA | Antybiotyki i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01BC | Pochodne chinoliny i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01BD | Antyseptyki i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01BE | Sulfonamidy i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | G01BF | Pochodne imidazolu i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | G02 | INNE LEKI STOSOWANE W GINEKOLOGII | WHO Anatomical Therapeutic Chemical classification
0‑L | G02A | LEKI PRZYSPIESZAJĄCE PORÓD | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AB | Alkaloidy sporyszu | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AB01 | metyloergometryna | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AB02 | alkaloidy sporyszu | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AB03 | ergometryna | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AC | Alkaloidy sporyszu i oksytocyna włącznie z analogami, w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AC01 | metyloergometryna i oksytocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AD | Prostaglandyny | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AD01 | dinoprost | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AD02 | dinoproston | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AD03 | gemeprost | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AD04 | karboprost | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AD05 | sulproston | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AD06 | mizoprostol | WHO Anatomical Therapeutic Chemical classification
0‑L | G02AX | Inne leki przyspieszające poród | WHO Anatomical Therapeutic Chemical classification
0‑L | G02B | ŚRODKI ANTYKONCEPCYJNE DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | G02BA | Środki antykoncepcyjne domaciczne | WHO Anatomical Therapeutic Chemical classification
0‑L | G02BA01 | wkładka domaciczna | WHO Anatomical Therapeutic Chemical classification
0‑L | G02BA02 | wkładka domaciczna zawierająca miedź | WHO Anatomical Therapeutic Chemical classification
0‑L | G02BA03 | wkładka domaciczna z progestagenem | WHO Anatomical Therapeutic Chemical classification
0‑L | G02BB | Dopochwowe środki antykoncepcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | G02BB01 | pierścień dopochwowy z progestagenem i estrogenem | WHO Anatomical Therapeutic Chemical classification
0‑L | G02BB02 | pierścień dopochwowy z progestagenem | WHO Anatomical Therapeutic Chemical classification
0‑L | G02C | INNE LEKI STOSOWANE W GINEKOLOGII | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CA | Sympatykomimetyki hamujące poród | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CA01 | rytodryna | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CA02 | bufenina | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CA03 | fenoterol | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CB | Inhibitory prolaktyny | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CB01 | bromokryptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CB02 | lizuryd | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CB03 | kabergolina | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CB04 | chinagolid | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CB05 | metergolina | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CB06 | terguryd | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CC | Dopochwowe leki przeciwzapalne | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CC01 | ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CC02 | naproksen | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CC03 | benzydamina | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CC04 | flunoksaprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CX | Inne leki stosowane w ginekologii | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CX01 | atozyban | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CX02 | flibanseryna | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CX03 | owoc niepokalanka pospolitego | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CX04 | kłącze pluskwicy groniastej | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CX05 | bremelanotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | G02CX06 | fezolinetant | WHO Anatomical Therapeutic Chemical classification
0‑L | G03 | HORMONY PŁCIOWE I MODULATORY UKŁADU PŁCIOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | G03A | HORMONALNE ŚRODKI ANTYKONCEPCYJNE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA | Progestageny i estrogeny, stałe połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA01 | etynodiol i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA02 | chingestanol i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA03 | linestrenol i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA04 | megestrol i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA05 | noretysteron i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA06 | norgestrel i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA07 | lewonorgestrel i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA08 | medroksyprogesteron i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA09 | dezogestrel i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA10 | gestoden i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA11 | norgestymat i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA12 | drospirenon i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA13 | norelgestromin i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA14 | nomegestrol i estradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA15 | chlormadynon i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA16 | dienogest i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA17 | medroksyprogesteron i estradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AA18 | drospirenon i estetrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB | Progestageny i estrogeny, preparaty sekwencyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB01 | megestrol i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB02 | linestrenol i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB03 | lewonorgestrel i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB04 | noretysteron i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB05 | dezogestrel i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB06 | gestoden i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB07 | chlormadynon i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB08 | dienogest i estradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AB09 | norgestymat i etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC | Progestageny | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC01 | noretysteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC02 | linestrenol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC03 | lewonorgestrel | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC04 | chingestanol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC05 | megestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC06 | medroksyprogesteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC07 | norgestrienon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC08 | etonogestrel | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC09 | dezogestrel | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AC10 | drospirenon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AD | Preparaty stosowane w antykoncepcji postkoitalnej | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AD01 | lewonorgestrel | WHO Anatomical Therapeutic Chemical classification
0‑L | G03AD02 | uliprystal | WHO Anatomical Therapeutic Chemical classification
0‑L | G03B | ANDROGENY | WHO Anatomical Therapeutic Chemical classification
0‑L | G03BA | pochodne 3-oksoandrostenu (4) | WHO Anatomical Therapeutic Chemical classification
0‑L | G03BA01 | fluoksymesteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03BA02 | metylotestosteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03BA03 | testosteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03BB | pochodne 5-androstanonu (3) | WHO Anatomical Therapeutic Chemical classification
0‑L | G03BB01 | mesterolon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03BB02 | androstanolon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03C | ESTROGENY | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA | Estrogeny naturalne i półsyntetyczne, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA01 | etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA03 | estradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA04 | estriol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA06 | chlorotrianizen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA07 | estron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA09 | promestrien | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA53 | estradiol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CA57 | estrogeny skoniugowane | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CB | Estrogeny syntetyczne, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CB01 | dienestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CB02 | dietylostylbestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CB03 | metalenestryl | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CB04 | moksestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CC | Estrogeny, połączenia z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CC02 | dienestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CC03 | metalenestryl | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CC04 | estron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CC05 | dietylostylbestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CC06 | estriol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CC07 | estrogeny skoniugowane i bazedoksyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CX | Inne estrogeny | WHO Anatomical Therapeutic Chemical classification
0‑L | G03CX01 | tybolon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03D | PROGESTAGENY | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DA | Pochodne pregnenu (4) | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DA01 | gestonoron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DA02 | medroksyprogesteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DA03 | hydroksyprogesteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DA04 | progesteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB | Pochodne pregnadienu | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB01 | dydrogesteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB02 | megestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB03 | medrogeston | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB04 | nomegestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB05 | demegeston | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB06 | chlormadynon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB07 | promegeston | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DB08 | dienogest | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DC | Pochodne estrenu | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DC01 | allilestrenol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DC02 | noretysteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DC03 | linestrenol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DC04 | etysteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DC06 | etynodiol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03DC31 | metyloestrenolon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03E | ANDROGENY I ŻEŃSKIE HORMONY PŁCIOWE W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | G03EA | Androgeny i estrogeny | WHO Anatomical Therapeutic Chemical classification
0‑L | G03EA01 | metylotestosteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03EA02 | testosteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03EA03 | prasteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03EB | Androgen, progestagen i estrogen w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | G03EK | Androgeny i żeńskie hormony płciowe w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | G03EK01 | metylotestosteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03F | PROGESTAGENY I ESTROGENY W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA | Progestageny i estrogeny, stałe połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA01 | noretysteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA02 | hydroksyprogesteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA03 | etysteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA04 | progesteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA05 | metylonortestosteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA06 | etynodiol i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA07 | linestrenol i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA08 | megestrol i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA09 | noretynodrel i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA10 | norgestrel i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA11 | lewonorgestrel i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA12 | medroksyprogesteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA13 | norgestymat i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA14 | dydrogesteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA15 | dienogest i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA16 | trimegeston i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FA17 | drospirenon i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB | Progestageny i estrogeny, preparaty sekwencyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB01 | norgestrel i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB02 | linestrenol i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB03 | chlormadynon i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB04 | megestrol i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB05 | noretysteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB06 | medroksyprogesteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB07 | medrogeston i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB08 | dydrogesteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB09 | lewonorgestrel i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB10 | dezogestrel i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB11 | trimegeston i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03FB12 | nomegestrol i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03G | GONADOTROPINY I INNE LEKI POBUDZAJĄCE OWULACJĘ | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA | Gonadotropiny | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA01 | gonadotropina kosmówkowa | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA02 | gonadotropina ludzka menopauzalna | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA03 | gonadotropina surowicy | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA04 | urofolitropina | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA05 | folitropina alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA06 | folitropina beta | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA07 | lutropina alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA08 | choriogonadotropina alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA09 | koryfolitropina alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA10 | folitropina delta | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GA30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GB | Leki pobudzjące owulację, syntetyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GB01 | cyklofenil | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GB02 | klomifen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03GB03 | epimestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03H | ANTYANDROGENY | WHO Anatomical Therapeutic Chemical classification
0‑L | G03HA | Antyandrogeny, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | G03HA01 | cyproteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G03HB | Antyandrogeny i estrogeny | WHO Anatomical Therapeutic Chemical classification
0‑L | G03HB01 | cyproteron i estrogen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03X | INNE HORMONY PŁCIOWE I MODULATORY UKŁADU PŁCIOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XA | Antygonadotropiny i związki podobne | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XA01 | danazol | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XA02 | gestrinon | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XB | Modulatory receptora progesteronowego | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XB01 | mifepryston | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XB02 | uliprystal | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XB51 | mifepryston, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XC | Selektywne modulatory receptora estrogenowego | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XC01 | raloksyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XC02 | bazedoksyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XC03 | lazofoksyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XC04 | ormeloksyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XC05 | ospemifen | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XX | Inne hormony płciowe i modulatory układu płciowego | WHO Anatomical Therapeutic Chemical classification
0‑L | G03XX01 | prasteron | WHO Anatomical Therapeutic Chemical classification
0‑L | G04 | LEKI UROLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | G04B | LEKI UROLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BA | Leki zakwaszające | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BA01 | amo chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BA03 | wapnia chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BC | Leki rozpuszczające złogi | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD | Leki stosowane w częstomoczu i w nietrzymaniu moczu | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD01 | emepronium | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD02 | flawoksat | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD03 | meladrazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD04 | oksybutynina | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD05 | terodylina | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD06 | propiweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD07 | tolterodyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD08 | solifenacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD09 | trospium | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD10 | daryfenacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD11 | fezoterodyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD12 | mirabegron | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD13 | desfezoterodyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD14 | imidafenacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BD15 | wibegron | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE | Leki stosowane w zaburzeniach erekcji | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE01 | alprostadyl | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE02 | papaweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE03 | syldenafil | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE04 | johimbina | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE06 | moksysylit | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE07 | apomorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE08 | tadalafil | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE09 | wardenafil | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE10 | awanafil | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE11 | udenafil | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BE52 | papaweryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX | Inne leki urologiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX01 | magnezu wodorotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX03 | kwas acetohydroksamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX06 | fenazopirydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX10 | sukcynimid | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX11 | kolagen | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX12 | fenylu salicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX13 | dimetylosulfotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX14 | dapoksetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX15 | sodu pentozanu polisiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX16 | tiopronina | WHO Anatomical Therapeutic Chemical classification
0‑L | G04BX17 | salicylan sodu i metenamina | WHO Anatomical Therapeutic Chemical classification
0‑L | G04C | LEKI STOSOWANE W ŁAGODNYM ROZROŚCIE GRUCZOŁU KROKOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA | Antagoniści receptora alfa-adrenergicznego | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA01 | alfuzosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA02 | tamsulosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA03 | terazosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA04 | sylodosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA51 | alfuzosyna i finasteryd | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA52 | tamsulosyna i dutasteryd | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA53 | tamsulosyna i solifenacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA54 | tamsulozyna i tadalafil | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CA55 | doksazosyna i finasteryd | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CB | Inhibitory 5-alfa reduktazy testosteronu | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CB01 | finasteryd | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CB02 | dutasteryd | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CB51 | finasteryd i tadalafil | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CX | Inne leki stosowane w łagodnym rozroście gruczołu krokowego | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CX01 | Kora śliwy afrykańskiej | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CX02 | Owoc palmy sabal | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CX03 | mepartrycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | G04CX04 | feksapotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H | LEKI HORMONALNE DO STOSOWANIA OGÓLNEGO, Z WYŁĄCZENIEM HORMONÓW PŁCIOWYCH I INSULIN | WHO Anatomical Therapeutic Chemical classification
0‑L | H01 | HORMONY PRZYSADKI I PODWZGÓRZA I ANALOGI | WHO Anatomical Therapeutic Chemical classification
0‑L | H01A | HORMONY PRZEDNIEGO PŁATA PRZYSADKI I ANALOGI | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AA | ACTH (Adrenokortykotropina) | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AA01 | kortykotropina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AA02 | tetrakozaktyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AB | Tyreotropina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AB01 | tyreotropina alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC | Somatropina i agoniści somatropiny | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC01 | somatropina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC02 | somatrem | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC03 | mekasermina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC04 | sermorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC05 | rinfabat mekaserminy | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC06 | tesamorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC07 | somapacytan | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC08 | somatrogon | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AC09 | lonapegsomatropina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AX | Inne hormony przedniego płata przysadki i analogów | WHO Anatomical Therapeutic Chemical classification
0‑L | H01AX01 | pegwisomant | WHO Anatomical Therapeutic Chemical classification
0‑L | H01B | HORMONY TYLNEGO PŁATA PRZYSADKI | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BA | Wazopresyna i analogi | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BA01 | wazopresyna (argipresyna) | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BA02 | desmopresyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BA03 | lipresyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BA04 | terlipresyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BA05 | ornipresyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BB | Oksytocyna i analogi | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BB01 | demoksytocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BB02 | oksytocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01BB03 | karbetocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01C | HORMONY PODWZGÓRZA | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CA | Hormony uwalniające gonadotropinę | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CA01 | gonadorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CA02 | nafarelina | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CB | Somatostatyna i analogi | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CB01 | somatostatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CB02 | oktreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CB03 | lanreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CB04 | wapreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CB05 | pasyreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CC | Hormony uwalniające antygonadotropinę | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CC01 | ganireliks | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CC02 | cetroreliks | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CC03 | elagoliks | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CC04 | linzagoliks | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CC53 | elagoliks, estradiol i noretysteron | WHO Anatomical Therapeutic Chemical classification
0‑L | H01CC54 | relugoliks, estradiol i noretysteron | WHO Anatomical Therapeutic Chemical classification
0‑L | H02 | KORTYKOSTEROIDY DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | H02A | KORTYKOSTEROIDY DO STOSOWANIA OGÓLNEGO, BEZ DODATKÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AA | Mineralokortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AA01 | aldosteron | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AA02 | fludrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AA03 | dezoksykorton | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB | Glikokortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB01 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB02 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB03 | fluokortolon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB04 | metyloprednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB05 | parametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB06 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB07 | prednizon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB08 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB09 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB10 | kortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB11 | prednyliden | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB12 | rymeksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB13 | deflazakort | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB14 | kloprednol | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB15 | meprednizon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB17 | kortywazol | WHO Anatomical Therapeutic Chemical classification
0‑L | H02AB18 | wamorolon | WHO Anatomical Therapeutic Chemical classification
0‑L | H02B | KORTYKOSTEROIDY DO STOSOWANIA OGÓLNEGO, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | H02BX | Kortykosteroidy do stosowania ogólnego, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | H02BX01 | metyloprednizolon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | H02C | LEKI PRZECIWNADNERCZOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | H02CA | Antykortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | H02CA01 | trilostan | WHO Anatomical Therapeutic Chemical classification
0‑L | H02CA02 | osylodrostat | WHO Anatomical Therapeutic Chemical classification
0‑L | H02CA03 | ketokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | H02CA04 | lewoketokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | H03 | LEKI STOSOWANE W CHOROBACH TARCZYCY | WHO Anatomical Therapeutic Chemical classification
0‑L | H03A | LEKI ZAWIERAJĄCE HORMONY TARCZYCY | WHO Anatomical Therapeutic Chemical classification
0‑L | H03AA | Hormony tarczycy | WHO Anatomical Therapeutic Chemical classification
0‑L | H03AA01 | lewotyroksyna sodowa | WHO Anatomical Therapeutic Chemical classification
0‑L | H03AA02 | liotyronina sodowa | WHO Anatomical Therapeutic Chemical classification
0‑L | H03AA03 | połączenia lewotyroksyny i liotyroniny | WHO Anatomical Therapeutic Chemical classification
0‑L | H03AA04 | tyratrykol | WHO Anatomical Therapeutic Chemical classification
0‑L | H03AA05 | preparaty gruczołu tarczycowego | WHO Anatomical Therapeutic Chemical classification
0‑L | H03AA51 | sól sodowa lewotyroksyny i związki jodu | WHO Anatomical Therapeutic Chemical classification
0‑L | H03B | LEKI PRZECIWTARCZYCOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BA | Tiouracyle | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BA01 | metylotiouracyl | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BA02 | propylotiouracyl | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BA03 | benzylotiouracyl | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BB | Pochodne imidazolu zawierające siarkę | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BB01 | karbimazol | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BB02 | tiamazol | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BB52 | tiamazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BC | Nadchlorany | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BC01 | potasu nadchloran | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BX | Inne leki przeciwtarczycowe | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BX01 | dijodotyrozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H03BX02 | dibromotyrozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | H03C | LECZENIE JODEM | WHO Anatomical Therapeutic Chemical classification
0‑L | H03CA | Leczenie jodem | WHO Anatomical Therapeutic Chemical classification
0‑L | H04 | HORMONY TRZUSTKI | WHO Anatomical Therapeutic Chemical classification
0‑L | H04A | HORMONY GLIKOGENOLITYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | H04AA | Hormony glikogenolityczne | WHO Anatomical Therapeutic Chemical classification
0‑L | H04AA01 | glukagon | WHO Anatomical Therapeutic Chemical classification
0‑L | H04AA02 | dasiglukagon | WHO Anatomical Therapeutic Chemical classification
0‑L | H05 | LEKI WPŁYWAJĄCE NA HOMEOSTAZĘ WAPNIA | WHO Anatomical Therapeutic Chemical classification
0‑L | H05A | HORMONY PRZYTARCZYC I ANALOGI | WHO Anatomical Therapeutic Chemical classification
0‑L | H05AA | Hormony przytarczyc i analogi | WHO Anatomical Therapeutic Chemical classification
0‑L | H05AA01 | wyciąg z gruczołów przytarczycznych | WHO Anatomical Therapeutic Chemical classification
0‑L | H05AA02 | teryparatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H05AA03 | hormon przytarczycowy | WHO Anatomical Therapeutic Chemical classification
0‑L | H05AA04 | abaloparatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H05AA05 | palopegteryparatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H05B | HORMONY PRZECIWPRZYTARCZYCOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BA | Preparaty kalcytoniny | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BA01 | kalcytonina łososiowa syntetyczna | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BA02 | kalcytonina wieprzowa naturalna | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BA03 | kalcytonina ludzka syntetyczna | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BA04 | elkatonina | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BX | Inne hormony przeciwprzytarczycowe | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BX01 | cynakalcet | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BX02 | parykalcytol | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BX03 | dokserkalcyferol | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BX04 | etelkalcetyd | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BX05 | kalcyfediol | WHO Anatomical Therapeutic Chemical classification
0‑L | H05BX06 | ewokalcet | WHO Anatomical Therapeutic Chemical classification
0‑L | J | LEKI PRZECIWINFEKCYJNE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | J01 | LEKI PRZECIWBAKTERYJNE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | J01A | TETRACYKLINY | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA | Tetracykliny | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA01 | demeklocyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA02 | doksycyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA03 | chlorotetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA04 | limecyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA05 | metacyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA06 | oksytetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA07 | tetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA08 | minocyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA09 | rolitetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA10 | penimepicyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA11 | klomocyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA12 | tygecyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA13 | erawacyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA14 | sarecyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA15 | omadacyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA20 | połączenia tetracyklin | WHO Anatomical Therapeutic Chemical classification
0‑L | J01AA56 | oksytetracyklina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01B | AMFENIKOLE | WHO Anatomical Therapeutic Chemical classification
0‑L | J01BA | Amfenikole | WHO Anatomical Therapeutic Chemical classification
0‑L | J01BA01 | chloramfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01BA02 | tiamfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01BA52 | tiamfenikol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01C | BETA-LAKTAMOWE LEKI PRZECIWBAKTERYJNE, PENICYLINY | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA | Penicyliny o szerokim spektrum działania | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA01 | ampicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA02 | piwampicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA03 | karbenicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA04 | amoksycylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA05 | karindacylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA06 | bakampicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA07 | epicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA08 | piwmecylinam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA09 | azlocylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA10 | mezlocylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA11 | mecylinam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA12 | piperacylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA13 | tykarcylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA14 | metampicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA15 | talampicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA16 | sulbenicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA17 | temocylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA18 | hetacylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA19 | aspoksycylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CA51 | ampicylina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE | Penicyliny wrażliwe na beta-laktamazę | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE01 | benzylopenicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE02 | fenoksymetylopenicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE03 | propycylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE04 | azydocylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE05 | fenetycylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE06 | penamecylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE07 | klometocylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE08 | benzylopenicylina benzatynowa | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE09 | benzylopenicylina prokainowa | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE10 | fenoksymetylopenicylina benzatynowa | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CE30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CF | Penicyliny oporne na beta-laktamazę | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CF01 | dikloksacylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CF02 | kloksacylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CF03 | metycylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CF04 | oksacylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CF05 | flukloksacylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CF06 | nafcylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CG | Inhibitory beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CG01 | sulbaktam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CG02 | tazobaktam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CR | Połączenia penicylin, włącznie z inhibitorami beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CR01 | ampicylina i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CR02 | amoksycylina i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CR03 | tykarcylina i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CR04 | sultamycylina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CR05 | piperacylina i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01CR50 | połączenia penicylin | WHO Anatomical Therapeutic Chemical classification
0‑L | J01D | INNE BETA-LAKTAMOWE LEKI PRZECIWBAKTERYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB | Cefalosporyny I generacji | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB01 | cefaleksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB02 | cefalorydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB03 | cefalotyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB04 | cefazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB05 | cefadroksyl | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB06 | cefazedon | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB07 | cefatryzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB08 | cefapiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB09 | cefradyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB10 | cefacetryl | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB11 | cefroksadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DB12 | ceftezol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC | Cefalosporyny II generacji | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC01 | cefoksytyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC02 | cefuroksym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC03 | cefamandol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC04 | cefaklor | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC05 | cefotetan | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC06 | cefonicyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC07 | cefotiam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC08 | lorakarbef | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC09 | cefmetazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC10 | cefprozyl | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC11 | ceforanid | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC12 | cefminoks | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC13 | cefbuperazon | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC14 | flomoksef | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DC52 | cefuroksym i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD | Cefalosporyny III generacji | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD01 | cefotaksym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD02 | ceftazydym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD03 | cefsulodyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD04 | ceftriakson | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD05 | cefmenoksym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD06 | latamoksef | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD07 | ceftyzoksym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD08 | cefiksym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD09 | cefodyzym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD10 | cefetamet | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD11 | cefpiramid | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD12 | cefoperazon | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD13 | cefpodoksym | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD14 | ceftibuten | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD15 | cefdynir | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD16 | cefditoren | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD17 | cefkapen | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD18 | cefteram | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD51 | cefotaksym i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD52 | ceftazydym i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD54 | ceftriakson, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD58 | cefiksym i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD62 | cefoperazon i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD63 | ceftriakson i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DD64 | cefpodoksym i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DE | Cefalosporyny IV generacji | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DE01 | cefepim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DE02 | cefpirom | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DE03 | cefozopran | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DE51 | cefepim i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DF | Monobaktamy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DF01 | aztreonam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DF02 | karumonam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH | Karbapenemy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH02 | meropenem | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH03 | ertapenem | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH04 | doripenem | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH05 | biapenem | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH06 | tebipenem piwoksyl | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH51 | imipenem i cylastatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH52 | meropenem i waborbaktam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH55 | panipenem i betamipron | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DH56 | imipenem, cylastatyna i relebaktam | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DI | Inne cefalosporyny i penemy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DI01 | ceftobiprol medokaril | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DI02 | ceftarolina fosamil | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DI03 | faropenem | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DI04 | cefiderokol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01DI54 | ceftolozan i inhibitor beta-laktamazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01E | SULFONAMIDY I TRIMETOPRIM | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EA | Trimetoprim i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EA01 | trimetoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EA02 | bromidoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EA03 | iklaprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB | Sulfonamidy krótko działające | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB01 | sulfaizodymidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB02 | sulfametyzol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB03 | sulfadymidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB04 | sulfapirydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB05 | sulfafurazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB06 | sulfanilamid | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB07 | sulfatiazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB08 | sulfatiomocznik | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EB20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EC | Sulfonamidy o średnim czasie działania | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EC01 | sulfametoksazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EC02 | sulfadiazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EC03 | sulfamoksol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EC20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED | Sulfonamidy długo działające | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED01 | sulfadimetoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED02 | sulfalen | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED03 | sulfametomidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED04 | sulfametoksydiazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED05 | sulfametoksypirydazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED06 | sulfaperyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED07 | sulfamerazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED08 | sulfafenazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED09 | sulfamazon | WHO Anatomical Therapeutic Chemical classification
0‑L | J01ED20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE | Połączenia sulfonamidów i trimetoprimu, włącznie z pochodnymi | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE01 | sulfametoksazol i trimetoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE02 | sulfadiazyna i trimetoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE03 | sulfametrol i trimetoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE04 | sulfamoksol i trimetoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE05 | sulfadymidyna i trimetoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE06 | sulfadiazyna i tetroksoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01EE07 | sulfamerazyna i trimetoprim | WHO Anatomical Therapeutic Chemical classification
0‑L | J01F | MAKROLIDY, LINKOZAMIDY I STREPTOGRAMINY | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA | Makrolidy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA01 | erytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA02 | spiramycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA03 | midekamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA05 | oleandomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA06 | roksytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA07 | jozamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA08 | troleandomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA09 | klarytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA10 | azytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA11 | miokamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA12 | rokitamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA13 | dirytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA14 | flurytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA15 | telitromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FA16 | solitromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FF | Linkozamidy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FF01 | klindamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FF02 | linkomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FG | Streptograminy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FG01 | prystynamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01FG02 | chinuprystyna/dalfoprystyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01G | AMINOGLIKOZYDY | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GA | Streptomycyny | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GA01 | streptomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GA02 | streptoduocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB | Inne aminoglikozydy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB01 | tobramycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB03 | gentamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB04 | kanamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB05 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB06 | amikacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB07 | netylmycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB08 | sysomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB09 | dibekacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB10 | rybostamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB11 | izepamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB12 | arbekacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB13 | bekanamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01GB14 | plazomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01M | CHINOLONY | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA | Fluorochinolony | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA01 | ofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA02 | cyprofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA03 | pefloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA04 | enoksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA05 | temafloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA06 | norfloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA07 | lomefloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA08 | fleroksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA09 | sparfloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA10 | rufloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA11 | grepafloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA12 | lewofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA13 | trowafloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA14 | moksyfloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA15 | gemifloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA16 | gatifloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA17 | prulifloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA18 | pazufloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA19 | garenoksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA21 | sytafloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA22 | tozufloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA23 | delafloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA24 | lewonadifloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MA25 | laskufloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB | Inne chinolony | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB01 | rozoksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB02 | kwas nalidyksowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB03 | kwas piromidowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB04 | kwas pipemidowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB05 | kwas oksoli | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB06 | cynoksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB07 | flumechina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01MB08 | nemonoksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01R | POŁĄCZENIA LEKÓW PRZECIWBAKTERYJNYCH | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA | Połączenia leków przeciwbakteryjnych | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA01 | penicyliny, połączenia z innymi lekami przeciwbakteryjnymi | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA02 | sulfonamidy, połączenia z innymi lekami przeciwbakteryjnymi (z wyłączeniem trimetoprimu) | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA03 | cefuroksym i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA04 | spiramycyna i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA05 | lewofloksacyna i ornidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA06 | cefepim i amikacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA07 | azytromycyna, flukonazol i seknidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA08 | tetracyklina i oleandomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA09 | ofloksacyna i ornidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA10 | cyprofloksacyna i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA11 | cyprofloksacyna i tynidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA12 | cyprofloksacyna i ornidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA13 | norfloksacyna i tynidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA14 | norfloksacyna i metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA15 | cefiksym i ornidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01RA16 | cefyksym i azytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01X | INNE LEKI PRZECIWBAKTERYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XA | Glikopeptydy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XA01 | wankomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XA02 | teikoplanina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XA03 | telawancyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XA04 | dalbawancyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XA05 | orytawancyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XB | Polimyksyny | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XB01 | kolistyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XB02 | polimyksyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XC | Steroidowe leki przeciwbakteryjne | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XC01 | kwas fusydy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XD | Pochodne imidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XD01 | metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XD02 | tynidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XD03 | ornidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XE | Pochodne nitrofuranu | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XE01 | nitrofurantoina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XE02 | nifurtoinol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XE03 | furazydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XE51 | nitrofurantoina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX | Inne leki przeciwbakteryjne | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX01 | fosfomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX02 | ksybornol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX03 | klofoktol | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX04 | spektynomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX05 | metenamina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX06 | kwas migdałowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX07 | nitroksolina | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX08 | linezolid | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX09 | daptomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX10 | bacytracyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX11 | tedyzolid | WHO Anatomical Therapeutic Chemical classification
0‑L | J01XX12 | lefamulina | WHO Anatomical Therapeutic Chemical classification
0‑L | J02 | LEKI PRZECIWGRZYBICZE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | J02A | LEKI PRZECIWGRZYBICZE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AA | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AA01 | amfoterycyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AA02 | hachimycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AB | Pochodne imidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AB01 | mikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AB02 | ketokonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AC | Pochodne triazolu i tetrazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AC01 | flukonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AC02 | itrakonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AC03 | worykonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AC04 | posakonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AC05 | izawukonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AC06 | otesekonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AX | Inne leki przeciwgrzybicze do stosowania ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AX01 | flucytozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AX04 | kaspofungina | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AX05 | mykafungina | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AX06 | anidulafungina | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AX07 | ibreksafungerp | WHO Anatomical Therapeutic Chemical classification
0‑L | J02AX08 | octan rezafunginy | WHO Anatomical Therapeutic Chemical classification
0‑L | J04 | Leki przeciwprątkowe | WHO Anatomical Therapeutic Chemical classification
0‑L | J04A | Leki stosowane w leczeniu gruźlicy | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AA | Kwas aminosalicylowy i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AA01 | kwas 4-aminosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AA02 | sodu aminosalicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AA03 | wapnia aminosalicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB01 | cykloseryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB02 | ryfampicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB03 | ryfamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB04 | ryfabutyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB05 | ryfapentyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB06 | enwiomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AB30 | kapreomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AC | Hydrazydy | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AC01 | izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AC51 | izoniazyd, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AD | Pochodne tiomocznika | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AD01 | protionamid | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AD02 | tiokarlid | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AD03 | etionamid | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK | Inne leki stosowane w leczeniu gruźlicy | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK01 | pirazynamid | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK02 | etambutol | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK03 | teryzydon | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK04 | morynamid | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK05 | bedakilina | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK06 | delamanid | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK07 | tioacetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AK08 | pretomanid | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM | Leki stosowane w leczeniu gruźlicy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM01 | streptomycyna i izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM02 | ryfampicyna i izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM03 | etambutol i izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM04 | tioacetazon i izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM05 | ryfampicyna, pirazynamid i izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM06 | ryfampicyna, pirazynamid, etambutol i izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM07 | ryfampicyna, etambutol i izoniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J04AM08 | izoniazyd, sulfametoksazol, trimetoprim i pirydoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04B | LEKI STOSOWANE W LECZENIU TRĄDU | WHO Anatomical Therapeutic Chemical classification
0‑L | J04BA | Leki stosowane w leczeniu trądu | WHO Anatomical Therapeutic Chemical classification
0‑L | J04BA01 | klofazymina | WHO Anatomical Therapeutic Chemical classification
0‑L | J04BA02 | dapson | WHO Anatomical Therapeutic Chemical classification
0‑L | J04BA03 | aldesulfon sodowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J04BA50 | dapson i ryfampicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J04BA51 | dapson, ryfampicyna i klofazymina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05 | LEKI PRZECIWWIRUSOWE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | J05A | LEKI O BEZPOŚREDNIM DZIAŁANIU PRZECIWWIRUSOWYM | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AA | Tiosemikarbazony | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AA01 | metysazon | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB | Nukleozydy i nukleotydy z wyłączeniem inhibitorów odwrotnej transkryptazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB01 | acyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB02 | idoksurydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB03 | widarabina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB06 | gancyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB09 | famcyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB11 | walacyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB12 | cydofowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB13 | pencyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB14 | walgancyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB15 | brywudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB16 | remdesiwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB17 | brincydofowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AB18 | molnupirawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AC | Cykliczne aminy | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AC02 | rymantadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AC03 | tromantadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AD | Pochodne kwasu fosfonowego | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AD01 | foskarnet | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AD02 | fosfonet | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE | Inhibitory proteazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE01 | sakwinawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE02 | indynawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE03 | rytonawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE04 | nelfinawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE05 | amprenawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE07 | fozamprenawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE08 | atazanawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE09 | typranawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE10 | darunawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE16 | enzytrelwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AE30 | nirmatrelwir i rytonawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF | Nukleozydy i nukleotydy – inhibitory odwrotnej transkryptazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF01 | zydowudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF02 | didanozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF03 | zalcytabina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF04 | stawudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF05 | lamiwudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF06 | abakawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF07 | tenofowir dizoproksyl | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF08 | adefowir dipiwoksyl | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF09 | emtrycytabina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF10 | entekawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF11 | telbiwudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF12 | klewudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AF13 | tenofowir alafenamid | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AG | Nienukleozydowe inhibitory odwrotnej transkryptazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AG01 | newirapina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AG02 | delawirdyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AG03 | efawirenz | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AG04 | etrawiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AG05 | rilpiwiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AG06 | dorawiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AH | Inhibitory neuraminidazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AH01 | zanamiwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AH02 | oseltamiwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AH03 | peramiwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AH04 | laninamiwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AJ | Inhibitory integrazy | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AJ01 | raltegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AJ02 | elwitegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AJ03 | dolutegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AJ04 | kabotagrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP | Leki przeciwwirusowe stosowane w leczeniu zakażeń HCV | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP01 | rybawiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP02 | telaprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP03 | boceprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP04 | faldaprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP05 | symeprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP06 | azunaprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP07 | daklataswir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP08 | sofosbuwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP09 | dazabuwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP10 | elbaswir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP11 | grazoprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP12 | koblopaswir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP13 | rawidaswir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP51 | sofosbuwir i ledypaswir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP52 | dazabuwir, ombitaswir, parytaprewir i rytonawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP53 | ombitaswir, parytaprewir i rytonawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP54 | elbaswir i grazoprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP55 | sofosbuwir i welpataswir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP56 | sofosbuwir, welpataswir i woksylaprewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP57 | glekaprewir i pibrentaswir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AP58 | daklataswir, azunaprewir i beklabuwir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR | Leki przeciwwirusowe stosowanie w leczeniu zakażenia HIV, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR01 | zydowudyna i lamiwudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR02 | lamiwudyna i abakawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR03 | tenofowir dizoproksyl i emtrycytabina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR04 | zydowudyna, lamiwudyna i abakawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR05 | zydowudyna, lamiwudyna i newirapina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR06 | emtrycytabina, tenofowir dizoproksyl i efawirenz | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR07 | stawudyna, lamiwudyna i newirapina | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR08 | emtrycytabina, tenofowir dizoproksyl i rylpiwiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR09 | emtrycytabina, tenofowir dizoproksyl, elwitegrawir i kobicystat | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR10 | lopinawir i rytonawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR11 | lamiwudyna, tenofowir dizoproksyl i efawirenz | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR12 | lamiwudyna i tenofowir dizoproksyl | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR13 | lamiwudyna, abakawir i dolutegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR14 | darunawir i kobicystat | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR15 | atazanawir i kobicystat | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR16 | lamiwudyna i raltegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR17 | emtrycytabina i tenofowir alafenamid | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR18 | emtrycytabina, tenofowir alafenamid, elwitegrawir i kobicystat | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR19 | emtrycytabina, tenofowir alafenamid i rylpiwiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR20 | emtrycytabina, tenofowir alafenamid i biktegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR21 | dolutegrawir i rylpiwiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR22 | emtrycytabina, tenofowir alafenamid, darunawir i kobicystat | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR23 | atazanawir i rytonawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR24 | lamiwudyna, tenofowir dizoproksyl i dorawiryna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR25 | lamiwudyna i dolutegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR26 | darunawir i rytonawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR27 | lamiwudyna, tenofowir, dizoproksyl i dolutegrawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AR28 | stawudyna i lamiwudyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX | Inne leki przeciwwirusowe | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX01 | moroksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX02 | lizozym | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX05 | inozyna pranobeks | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX06 | plekonaryl | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX07 | enfuwirtyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX09 | marawirok | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX10 | maribawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX13 | umifenowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX17 | enizaminy jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX18 | letermowir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX19 | tyloron | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX21 | kwas pentanediowy imidazoliloetanamidu | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX23 | ibalizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX24 | tekowirymat | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX25 | baloksawir marboksyl | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX26 | amenamewir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX27 | fawipirawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX28 | bulowirtyd | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX29 | fostemsawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J05AX31 | lenakapawir | WHO Anatomical Therapeutic Chemical classification
0‑L | J06 | SUROWICE ODPORNOŚCIOWE I IMMUNOGLOBULINY | WHO Anatomical Therapeutic Chemical classification
0‑L | J06A | SUROWICE ODPORNOŚCIOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | J06AA | Surowice odpornościowe | WHO Anatomical Therapeutic Chemical classification
0‑L | J06AA01 | antytoksyna błonicza | WHO Anatomical Therapeutic Chemical classification
0‑L | J06AA02 | antytoksyna tężcowa | WHO Anatomical Therapeutic Chemical classification
0‑L | J06AA03 | antytoksyna jadu węży | WHO Anatomical Therapeutic Chemical classification
0‑L | J06AA04 | antytoksyna botulinowa | WHO Anatomical Therapeutic Chemical classification
0‑L | J06AA05 | surowica przeciw zgorzeli gazowej | WHO Anatomical Therapeutic Chemical classification
0‑L | J06AA06 | surowica przeciw wściekliźnie | WHO Anatomical Therapeutic Chemical classification
0‑L | J06B | IMMUNOGLOBULINY | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BA | Immunoglobiliny ludzkie normalne | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BA01 | immoglobuliny ludzkie normalne do podania pozanaczyniowego | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BA02 | immoglobuliny ludzkie normalne do podania naczyniowego | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB | Immunoglobuliny swoiste | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB01 | immunoglobulina anty-D (Rh) | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB02 | immunoglobulina przeciw tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB03 | immunoglobulina przeciw ospie i półpaścowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB04 | immunoglobulina przeciw wirusowemu zapalniu wątroby typu B | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB05 | immunoglobulina przeciw wściekliznie | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB06 | immunoglobulina przeciw różyczce | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB07 | immunoglobulina przeciw wirusowi krowianki | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB08 | immunoglobulina przeciwgronkowcowa | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB09 | immunoglobulina przeciw wirusowi cytomegalii | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB10 | immunoglobulina przeciw błonicy | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB11 | immunoglobulina przeciw wirusowemu zapaleniu wątroby typu A | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB12 | immunoglobulina przeciw kleszczowemu zapaleniu mózgu | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB13 | immunoglobulina przeciw krztuścowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB14 | immunoglobulina przeciw odrze | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB15 | immunoglobulina przeciw śwince | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB19 | immunoglobulina przeciw wąglikowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BB30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BC | Przeciwbakteryjne przeciwciała monoklonalne | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BC01 | nebakumab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BC02 | raksybakumab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BC03 | bezlotoksumab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BC04 | obiltoksaksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD | Przeciwwirusowe przeciwciała monoklonalne | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD01 | paliwizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD02 | motawizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD03 | tiksagewymab i cilgawymab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD04 | ansuwimab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD05 | sotrowimab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD06 | regdanwimab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD07 | kasiriwimab i imdewimab | WHO Anatomical Therapeutic Chemical classification
0‑L | J06BD08 | nirsewimab | WHO Anatomical Therapeutic Chemical classification
0‑L | J07 | SZCZEPIONKI | WHO Anatomical Therapeutic Chemical classification
0‑L | J07A | SZCZEPIONKI PRZECIWBAKTERYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AC | Szczepionki przeciw wąglikowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AC01 | antygen wąglikowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AD | Szczepionki przeciw brucelozie | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AD01 | antygen brucelozy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AE | Szczepionki przeciw cholerze | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AE01 | szczepionka przeciw cholerze, inaktywowana, całe komórki | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AE02 | szczepionka przeciw cholerze, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AE51 | szczepionka przeciw cholerze w połączeniach ze szczepionką przeciw durowi brzusznemu, inaktywowana, całe komórki | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AF | Szczepionki przeciw błonicy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AF01 | toksoid błoniczy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AG | Szczepionki przeciw haemophilus typ b | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AG01 | szczepionka przeciw haemophilus typ b, oczyszczony antygen, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AG51 | szczepionka przeciw haemophilus typ b, połączenia z toksoidami | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AG52 | szczepionka przeciw haemophilus typ b, połączenia ze szczepionką przeciw krztuścowi i toksoidami | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AG53 | szczepionka przeciw haemophilus typ b, połączenia ze szczepionką meningokokową grupy C, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AG54 | szczepionka przeciw haemophilus typ b, połączenia ze szczepionką meningokokową grupy C,Y, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH | Szczepionki meningokokowe | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH01 | szczepionka meningokokowa grupy A, oczyszczony antygen polisacharydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH02 | inne szczepionki meningokokowe monowalentne, oczyszczony antygen polisacharydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH03 | szczepionka meningokokowa grupy A,C, dwuwalentna, oczyszczony antygen polisacharydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH04 | szczepionka meningokokowa grupy A,C,Y,W-135, czterowalentna, oczyszczony antygen polisacharydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH05 | inne szczepionki meningokokowe, poliwalentne, oczyszczony antygen polisacharydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH06 | szczepionka meningokokowa grupy B, antygen pęcherzyków zewnątrzbłoch | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH07 | szczepionka meningokokowa grupy C, oczyszczony antygen polisacharydowy, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH08 | szczepionka meningokokowa grupy A,C,Y,W-135, czterowalentna, oczyszczony antygen polisacharydowy, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH09 | szczepionka meningokokowa grupy B, poliwalentna | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AH10 | szczepionka meningokokowa grupy A, oczyszczony antygen polisacharydowy, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AJ | Szczepionki przeciw krztuścowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AJ01 | szczepionka przeciw krztuścowi, inaktywowana, całe komórki | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AJ02 | szczepionka przeciw krztuścowi, oczyszczony antygen | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AJ51 | szczepionka przeciw krztuścowi, połączenia z toksoidami, inaktywowana, całe komórki | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AJ52 | szczepionka przeciw krztuścowi, połączenia z toksoidami, oczyszczony antygen | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AK | Szczepionki przeciw dżumie | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AK01 | szczepionka przeciw dżumie, inaktywowana, całe komórki | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AL | Szczepionki przeciwpneumokokowe | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AL01 | szczepionka przeciw pneumokokom, oczyszczony antygen polisacharydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AL02 | szczepionka przeciw pneumokokom, oczyszczony antygen polisacharydowy, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AL52 | szczepionka przeciw pneumokokom, oczyszczony antygen polisacharydowy i przeciw haemophilus influenzae, skoniugowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AM | Szczepionki przeciw tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AM01 | toksoid tężcowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AM51 | toksid tężcowy, połączenia z toksoidem błoniczym | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AM52 | toksid tężcowy, połączenia z immunoglobulinami przeciwtężcowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AN | Szczepionki przeciw gruźlicy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AN01 | szczepionka przeciw gruźlicy, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AP | Szczepionki przeciw durowi brzusznemu | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AP01 | szczepionka przeciw durowi brzusznemu, doustna, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AP02 | szczepionka przeciw durowi brzusznemu, inaktywowana, całe komórki | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AP03 | szczepionka przeciw durowi brzusznemu, oczyszczony antygen polisacharydowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AP10 | szczepionki przeciw durowi brzusznemu, połączenia ze szczepionkami przeciw durowi rzekomemu | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AR | Szczepionki przeciw durowi plamistemu | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AR01 | szczepionka przeciw durowi plamistemu , inaktywowana, całe komórki | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AX | Inne szczepionki przeciwbakteryjne | WHO Anatomical Therapeutic Chemical classification
0‑L | J07AX01 | szczepionki przeciw leptospirze | WHO Anatomical Therapeutic Chemical classification
0‑L | J07B | Szczepionki przeciwwirusowe | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BA | Szczepionki przeciw wirusowemu zapaleniu mózgu | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BA01 | szczepionka przeciw kleszczowemu zapaleniu mózgu, inaktywowana, cały wirion | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BA02 | szczepionka przeciw japońskiemu zapaleniu mózgu, inaktywowana, cały wirion | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BA03 | szczepionka przeciw japońskiemu zapaleniu mózgu, żywa, atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BB | Szczepionki przeciw grypie | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BB01 | szczepionka przeciw grypie, inaktywowana, cały wirion | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BB02 | szczepionka przeciw grypie, inaktywowana, rozszczepiony wirion lub antygen powierzchniowy | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BB03 | szczepionka przeciw grypie, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BB04 | grypa, cząsteczki wirusopodobne | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BC | Szczepionki przeciw wirusowemu zapaleniu wątroby | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BC01 | szczepionka przeciw wirusowemu zapaleniu wątroby typu B, oczyszczony antygen | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BC02 | szczepionka przeciw wirusowemu zapaleniu wątroby typu A, inaktywowana cały wirion | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BC20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BD | Szczepionki przeciw odrze | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BD01 | szczepionka przeciw odrze, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BD51 | szczepionka przeciw odrze, połączenia ze szczepionką przeciw śwince, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BD52 | szczepionka przeciw odrze, połączenia ze szczepionkami przeciw śwince i różyczce, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BD53 | szczepionka przeciw odrze, połączenia ze szczepionką przeciw różyczce, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BD54 | Szczepionka przeciw odrze, połączenia ze szczepionkami przeciw śwince, różyczce i ospie wietrznej, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BE | Szczepionki przeciw śwince | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BE01 | szczepionka przeciw śwince, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BF | Szczepionki przeciw poliomyelitis | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BF01 | szczepionka przeciw poliomyelitis, monowalentna, doustna, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BF02 | szczepionka przeciw poliomyelitis, trójwalentna, doustna, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BF03 | szczepionka przeciw poliomyelitis, trójwalentna, doustna, inaktywowana, cały wirion | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BF04 | szczepionka przeciw poliomyelitis, dwuwalentna, doustna, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BG | Szczepionki przeciw wściekliźnie | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BG01 | szczepionka przeciw wściekliźnie, inaktywowana, cały wirion | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BH | Szczepionki przeciw rotawirusom | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BH01 | szczepionka przeciw rotawirusom, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BH02 | szczepionka przeciw rotawirusom, pięciowalentna, zawierająca reasortanty ludzko-bydlęce | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BJ | Szczepionki przeciw różyczce | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BJ01 | szczepionka przeciw różyczce, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BJ51 | szczepionka przeciw różyczce, połączenia ze szczepionką przeciw śwince, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BK | Szczepionki przeciw ospie wietrznej i półpaścowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BK01 | szczepionka przeciw ospie wietrznej, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BK02 | szczepionka przeciw półpaścowi, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BK03 | szczepionka przeciw półpaścowi, oczyszczony antygen | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BL | Szczepionki przeciw żółtej febrze | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BL01 | szczepionka przeciw żółtej febrze, żywa atenuowana | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BM | Szczepionki przeciw ludzkiemu wirusowi brodawczaka | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BM01 | szczepionka przeciw ludzkiemu wirusowi brodawczaka, podtypy wirusa 6, 11, 16, 18 | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BM02 | szczepionka przeciw ludzkiemu wirusowi brodawczaka, podtypy wirusa 16, 18 | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BM03 | szczepionka przeciw ludzkiemu wirusowi brodawczaka, podtypy wirusa 6, 11, 16, 18, 31, 33, 45, 52 i 58 | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BN | szczepionki Covid-19 | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BN01 | covid-19, szczepionka oparta na RNA | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BN02 | covid-19, wektor wirusowy, niereplikujący się | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BN03 | covid-19, inaktywowany wirus | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BN04 | covid-19, podjednostka białkowa | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BN05 | covid-19, cząsteczki wirusopodobne | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BX | Inne szczepionki przeciwwirusowe | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BX01 | szczepionki przeciwko ospie prawdziwej i ospie małpiej | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BX02 | szczepionki przeciwko eboli | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BX04 | szczepionki przeciwko wirusowi dengi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BX05 | szczepionki przeciwko syncytialnemu wirusowi oddechowemu | WHO Anatomical Therapeutic Chemical classification
0‑L | J07BX06 | szczepionki przeciwko enterowirusowi 71 | WHO Anatomical Therapeutic Chemical classification
0‑L | J07C | SZCZEPIONKI PRZECIWBAKTERYJNE I PRZECIWWIRUSOWE, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA | szczepionki przeciwbakteryjne i przeciwwirusowe, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA01 | szczepionka przeciw błonicy, poliomyelitis i tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA02 | szczepionka przeciw błonicy, krztuścowi, poliomyelitis i tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA03 | szczepionka przeciw błonicy, różyczce i tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA04 | szczepionka przeciw haemophilus typ b i poliomyelitis | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA05 | szczepionka przeciw błonicy, wirusowemu zapaleniu wątroby typu B, krztuścowi i tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA06 | szczepionka przeciw błonicy, haemophilus typ b, krztuścowi, poliomyelitis i tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA07 | szczepionka przeciw błonicy, wirusowemu zapaleniu wątroby typu B i tężcowi | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA08 | szczepionka przeciw haemophilus typ b i wirusowemu zapaleniu wątroby typu B | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA09 | szczepionka przeciw błonicy, haemophilus typ b, krztuścowi, poliomyelitis, tężcowi i wirusowemu zapaleniu wątroby typu B | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA10 | szczepionka przeciw durowi brzusznemu i wirusowemu zapaleniu wątroby typu A | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA11 | szczepionka przeciw błonicy, haemophilus typ b, krztuścowi, tężcowi i wirusowemu zapaleniu wątroby typu B | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA12 | szczepionka przeciw błonicy, krztuścowi, poliomyelitis, tężcowi i wirusowemu zapaleniu wątroby typu B | WHO Anatomical Therapeutic Chemical classification
0‑L | J07CA13 | szczepionka przeciw błonicy, haemophilus typ b, krztuścowi, tężcowi, wirusowemu zapaleniu wątroby typu B i meningokokowa grupy A+C | WHO Anatomical Therapeutic Chemical classification
0‑L | J07X | INNE SZCZEPIONKI | WHO Anatomical Therapeutic Chemical classification
0‑L | J07XA | Szczepionki pasożytnicze | WHO Anatomical Therapeutic Chemical classification
0‑L | J07XA01 | szczepionki na malarię | WHO Anatomical Therapeutic Chemical classification
0‑L | L | LEKI PRZECIWNOWOTWOROWE I IMMUNOMODULUJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | L01 | CYTOSTATYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | L01A | LEKI ALKILUJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA | Analogi iperytu azotowego | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA01 | cyklofosfamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA02 | chlorambucyl | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA03 | melfalan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA05 | chlormetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA06 | ifosfamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA07 | trofosfamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA08 | prednimustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA09 | bendamustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AA10 | melfalan flufenamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AB | Alkilosulfoniany | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AB01 | busulfan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AB02 | treosulfan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AB03 | mannosulfan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AC | Etylenoiminy | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AC01 | tiotepa | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AC02 | triazychon | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AC03 | karbochon | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD | Pochodne nitrozomocznika | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD01 | karmustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD02 | lomustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD03 | semustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD04 | streptozotocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD05 | fotemustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD06 | nimustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD07 | ranimustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AD08 | uramustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AG | Epoksydy | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AG01 | etoglucyd | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AX | Inne leki alkilujące | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AX01 | mitobronitol | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AX02 | pipobroman | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AX03 | temozolomid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01AX04 | dakarbazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01B | ANTYMETABOLITY | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BA | Analogi kwasu foliowego | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BA01 | metotreksat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BA03 | raltitreksed | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BA04 | pemetreksed | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BA05 | pralatreksat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BB | Analogi puryn | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BB02 | merkaptopuryna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BB03 | tioguanina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BB04 | kladrybina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BB05 | fludarabina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BB06 | klofarabina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BB07 | nelarabina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC | Analogi pirymidyn | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC01 | cytarabina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC02 | fluorouracyl | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC03 | tegafur | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC04 | karmofur | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC05 | gemcytabina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC06 | kapecytabina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC07 | azacytydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC08 | decytabina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC09 | floksurydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC52 | fluorouracyl, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC53 | tegafur, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC58 | decytabina, kombinacje | WHO Anatomical Therapeutic Chemical classification
0‑L | L01BC59 | triflurydyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | L01C | ALKALOIDY ROŚLINNE I INNE ZWIĄZKI POCHODZENIA NATURALNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CA | Alkaloidy Vinca i analogi | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CA01 | winblastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CA02 | winkrystyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CA03 | windezyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CA04 | winorelbina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CA05 | winflunina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CA06 | wintafolid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CB | Pochodne podofilotoksyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CB01 | etopozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CB02 | tenipozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CC | Pochodne kolchicyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CC01 | demekolcyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CD | Taksoidy | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CD01 | paklitaksel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CD02 | docetaksel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CD03 | paklitaksel poliglumeks | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CD04 | kabazytaksel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CD51 | paklitaksel i encekwidar | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CE | Inhibitory topoizomerazy 1 (TOP1) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CE01 | topotekan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CE02 | irinotekan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CE03 | etirinotekan pegol | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CE04 | belotekan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CX | Inne alkaloidy roślinne i związki pochodzenia naturalnego | WHO Anatomical Therapeutic Chemical classification
0‑L | L01CX01 | trabektedyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01D | ANTYBIOTYKI CYTOTOKSYCZNE I SUBSTANCJE POKREWNE | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DA | Aktynomycyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DA01 | daktynomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB | Antracykliny i substancje pokrewne | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB01 | doksorubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB02 | daunorubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB03 | epirubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB04 | aklarubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB05 | zorubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB06 | idarubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB07 | mitoksantron | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB08 | pirarubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB09 | walrubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB10 | amrubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DB11 | piksantron | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DC | Inne antybiotyki cytotoksyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DC01 | bleomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DC02 | plikamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DC03 | mitomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01DC04 | iksabepilon | WHO Anatomical Therapeutic Chemical classification
0‑L | L01E | INHIBITORY KINAZY PROTEINOWEJ | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EA | Inhibitory kinazy tyrozynowej BCR-ABL | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EA01 | imatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EA02 | dazatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EA03 | nilotynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EA04 | bosutynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EA05 | ponatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EA06 | ascyminib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB | Inhibitory kinazy tyrozynowej receptora naskórkowego czynnika wzrostu (EGFR) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB01 | gefitynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB02 | erlotynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB03 | afatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB04 | ozymertynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB05 | rocyletynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB06 | olmutynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB07 | dakomitynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB08 | ikotynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB09 | lazertynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB10 | mobocertynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EB11 | aumolertynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EC | Inhibitory kinazy serynowo-treoninowej B-Raf (BRAF) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EC01 | wemurafenib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EC02 | dabrafenib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EC03 | enkorafenib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01ED | Inhibitory kinazy chłoniaka anaplastycznego (ALK) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01ED01 | kryzotynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01ED02 | cerytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01ED03 | alektynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01ED04 | brygatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01ED05 | lorlatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EE | Inhibitory kinazy białkowej aktywowanej mitogenami (MEK) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EE01 | trametynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EE02 | kobimetynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EE03 | binimetynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EE04 | selumetynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EF | Inhibitory kinazy cyklino-zależnej (CDK) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EF01 | palbocyklib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EF02 | rybocyklib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EF03 | abemacyklib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EG | Inhibitory kimazy mTOR ssaczego celu rapamycyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EG01 | temsyrolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EG02 | ewerolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EG03 | ridaforolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EG04 | sirolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EH | Inhibitory kinazy tyrozynowej receptora ludzkiego naskórkowego czynnika wzrostu 2 (HER2) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EH01 | lapatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EH02 | neratynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EH03 | tukatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EJ | Inhibitory kinazy janusowej (JAK) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EJ01 | ruksolitynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EJ02 | fedratynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EJ03 | pakrytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EJ04 | mamelotynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EK | Inhibitory kinazy tyrozynowej receptora czynnika wzrostu śródbłonka naczyniowego (VEGFR) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EK01 | aksytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EK02 | cedyranib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EK03 | tiwozanib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EK04 | frukwitynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EL | Inhibitory kinazy tyrozynowej Brutona (BTK) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EL01 | ibrutynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EL02 | akalabrutynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EL03 | zanubrutynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EL04 | orelabrutynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EL05 | pitobrutynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EM | Inhibitory 3-kinazy fosfatydyloinozytolu (PI3K) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EM01 | idelalizyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EM02 | kopanlizyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EM03 | alpelizyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EM04 | duwelizyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EM05 | parsaklizib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EN | Inhibitory kinazy tyrozynowej receptora czynnika wzrostu fibroblastów (FGFR) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EN01 | erdafitynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EN02 | pemigatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EN03 | infigratynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EN04 | futybatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX | Inne inhibitory kinaz białkowych | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX01 | sunitynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX02 | sorafenib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX03 | pazopanib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX04 | wandetanib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX05 | regorafenib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX06 | masytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX07 | kabozantynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX08 | lenwatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX09 | nintedanib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX10 | midostauryna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX11 | kwizartynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX12 | larotrektynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX13 | gilterytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX14 | entrektynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX15 | peksydartynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX17 | kapmatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX18 | awaprytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX19 | ripretynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX21 | tepotynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX22 | selperkatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX23 | pralsetynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX24 | surufatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX25 | umbralizyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX26 | sitrawatynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01EX27 | kapiwasertyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01F | PRZECIWCIAŁA MONOKLONALNE I KONIUGATY LEKÓW Z PRZECIWCIAŁAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FA | Inhibitory CD20 (Klastry różnicowania 20) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FA01 | rytuksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FA02 | ofatumumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FA03 | obinutuzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FB | Inhibitory CD22 (Klastry różnicowania 22) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FB01 | inotuzumab ozogamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FB02 | moksetumomab pasudotoks | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FC | Inhibitory CD38 (Klastry różnicowania 38) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FC01 | daratumumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FC02 | izatuksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FD | Inhibitory HER2 (Receptora ludzkiego naskórkowego czynnika wzrostu 2) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FD01 | trastuzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FD02 | pertuzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FD03 | trastuzumab emtanzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FD04 | trastuzumab derukstekan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FD05 | trastuzumab duokarmazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FD06 | margetuksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FE | Inhibitory EGFR (receptora naskórkowego czynnika wzrostu) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FE01 | cetuksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FE02 | panitumumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FE03 | necitumumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF | Inhibitory receptora PD-1/PDL-1 (Białko programowanej śmierci komórkowej 1/ligand śmierci 1) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF01 | niwolumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF02 | pembrolizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF03 | durwalumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF04 | awelumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF05 | atezolizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF06 | cemiplimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF07 | dostarlimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF08 | prolgolimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF09 | tislelizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF10 | retifanlimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF11 | sugemalimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF12 | serplulimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FF13 | toripalimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FG | Inhibitory VEGF/VEGFR (czynnik wzrostu śródbłonka naczyniowego) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FG01 | bewacyzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FG02 | ramucyrumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX | Inne przeciwciała monoklonalne i koniugaty leków z przeciwciałami | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX01 | edrekolomab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX02 | gemtuzumab ozogamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX03 | katumaksomab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX04 | ipilimumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX05 | brentuksymab wedotyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX06 | dinutuksymab beta | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX07 | blinatumomab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX08 | elotuzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX09 | mogamulizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX10 | olaratumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX11 | bermekimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX12 | tafasitamab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX13 | enfortumab wedotyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX14 | polatuzumab wedotyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX15 | belantamab mafodotyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX16 | oportuzumab monatoks | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX17 | sakituzumab gowitekan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX18 | amiwantamab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX19 | sabatolimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX20 | tremelimumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX21 | naksytamab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX22 | lonkastuksymab tezyryna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX23 | tisotumab wedotin | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX24 | teklistamab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX25 | mosunetuzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX26 | mirwetuksymab sorawtanzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX27 | epkoritamab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX28 | glofitamab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FX29 | talkwetamab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FY | Kombinacje przeciwciał monoklonalnych i koniugatów przeciwciało-lek | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FY01 | pertuzumab i trastuzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FY02 | niwolumab i relatlimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01FY03 | prolgolimab i nurulimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L01X | INNE LEKI PRZECIWNOWOTWOROWE | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XA | Związki platyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XA01 | cisplatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XA02 | karboplatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XA03 | oksaliplatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XA04 | satraplatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XA05 | poliplatilen | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XB | Metylohydrazyny | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XB01 | prokarbazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XD | Leki stosowane w terapii fotodynamicznej | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XD01 | porfimer sodowy | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XD03 | metylu aminolewulinian | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XD04 | kwas aminolewuli | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XD05 | temoporfina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XD06 | efaproksiral | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XD07 | padeliporfina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XF | Retinody stosowane w leczeniu nowotworów | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XF01 | tretynoina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XF02 | alitretynoina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XF03 | beksaroten | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XG | Inhibitory proteasomów | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XG01 | bortezomib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XG02 | karfilzomib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XG03 | iksazomib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XH | Inhibitory deacetylazy histonowej (HDAC) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XH01 | worynostat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XH02 | romidepsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XH03 | panobinostat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XH04 | belinostat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XH05 | entynostat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XJ | inhibitor szlaku hedgehog | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XJ01 | wismodegib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XJ02 | sonidegib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XJ03 | glasdegib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK | Inhibitory polimerazy poli(ADP-rybozy) | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK01 | olaparyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK02 | niraparyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK03 | rucaparyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK04 | talazoparyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK05 | weliparyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK06 | pamiparyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XK52 | niraparyb i abirateron | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL | Przeciwnowotworowa terapia komórkowa i genowa | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL01 | sitimagen ceradenowek | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL02 | talimogen laherparepwek | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL03 | aksykabtagen cyloleucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL04 | tisagenlecleucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL05 | ciltakabtagen autoleucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL06 | breksukabtagen autoleucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL07 | idekabtagen wicleucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL08 | lisokabtagen maraleucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL09 | tabelekleucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL10 | nadofaragen firadenowek | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XL11 | lifileucel | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX | Inne leki przeciwnowotworowe | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX01 | amsakryna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX02 | asparaginaza | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX03 | altretamina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX05 | hydroksymocznik | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX07 | lonidamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX08 | pentostatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX10 | mazoprokol | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX11 | estramustyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX16 | mitoguazon | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX18 | tiofurazon | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX23 | mitotan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX24 | pegaspargaza | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX27 | arsenu trójtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX29 | denileukina diftitoks | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX33 | celekoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX35 | anagrelid | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX36 | oblimersen | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX40 | omacetaksyny mepebursztynian | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX41 | eribulina | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX44 | aflibercept | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX52 | wenetoklaks | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX53 | wozaroksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX57 | plitydepsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX58 | epakadostat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX59 | enazydenib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX62 | iwosydenib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX66 | selineksor | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX67 | tagraksofusp | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX69 | lurbinektedyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX72 | tazemetostat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX73 | sotorasib | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX74 | belzutifan | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX75 | tebentafusp | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX77 | adagrazyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX78 | nawitoklaks | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX79 | eflornityna | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XX80 | imetelstat | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XY | Połączenia leków przeciwnowotworowych | WHO Anatomical Therapeutic Chemical classification
0‑L | L01XY01 | cytarabina i daunorubicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L02 | LEKI HORMONALNE | WHO Anatomical Therapeutic Chemical classification
0‑L | L02A | HORMONY I ZWIĄZKI POKREWNE | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AA | Estrogeny | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AA01 | dietylostylbestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AA02 | poliestradiolu fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AA03 | etynyloestradiol | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AA04 | fosfestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AB | Progestageny | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AB01 | megestrol | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AB02 | medroksyprogesteron | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AB03 | gestonoron | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AE | Analogi hormonu uwalniającego gonadotropinę | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AE01 | buserelina | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AE02 | leuprorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AE03 | goserelina | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AE04 | tryptorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AE05 | histrelina | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AE51 | leuprorelina i bikalutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02AX | Inne hormony | WHO Anatomical Therapeutic Chemical classification
0‑L | L02B | ANTAGONIŚCI HORMONÓW I ZWIĄZKI POKREWNE | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BA | Antyestrogeny | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BA01 | tamoksyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BA02 | toremifen | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BA03 | fulwestrant | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BA04 | elacestrant | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BB | Antyandrogeny | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BB01 | flutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BB02 | nilutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BB03 | bikalutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BB04 | enzalutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BB05 | apalutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BB06 | darolutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BG | Inhibitory aromatazy | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BG01 | aminoglutetymid | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BG02 | formestan | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BG03 | anastrozol | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BG04 | letrozol | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BG05 | worozol | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BG06 | eksemestan | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BX | Inni antagoniści hormonów i związki pokrewne | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BX01 | abareliks | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BX02 | degareliks | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BX03 | abirateron | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BX04 | relugoliks | WHO Anatomical Therapeutic Chemical classification
0‑L | L02BX53 | abirateron i prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | L03 | LEKI IMMUNOSTYMULUJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | L03A | LEKI IMMUNOSTYMULUJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA | Czynniki stymulujące tworzenie kolonii | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA02 | filgrastym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA03 | molgramostym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA09 | sargramostym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA10 | lenograstym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA12 | ancestym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA13 | pegfilgrastym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA14 | lipegfilgrastym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA15 | balugrastym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA16 | empegfilgrastym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA17 | pegteograstym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA18 | efbemalenograstym alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AA19 | eflapegrastym | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB | Interferony | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB01 | interferon alfa naturalny | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB02 | interferon beta naturalny | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB03 | interferon gamma | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB04 | interferon alfa-2a | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB05 | interferon alfa-2b | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB06 | interferon alfa-n1 | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB07 | interferon beta-1a | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB08 | interferon beta-1b | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB09 | interferon alfakon-1 | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB10 | peginterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB11 | peginterferon alfa-2a | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB12 | albinterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB13 | peginterferon beta-1a | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB14 | cepeginterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB15 | ropeginterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB16 | peginterferon alfakon-2 | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB17 | sampeginterferon beta-1a | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB60 | peginterferon alfa-2b, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AB61 | peginterferon alfa-2a, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AC | Interleukiny | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AC01 | aldesleukina | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AC02 | oprelwekina | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX | Inne leki immunostymulujące | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX01 | lentinan | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX02 | rochinimeks | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX03 | szczepionka BCG | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX04 | pegademaza | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX05 | pidotymod | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX07 | kwas poliinozyno-cytydylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX08 | kwas poliinozyno-cytydylowy związany z polikationową polietylenoiminą | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX09 | tymopentyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX10 | immunocyjanina | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX11 | tazonermina | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX12 | szczepionka przeciw czerniakowi | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX13 | glatirameru octan | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX14 | histaminy dichlorowodorek | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX15 | mifamurtyd | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX16 | pleryksafor | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX17 | sipuleucel-T | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX18 | krydanimod | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX19 | dazyprotymut-T | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX21 | elapegademaza | WHO Anatomical Therapeutic Chemical classification
0‑L | L03AX22 | leniolizyb | WHO Anatomical Therapeutic Chemical classification
0‑L | L04 | LEKI IMMUNOSUPRESYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | L04A | LEKI IMMUNOSUPRESYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA | Selektywne leki immunosupresyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA03 | immunoglobulina przeciw limfocytom T (końska) | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA04 | immunoglobulina przeciw limfocytom T (królicza) | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA06 | kwas mykofenolowy | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA15 | alefacept | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA19 | gusperymus | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA22 | abetymus | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA24 | abatacept | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA28 | belatacept | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA32 | apremilast | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA40 | kladrybina | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA41 | imlifidaza | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA48 | belumosudil | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AA58 | efgartigimod alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB | Inhibitory czynnika martwicy nowotworu alfa (TNF-alfa) | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB01 | etanercept | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB02 | infliksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB03 | afelimomab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB04 | adalimumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB05 | certolizumab pegol | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB06 | golimumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AB07 | opinercept | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC | Inhibitory interleukiny | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC01 | daklizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC02 | bazyliksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC03 | anakinra | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC04 | rylonacept | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC05 | ustekinumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC07 | tocylizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC08 | kanakinumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC09 | briakinumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC10 | sekukinumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC11 | syltuksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC12 | brodalumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC13 | iksekizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC14 | sarylumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC15 | syrukumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC16 | guzelkumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC17 | tyldrakizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC18 | rizankizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC19 | satralizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC20 | netakimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC21 | bimekizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC22 | spesolimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC23 | olokizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC24 | mirikizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AC25 | lewilimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AD | Inhibitory kalcyneuryny | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AD01 | cyklosporyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AD02 | takrolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AD03 | woklosporyna | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AE | Modulatory receptora 1-fosforanu sfingozyny (S1P). | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AE01 | fingolimod | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AE02 | ozanimod | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AE03 | siponimod | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AE04 | ponesimod | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AE05 | etrasimod | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF | Inhibitory kinazy janusowej (JAK) | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF01 | tofacytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF02 | barycytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF03 | upadacytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF04 | filgotynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF05 | itacytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF06 | peficytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF07 | deukrawacytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AF08 | ritlecytynib | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG | Przeciwciała monoklonalne | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG01 | muromonab-CD3 | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG02 | efalizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG03 | natalizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG04 | belimumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG05 | wedolizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG06 | alemtuzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG07 | begelomab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG08 | okrelizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG09 | emapalumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG10 | inebilizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG11 | anifrolumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG12 | ofatumumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG13 | teprotumumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG14 | ublituksymab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG15 | diwozylimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AG16 | rozanoliksizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AH | Inhibitory kinazy rapamycyny (mTOR) u ssaków | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AH01 | sirolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AH02 | ewerolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ | Inhibitory dopełniacza | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ01 | ekulizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ02 | rawulizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ03 | pegketakoplan | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ04 | sutimlimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ05 | awakopan | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ06 | zilukoplan | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ07 | krowalimab | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ08 | iptakopan | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AJ09 | danikopan | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AK | Inhibitory dehydrogenazy dihydroorotanowej (DHODH). | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AK01 | leflunomid | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AK02 | teryflunomid | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX | Inne leki immunosupresyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX01 | azatiopryna | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX02 | talidomid | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX03 | metotreksat | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX04 | lenalidomid | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX05 | pirfenidon | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX06 | pomalidomid | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX07 | dimetylu fumaran | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX08 | darwadstrocel | WHO Anatomical Therapeutic Chemical classification
0‑L | L04AX09 | fumaran diroksymelu | WHO Anatomical Therapeutic Chemical classification
0‑L | M | UKŁAD MIĘŚNIOWO-SZKIELETOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | M01 | LEKI PRZECIWZAPALNE I PRZECIWREUMATYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | M01A | NIESTEROIDOWE LEKI PRZECIWZAPALNE I PRZECIWREUMATYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AA | Butylopirazolidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AA01 | fenylobutazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AA02 | mofebutazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AA03 | oksyfenbutazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AA05 | klofezon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AA06 | kebuzon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB | Pochodne kwasu octowego i substancje pokrewne | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB01 | indometacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB02 | sulindak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB03 | tolmetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB04 | zomepirak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB05 | diklofenak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB06 | alklofenak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB07 | bumadyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB08 | etodolak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB09 | lonazolak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB10 | fentiazak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB11 | acemetacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB12 | difenpiramid | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB13 | oksametacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB14 | proglumetacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB15 | ketorolak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB16 | aceklofenak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB17 | bufeksamak | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB51 | indometacyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AB55 | diklofenak, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AC | Oksykamy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AC01 | piroksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AC02 | tenoksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AC04 | droksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AC05 | lornoksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AC06 | meloksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AC56 | meloksykam, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE | Pochodne kwasu propionowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE01 | ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE02 | naproksen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE03 | ketoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE04 | fenoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE05 | fenbufen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE06 | benoksaprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE07 | suprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE08 | pirprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE09 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE10 | indoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE11 | kwas tiaprofe | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE12 | oksaprozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE13 | ibuproksam | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE14 | deksibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE15 | flunoksaprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE16 | alminoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE17 | deksketoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE18 | naprokscynod | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE51 | ibuprofen, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE52 | naproksen i ezomeprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE53 | ketoprofen, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE56 | naproksen i mizoprostol | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AE57 | naproksen i difenhydramina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AG | Fenamaty | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AG01 | kwas mefenamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AG02 | kwas tolfenamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AG03 | kwas flufenamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AG04 | kwas meklofenamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH | Koksyby | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH01 | celekoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH02 | rofekoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH03 | waldekoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH04 | parekoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH05 | etorykoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH06 | lumirakoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AH07 | polmakoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX | Inne niesteroidowe leki przeciwzapalne i przeciwreumatyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX01 | nabumeton | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX02 | kwas niflumi | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX04 | azapropazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX05 | glukozamina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX07 | benzydamina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX12 | glukozaminoglikanu polisiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX13 | prokwazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX14 | orgoteina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX17 | nimesulid | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX18 | feprazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX21 | diacereina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX22 | morniflumat | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX23 | tenidap | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX24 | oksaceprol | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX25 | chondroityny siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX26 | awokado i soi olej, frakcje niezmydlające się | WHO Anatomical Therapeutic Chemical classification
0‑L | M01AX68 | feprazon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M01B | LEKI PRZECIWZAPALNE/PRZECIWREUMATYCZNE W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | M01BA | Leki przeciwzapalne/przeciwreumatyczne w połączeniu z kortykosteroidami | WHO Anatomical Therapeutic Chemical classification
0‑L | M01BA01 | fenylobutazon i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01BA02 | dipirocetyl i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01BA03 | kwas acetylosalicylowy i kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | M01BX | Inne leki przeciwzapalne/przeciwreumatyczne w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | M01C | SWOISTE LEKI PRZECIWREUMATYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CA | Chinoliny | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CA03 | oksycynchofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CB | Preparaty złota | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CB01 | sodu aurotiojabłczan | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CB02 | sodu aurotiosiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CB03 | auranofina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CB04 | aurotioglukoza | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CB05 | aurotioprol | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CC | Penicylamina i związki podobne | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CC01 | penicylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CC02 | bucylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | M01CX | Inne swoiste leki przeciwreumatyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | M02 | LEKI DO STOSOWANIA MIEJSCOWEGO W BÓLACH STAWÓW I MIĘŚNI | WHO Anatomical Therapeutic Chemical classification
0‑L | M02A | LEKI DO STOSOWANIA MIEJSCOWEGO W BÓLACH STAWÓW I MIĘŚNI | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA | Niesteroidowe leki przeciwzapalne do stosowania miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA01 | fenylobutazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA02 | mofebutazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA03 | klofezon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA04 | oksyfenbutazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA05 | benzydamina | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA06 | etofenamat | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA07 | piroksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA08 | felbinak | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA09 | bufeksamak | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA10 | ketoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA11 | bendazak | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA12 | naproksen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA13 | ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA14 | fentiazak | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA15 | diklofenak | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA16 | feprazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA17 | kwas niflumi | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA18 | kwas meklofenamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA19 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA21 | tolmetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA22 | suksybuzon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA23 | indometacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA24 | nifenazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA25 | aceklofenak | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA26 | nimesulid | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA27 | deksketoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA28 | piketoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA29 | esflurbiprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AA31 | loksoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AB | Kapsaicyna i związki podobne | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AB01 | kapsaicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AB02 | zukapsaicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AC | Leki z pochodnymi kwasu salicylowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AX | Inne leki do stosowania miejscowego w bólach stawów i mięśni | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AX02 | tolazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AX03 | dimetylosulfotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AX05 | idrocylamid | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AX06 | tolperyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | M02AX10 | różne | WHO Anatomical Therapeutic Chemical classification
0‑L | M03 | LEKI ZWIOTCZAJĄCE MIĘŚNIE | WHO Anatomical Therapeutic Chemical classification
0‑L | M03A | LEKI ZWIOTCZAJĄCE MIĘŚNIE DZIAŁAJĄCE OBWODOWO | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AA | Alkaloidy kurary | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AA01 | alkuronium | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AA02 | tubokuraryna | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AA04 | dimetylotubokuraryna | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AB | Pochodne choliny | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AB01 | suksametonium | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC | Inne czwartorzędowe związki amoniowe | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC01 | pankuronium | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC02 | galamina | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC03 | wekuronium | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC04 | atrakurium | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC05 | heksafluronium | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC06 | pipekuroniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC07 | doksakuriowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC08 | fazadyniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC09 | rokuroniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC10 | miwakuriowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AC11 | cisatrakurium | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AX | Inne leki zwiotczające mięśnie działające obwodowo | WHO Anatomical Therapeutic Chemical classification
0‑L | M03AX01 | toksyna botulinowa | WHO Anatomical Therapeutic Chemical classification
0‑L | M03B | LEKI ZWIOTCZAJĄCE MIĘŚNIE DZIAŁAJĄCE OŚRODKOWO | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA | Estry kwasu karbaminowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA01 | fenprobamat | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA02 | karyzoprodol | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA03 | metokarbamol | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA04 | styramat | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA05 | febarbamat | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA51 | fenprobamat, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA52 | karyzoprodol, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA53 | metokarbamol, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA71 | fenprobamat, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA72 | karyzoprodol, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BA73 | metokarbamol, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BB | Oksazolu, tiazyny i triazyny pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BB02 | chlormezanon | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BB03 | chlorzoksazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BB52 | chlormezanon, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BB53 | chlorzoksazon, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BB72 | chlormezanon, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BB73 | chlorzoksazon, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BC | Etery chemicznie zbliżone do leków przeciwhistamich | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BC01 | orfenadryna (cytrynian) | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BC51 | orfenadryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX | Inne leki działające ośrodkowo | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX01 | baklofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX02 | tyzanidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX03 | prydynol | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX04 | tolperyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX05 | tiokolchikozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX06 | mefenezyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX07 | tetrazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX08 | cyklobenzapryna | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX09 | eperyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX30 | fenyramidol | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX53 | pridinol, kombinacje | WHO Anatomical Therapeutic Chemical classification
0‑L | M03BX55 | tiokolchikozyd, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M03C | LEKI ZWIOTCZAJĄCE MIĘŚNIE DZIAŁAJĄCE BEZPOŚREDNIO | WHO Anatomical Therapeutic Chemical classification
0‑L | M03CA | Dantrolen i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | M03CA01 | dantrolen | WHO Anatomical Therapeutic Chemical classification
0‑L | M04 | LEKI PRZECIW DNIE MOCZANOWEJ | WHO Anatomical Therapeutic Chemical classification
0‑L | M04A | LEKI PRZECIW DNIE MOCZANOWEJ | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AA | Leki hamujące wytwarzanie kwasu moczowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AA01 | allopurynol | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AA02 | tizopuryna | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AA03 | febuksostat | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AA51 | allopurynol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AB | Leki zwiększające wydalanie kwasu moczowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AB01 | probenecyd | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AB02 | sulfinpirazon | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AB03 | benzbromaron | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AB04 | izobromindion | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AB05 | lezynurad | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AC | Leki niewpływające na metabolizm kwasu moczowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AC01 | kolchicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AC02 | cynchofen | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AC51 | kolchicyna i probenecyd | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AX | Inne leki przeciw dnie moczanowej | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AX01 | oksydaza moczanowa | WHO Anatomical Therapeutic Chemical classification
0‑L | M04AX02 | peglotykaza | WHO Anatomical Therapeutic Chemical classification
0‑L | M05 | LEKI STOSOWANE W CHOROBACH KOŚCI | WHO Anatomical Therapeutic Chemical classification
0‑L | M05B | LEKI WPŁYWAJĄCE NA STRUKTURĘ I MINERALIZACJĘ KOŚCI | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA | Bisfosfoniany | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA01 | kwas etydro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA02 | kwas klodro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA03 | kwas pamidro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA04 | kwas alendro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA05 | kwas tiludro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA06 | kwas ibandro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA07 | kwas ryzedro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BA08 | kwas zoledro | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB | Bisfosfoniany, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB01 | kwas etydro i wapń, sekwencyjnie | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB02 | kwas ryzedro i wapń, sekwencyjnie | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB03 | kwas alendro i cholekalcyferol | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB04 | kwas ryzedro, wapń i cholekalcyferol, sekwencyjnie | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB05 | kwas alendro, wapń i cholekalcyferol, sekwencyjnie | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB06 | kwas alendro i alfakalcydol, sekwencyjnie | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB07 | kwas ryzedro i cholekalcyferol | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB08 | kwas zoledro, wapń i cholekalcyferol, sekwencyjnie | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BB09 | kwas ibandro i cholekalcyferol | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BC | Morfogenetyczne białka kości | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BC01 | dibotermina alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BC02 | eptotermina alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX | Inne leki wpływające na strukturę i mineralizację kości | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX01 | ipryflawon | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX02 | glinu chlorowodorotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX03 | strontu ranelinian | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX04 | denosumab | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX05 | burosumab | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX06 | romosozumab | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX07 | wosorytyd | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX08 | menatetrenon | WHO Anatomical Therapeutic Chemical classification
0‑L | M05BX53 | strontu ranelinian i cholekalcyferol | WHO Anatomical Therapeutic Chemical classification
0‑L | M09 | INNE LEKI STOSOWANE W ZABURZENIACH UKŁADU MIĘŚNIOWO-SZKIELETOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | M09A | INNE LEKI STOSOWANE W ZABURZENIACH UKŁADU MIĘŚNIOWO-SZKIELETOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AA | Chinina i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AA01 | hydrochinina | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AA72 | chinina, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AB | Enzymy | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AB01 | chymopapaina | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AB02 | kolagenaza Clostridium histolyticum | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AB03 | bromelainy | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AB52 | trypsyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX | Inne leki stosowane w zaburzeniach układu mięśniowo-szkieletowego | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX01 | kwas hialuro | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX02 | chondrocyty, autologiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX03 | ataluren | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX04 | drisapersen | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX05 | kwas aceneuramowy | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX06 | eteplirsen | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX07 | nusinersen | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX08 | golodirsen | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX09 | onasemnogen abeparwowek | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX10 | rysdyplam | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX11 | palowaroten | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX12 | wiltolarsen | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX13 | kasimersen | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX14 | giwinostat | WHO Anatomical Therapeutic Chemical classification
0‑L | M09AX15 | delandistrogen mokseparwowek | WHO Anatomical Therapeutic Chemical classification
0‑L | N | UKŁAD NERWOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | N01 | LEKI ZNIECZULAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | N01A | LEKI DO ZNIECZULENIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AA | Etery | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AA01 | eter dietylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AA02 | eter winylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB | Chlorowcowane węglowodory | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB01 | halotan | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB02 | chloroform | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB04 | enfluran | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB05 | trichloroetylen | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB06 | izofluran | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB07 | desfluran | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AB08 | sewofluran | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AF | Barbiturany, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AF01 | metoheksytal | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AF02 | heksobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AF03 | tiopental | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AG | Barbiturany w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AG01 | narkobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH | Opioidowe leki znieczulające | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH01 | fentanyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH02 | alfentanyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH03 | sufentanyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH04 | fenoperydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH05 | anilerydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH06 | remifentanyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AH51 | fentanyl, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX | Inne leki do znieczulenia ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX03 | ketamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX04 | propanidyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX05 | alfaksalon | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX07 | etomidat | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX10 | propofol | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX11 | sodu hydroksymaślan | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX13 | podtlenek azotu | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX14 | esketamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX15 | ksenon | WHO Anatomical Therapeutic Chemical classification
0‑L | N01AX63 | podtlenek azotu, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01B | LEKI DO ZNIECZULENIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA | Estry kwasu aminobenzoesowego | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA01 | metabutetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA02 | prokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA03 | tetrakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA04 | chloroprokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA05 | benzokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA52 | prokaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BA53 | tetrakaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB | Amidy | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB01 | bupiwakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB02 | lidokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB03 | mepiwakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB04 | prylokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB05 | butanilikaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB06 | cynchokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB07 | etydokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB08 | artykaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB09 | ropiwakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB10 | lewobupiwakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB51 | bupiwakaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB52 | lidokaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB53 | mepiwakaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB54 | prylokaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB57 | etydokaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB58 | artykaina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BB59 | bupiwakaina i meloksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BC | Estry kwasu benzoesowego | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BC01 | kokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BX | Inne leki do znieczulenia miejscowego | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BX01 | etylu chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BX02 | dyklonina | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BX03 | fenol | WHO Anatomical Therapeutic Chemical classification
0‑L | N01BX04 | kapsaicyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02 | LEKI PRZECIWBÓLOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | N02A | OPIOIDY | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA | Naturalne alkaloidy opium | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA01 | morfina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA02 | opium | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA03 | hydromorfon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA04 | nikomorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA05 | oksykodon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA08 | dihydrokodeina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA10 | papaweretum | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA11 | oksymorfon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA51 | morfina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA53 | hydromorfon i nalokson | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA55 | oksykodon i nalokson | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA56 | oksykodon i naltrekson | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA58 | dihydrokodeina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA59 | kodeina, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AA79 | kodeina, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AB | Pochodne fenylopiperydyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AB01 | ketobemidon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AB02 | petydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AB03 | fentanyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AB52 | petydyna, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AB72 | petydyna, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC | Pochodne difenylopropyloaminy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC01 | dekstromoramid | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC03 | pirytramid | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC04 | dekstropropoksyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC05 | bezytramid | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC52 | metadon, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC54 | dekstropropoksyfen, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AC74 | dekstropropoksyfen, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AD | Pochodne benzomorfanu | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AD01 | pentazocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AD02 | fenazocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AD51 | pentazocyna i nalokson | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AE | Pochodne orypawiny | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AE01 | buprenorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AF | Pochodne morfinanu | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AF01 | butorfanol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AF02 | nalbufina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AG | Opioidy w połączeniu z lekami przeciwskurczowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AG01 | morfina i leki przeciwskurczowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AG02 | ketobemidon i leki przeciwskurczowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AG03 | petydyna i leki przeciwskurczowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AG04 | hydromorfon i leki przeciwskurczowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ | Opioidy w połączeniu z nieopioidowymi lekami przeciwbólowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ01 | dihydrokodeina i paracetamol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ02 | dihydrokodeina i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ03 | dihydrokodeina i inne nieopioidowe leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ06 | kodeina i paracetamol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ07 | kodeina i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ08 | kodeina i ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ09 | kodeina i inne nieopioidowe leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ13 | tramadol i paracetamol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ14 | tramadol i deksketoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ15 | tramadol i inne nieopioidowe leki przeciwbólowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ16 | tramadol i celekoksyb | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ17 | oksykodon i paracetamol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ18 | oksykodon i kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ19 | oksykodon i ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ22 | hydrokodon i paracetamol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AJ23 | hydrokodon i ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX | Inne opioidy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX01 | tylidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX02 | tramadol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX03 | dezocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX05 | meptazynol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX06 | tapentadol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX07 | olicerydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02AX51 | tilidyna i nalokson | WHO Anatomical Therapeutic Chemical classification
0‑L | N02B | INNE LEKI PRZECIWBÓLOWE I PRZECIWGORĄCZKOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA | Kwas salicylowy i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA01 | kwas acetylosalicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA02 | aloksypryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA03 | choliny salicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA04 | sodu salicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA05 | salicylamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA06 | salsalat | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA07 | etenzamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA08 | morfoliny salicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA09 | dipirocetyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA10 | benorylat | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA11 | diflunizal | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA12 | potasu salicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA14 | guacetyzal | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA15 | karbazalat wapniowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA16 | imidazolu salicylan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA51 | kwas acetylosalicylowy, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA55 | salicylamid, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA57 | etenzamid, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA59 | dipirocetyl, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA65 | karbazalat wapniowy, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA67 | salicylan magnezu, kombinacje, z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA71 | kwas acetylosalicylowy, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA75 | salicylamid, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA77 | etenzamid, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BA79 | dipirocetyl, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB | Pirazolony | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB01 | fenazon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB02 | metamizol sodowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB03 | aminofenazon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB04 | propyfenazon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB05 | nifenazon | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB51 | fenazon, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB52 | metamizol sodowy, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB53 | aminofenazon, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB54 | propyfenazon, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB71 | fenazon, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB72 | metamizol sodowy, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB73 | aminofenazon, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BB74 | propyfenazon, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE | Anilidy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE01 | paracetamol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE03 | fenacetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE04 | bucetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE05 | propacetamol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE51 | paracetamol, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE53 | fenacetyna, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE54 | bucetyna, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE71 | paracetamol, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE73 | fenacetyna, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BE74 | bucetyna, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BF | Gabapentynoidy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BF01 | gabapentyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BF02 | pregabalina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BF03 | mirogabalina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG | Inne leki przeciwbólowe i przeciwgorączkowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG02 | rymazolium | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG03 | glafenina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG04 | floktafenina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG05 | wiminol | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG06 | nefopam | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG07 | flupirtyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG08 | zykonotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG09 | metoksyfluran | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG10 | kannabinoidy | WHO Anatomical Therapeutic Chemical classification
0‑L | N02BG12 | tanezumab | WHO Anatomical Therapeutic Chemical classification
0‑L | N02C | LEKI PRZECIWMIGRENOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA | Alkaloidy sporyszu | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA01 | dihydroergotamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA02 | ergotamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA04 | metysergid | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA07 | lizuryd | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA51 | dihydroergotamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA52 | ergotamina, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CA72 | ergotamina, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CB | Pochodne kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CB01 | flumedrokson | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC | Selektywni agoniści receptora serotoninowego (5HT1) | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC01 | sumatryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC02 | naratryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC03 | zolmitryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC04 | ryzatryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC05 | almotryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC06 | eletryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC07 | frowatryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC08 | lasmiditan | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CC51 | sumatryptan i naproksen | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD | Antagoniści peptydów związanych z genem kalcytoniny (CGRP) | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD01 | erenumab | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD02 | galcanezumab | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD03 | fremanezumab | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD04 | ubrogepant | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD05 | eptinezumab | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD06 | rimegepant | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CD07 | atogepant | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CX | Inne leki przeciwmigrenowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CX01 | pizotyfen | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CX02 | klonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CX03 | iprazochrom | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CX05 | dimetotiazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N02CX06 | oksetoron | WHO Anatomical Therapeutic Chemical classification
0‑L | N03 | LEKI PRZECIWPADACZKOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | N03A | LEKI PRZECIWPADACZKOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AA | Barbiturany i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AA01 | metylofenobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AA02 | fenobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AA03 | prymidon | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AA04 | barbeksaklon | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AA30 | metarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB | Pochodne hydantoiny | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB01 | etotoina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB02 | fenytoina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB03 | amino(difenylohydantoiny) walerianian | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB04 | mefenytoina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB05 | fosfenytoina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB52 | fenytoina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AB54 | mefenytoina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AC | Pochodne oksazolidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AC01 | parametadion | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AC02 | trimetadion | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AC03 | etadion | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AD | Pochodne imidu kwasu bursztynowego | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AD01 | etosuksymid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AD02 | fensuksymid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AD03 | mesuksymid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AD51 | etosuksymid, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AE | Pochodne benzodiazepiny | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AE01 | klonazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AF | Pochodne karboksamidu | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AF01 | karbamazepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AF02 | okskarbazepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AF03 | rufinamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AF04 | eslikarbazepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AG | Pochodne kwasów tłuszczowych | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AG01 | kwas walproi | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AG02 | walpromid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AG03 | kwas aminomasłowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AG04 | wigabatryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AG05 | progabid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AG06 | tiagabina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX | Inne leki przeciwpadaczkowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX03 | sultiam | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX07 | fenacemid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX09 | lamotrygina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX10 | felbamat | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX11 | topiramat | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX13 | feneturyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX14 | lewetyracetam | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX15 | zonisamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX17 | styrypentol | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX18 | lakozamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX19 | karysbamat | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX21 | retygabina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX22 | perampanel | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX23 | brywaracetam | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX24 | kanabidiol | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX25 | cenobamat | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX26 | fenfluramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX27 | ganaksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | N03AX30 | beklamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N04 | LEKI STOSOWANE W CHOROBIE PARKINSONA | WHO Anatomical Therapeutic Chemical classification
0‑L | N04A | LEKI CHOLINOLITYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA | Aminy trzeciorzędowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA01 | triheksyfenidyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA02 | biperyden | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA03 | metyksen | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA04 | procyklidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA05 | profenamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA08 | deksetymid | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA09 | fenglutarymid | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA10 | mazatykol | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA11 | bornapryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AA12 | tropatepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AB | Etery chemicznie zbliżone do leków przeciwhistamich | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AB01 | etanautyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AB02 | orfenadryny chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AC | Etery tropiny lub pochodne tropiny | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AC01 | benzatropina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04AC30 | etybenzatropina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04B | LEKI DOPAMINERGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA | Dopa i pochodne dopy | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA01 | lewodopa | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA02 | lewodopa i inhibitor dekarboksylazy | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA03 | lewodopa, inhibitor dekarboksylazy i inhibitor COMT | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA04 | melewodopa | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA05 | melewodopa i inhibitor dekarboksylazy | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA06 | etylewodopa i inhibitor dekarboksylazy | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BA07 | foslewodopa i inhibitor dekarboksylazy | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BB | Pochodne adamantanu | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BB01 | amantadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC | Agoniści dopaminy | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC01 | bromokryptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC02 | pergolid | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC03 | dihydroergokryptyny mezylan | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC04 | ropinirol | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC05 | pramipeksol | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC06 | kabergolina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC07 | apomorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC08 | pirybedyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BC09 | rotygotyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BD | Inhibitory monoaminooksydazy typu B | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BD01 | selegilina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BD02 | rasagilina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BD03 | safinamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BX | Inne leki dopaminergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BX01 | tolkapon | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BX02 | entakapon | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BX03 | budypina | WHO Anatomical Therapeutic Chemical classification
0‑L | N04BX04 | opikapon | WHO Anatomical Therapeutic Chemical classification
0‑L | N04C | INNE LEKI STOSOWANE W CHOROBIE PARKINSONA | WHO Anatomical Therapeutic Chemical classification
0‑L | N04CX | Inne leki stosowane w leczeniu choroby parkinsona | WHO Anatomical Therapeutic Chemical classification
0‑L | N04CX01 | istradefylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05 | LEKI PSYCHOLEPTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | N05A | LEKI PRZECIWPSYCHOTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA | Fenotiazyny z alifatycznym łańcuchem bocznym | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA01 | chloropromazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA02 | lewomepromazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA03 | promazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA04 | acepromazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA05 | triflupromazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA06 | cyjamemazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AA07 | chloroproetazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB | Fenotiazyny ze strukturą piperazyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB01 | diksyrazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB02 | flufenazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB03 | perfenazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB04 | prochloroperazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB05 | tiopropazat | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB06 | trifluoperazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB07 | acetofenazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB08 | tioproperazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB09 | butaperazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AB10 | perazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AC | Fenotiazyny ze strukturą piperydyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AC01 | akceptacja | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AC02 | akceptacja | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AC03 | mezorydazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AC04 | pipotiazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD | akceptacja | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD01 | haloperydol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD02 | trifluperydol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD03 | melperon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD04 | moperon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD05 | pipamperon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD06 | bromoperydol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD07 | benperydol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD08 | droperydol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD09 | fluanizon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AD10 | lumateperon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AE | Pochodne indolu | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AE01 | oksypertyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AE02 | molindon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AE03 | sertyndol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AE04 | zyprazydon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AE05 | lurazydon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AF | Pochodne tioksantenu | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AF01 | flupentyksol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AF02 | klopentyksol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AF03 | chloroprotyksen | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AF04 | tiotyksen | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AF05 | zuklopentyksol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AG | Pochodne difenylobutylopiperydyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AG01 | fluspirylen | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AG02 | pimozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AG03 | penflurydol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH | Diazepiny, oksazepiny, tiazepiny i oksepiny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH01 | loksapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH02 | klozapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH03 | olanzapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH04 | kwetiapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH05 | azenapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH06 | klotiapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AH53 | olanzapina i samidorfan | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL | Benzamidy | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL01 | sulpiryd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL02 | sultopryd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL03 | tiapryd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL04 | remoksypryd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL05 | akceptacja | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL06 | weralipryd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AL07 | lewosulpiryd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AN | Lit | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AN01 | lit | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX | Inne leki przeciwpsychotyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX07 | protypendyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX08 | rysperydon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX10 | mozapramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX11 | zotepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX12 | arypiprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX13 | paliperydon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX14 | iloperydon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX15 | karyprazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX16 | brekspiprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05AX17 | pimawanseryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05B | ANKSJOLITYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA | Pochodne benzodiazepiny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA01 | diazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA02 | chlorodiazepoksyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA03 | medazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA04 | oksazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA05 | potasu klorazepan | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA06 | lorazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA07 | adynazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA08 | bromazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA09 | klobazam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA10 | ketazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA11 | prazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA12 | alprazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA13 | halazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA14 | pinazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA15 | kamazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA16 | nordazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA17 | fludiazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA18 | etylu loflazepan | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA19 | etyzolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA21 | klotiazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA22 | kloksazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA23 | tofizopam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA24 | bentazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA25 | meksazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BA56 | lorazepam, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BB | akceptacja | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BB01 | hydroksyzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BB02 | kaptodiam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BB51 | hydroksyzyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BC | Karbaminiany | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BC01 | meprobamat | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BC03 | emylkamat | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BC04 | mebutamat | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BC51 | meprobamat, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BD | Pochodne dibenzobicyklooktadienu | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BD01 | benzoktamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BE | Pochodne azaspirodekanodionu | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BE01 | buspiron | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BX | Inne anksjolityki | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BX01 | mefenoksalon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BX02 | gedokarnil | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BX03 | etyfoksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BX04 | fabomotyzol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05BX05 | olejek eteryczny lawendowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N05C | LEKI NASENNE I USPOKAJAJĄCE | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA | Barbiturany, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA01 | pentobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA02 | amobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA03 | butobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA04 | barbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA05 | aprobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA06 | sekobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA07 | talbutal | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA08 | winylbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA09 | winbarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA10 | cyklobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA11 | heptabarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA12 | repozal | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA15 | metoheksytal | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA16 | heksobarbital | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA19 | tiopental | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA20 | akceptacja | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA21 | akceptacja | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CA22 | proksybarbal | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CB | Barbiturany, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CB01 | połączenia barbituranów | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CB02 | barbiturany w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CC | Aldehydy i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CC01 | wodzian chloralu | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CC02 | chloralodol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CC03 | acetyloglicynoamidu chloralu wodzian | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CC04 | dichloralfenazon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CC05 | paraldehyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD | Pochodne benzodiazepiny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD01 | flurazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD02 | nitrazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD03 | flunitrazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD04 | estazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD05 | triazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD06 | lormetazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD07 | temazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD08 | midazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD09 | brotyzolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD10 | kwazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD11 | loprazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD12 | doksefazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD13 | cynolazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD14 | remimazolam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CD15 | nimetazepam | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CE | Pochodne piperydynodionu | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CE01 | glutetymid | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CE02 | metyprylon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CE03 | pirytyldion | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CF | Benzodiazepiny leki pokrewne | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CF01 | zopiklon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CF02 | zolpidem | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CF03 | zaleplon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CF04 | eszopiklon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CH | Agoniści receptora melatoniny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CH01 | melatonina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CH02 | ramelteon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CH03 | tazymelteon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CJ | Antagoniści receptora oreksyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CJ01 | suworeksant | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CJ02 | lemboreksant | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CJ03 | daridoreksant | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM | Inne leki nasenne i uspokajające | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM01 | metakwalon | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM02 | klometiazol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM03 | bromizowal | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM04 | karbromal | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM05 | skopolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM06 | propiomazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM07 | triklofos | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM08 | etchlorwynol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM09 | Korzeń kozłka | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM10 | heksapropymat | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM11 | bromki | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM12 | apronal | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM13 | walnoktamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM15 | metylopentynol | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM16 | niaprazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CM18 | deksmedetomidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CX | Leki nasenne i uspokajające w połączeniu, z wyłączeniem barbituranów | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CX01 | meprobamat, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CX02 | metakwalon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CX03 | metylopentynol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CX04 | klometiazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CX05 | emepronium, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N05CX06 | dipiperonyloaminoetanol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N06 | LEKI PSYCHOANALEPTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | N06A | LEKI PRZECIWDEPRESYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA | Nieselektywne inhibitory wychwytu zwrotnego monoaminy | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA01 | dezypramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA02 | imipramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA03 | imipraminy tlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA04 | klomipramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA05 | opipramol | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA06 | trimipramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA07 | lofepramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA08 | dibenzepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA09 | amitryptylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA10 | nortryptylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA11 | protryptylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA12 | doksepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA13 | ipryndol | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA14 | melitracen | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA15 | butryptylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA16 | dozulepina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA17 | amoksapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA18 | dimetakryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA19 | amineptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA21 | maprotylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AA23 | chinupramina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB | Selektywne inhibitory wychwytu zwrotnego serotoniny | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB02 | zymeldyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB03 | fluoksetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB04 | cytalopram | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB05 | paroksetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB06 | sertralina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB07 | alaproklat | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB08 | fluwoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB09 | etoperydon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AB10 | escytalopram | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AF | Nieselektywne inhibitory monoaminooksydazy | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AF01 | izokarboksazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AF02 | nialamid | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AF03 | fenelzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AF04 | tranylcypromina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AF05 | iproniazyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AF06 | iproklozyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AG | Inhibitory monoaminooksydazy typu A | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AG02 | moklobemid | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AG03 | toloksaton | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX | Inne leki przeciwdepresyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX01 | oksytryptan | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX02 | tryptofan | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX03 | mianseryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX04 | nomifensyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX05 | trazodon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX06 | nefazodon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX07 | minapryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX08 | bifemelan | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX09 | wiloksazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX10 | oksaflozan | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX11 | mirtazapina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX12 | bupropion | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX13 | medyfoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX14 | tianeptyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX15 | piwagabina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX16 | wenlafaksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX17 | milnacypran | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX18 | reboksetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX19 | gepiron | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX21 | duloksetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX22 | agomelatyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX23 | deswenlafaksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX24 | wilazodon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX25 | Ziele dziurawca | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX26 | wortioksetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX27 | esketamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX28 | lewomilnacypran | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX29 | breksanolon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06AX62 | bupropion i dekstrometorfan | WHO Anatomical Therapeutic Chemical classification
0‑L | N06B | LEKI PSYCHOSTYMULUJĄCE, LEKI STOSOWANE W ADHD I NOOTROPOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA | Sympatykomimetyki działające ośrodkowo | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA01 | amfetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA02 | deksamfetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA03 | metamfetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA04 | metylofenidat | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA05 | pemolina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA06 | fenkamfamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA07 | modafinil | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA08 | fenozolon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA09 | atomoksetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA10 | fenetylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA11 | deksmetylofenidat | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA12 | lisdeksamfetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA13 | armodafinil | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA14 | solriamfetol | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BA15 | deksmetylofenidat i serdeksmetylofenidat | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BC | Pochodne ksantyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BC01 | kofeina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BC02 | propentofylina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX | Inne leki psychostymulujące i nootropowe | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX01 | meklofenoksat | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX02 | pirytynol | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX03 | piracetam | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX04 | deanol | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX05 | fipeksyd | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX06 | cytykolina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX07 | oksyracetam | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX08 | pirysudanol | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX09 | linopirdyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX10 | nizofenon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX11 | aniracetam | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX12 | acetylokarnityna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX13 | idebenon | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX14 | prolintan | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX15 | pipradrol | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX16 | pramiracetam | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX17 | adrafinil | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX18 | winpocetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX21 | temgikoluryl | WHO Anatomical Therapeutic Chemical classification
0‑L | N06BX22 | fenibut | WHO Anatomical Therapeutic Chemical classification
0‑L | N06C | LEKI PSYCHOLEPTYCZNE I PSYCHOANALEPTYCZNE W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | N06CA | Leki przeciwdepresyjne w połączeniu z lekami psycholeptycznymi | WHO Anatomical Therapeutic Chemical classification
0‑L | N06CA01 | amitryptylina i leki psycholeptyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | N06CA02 | melitracen i leki psycholeptyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | N06CA03 | fluoksetyna i leki psycholeptyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | N06CB | Leki psychostymulujące w połączeniu z lekami psycholeptycznymi | WHO Anatomical Therapeutic Chemical classification
0‑L | N06D | LEKI STOSOWANE W ZESPOŁACH OTĘPIENNYCH | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA | Inhibitory cholinoesterazy | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA01 | takryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA02 | donepezyl | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA03 | rywastygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA04 | galantamina | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA05 | ipidakryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA52 | donepezyl i memantyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DA53 | donepezyl, memantyna i liść miłorzębu japońskiego | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DX | Inne leki stosowane w zespołach otępiennych | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DX01 | memantyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DX02 | Liść miłorzębu japońskiego | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DX03 | adukanumab | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DX04 | lekanemab | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DX05 | donanemab | WHO Anatomical Therapeutic Chemical classification
0‑L | N06DX30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N07 | INNE LEKI DZIAŁAJĄCE NA UKŁAD NERWOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | N07A | PARASYMPATYKOMIMETYKI | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AA | Inhibitory cholinoesterazy | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AA01 | neostygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AA02 | pirydostygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AA03 | distygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AA30 | ambenonium | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AA51 | neostygmina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AB | Estry choliny | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AB01 | karbachol | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AB02 | betanechol | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AX | Inne parasympatykomimetyki | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AX01 | pilokarpina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AX02 | choliny alfosceran | WHO Anatomical Therapeutic Chemical classification
0‑L | N07AX03 | cewimelina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07B | LEKI STOSOWANE W UZALEŻNIENIACH | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BA | Leki stosowane w uzależnieniu od nikotyny | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BA01 | nikotyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BA03 | wareniklina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BA04 | cytyzynyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BB | Leki stosowane w uzależnieniu od alkoholu | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BB01 | disulfiram | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BB02 | wapnia karbimid | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BB03 | akamprozat | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BB04 | naltrekson | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BB05 | nalmefen | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC | Leki stosowane w uzależnieniu od opioidów | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC01 | buprenorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC02 | metadon | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC03 | lewacetylometadol | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC04 | lofeksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC05 | lewometadon | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC06 | diamorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | N07BC51 | buprenorfina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N07C | LEKI PRZECIW ZAWROTOM GŁOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | N07CA | Leki przeciw zawrotom głowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N07CA01 | betahistyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07CA02 | cynaryzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07CA03 | flunaryzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07CA04 | acetyloleucyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07CA52 | cynaryzyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | N07X | INNE LEKI DZIAŁAJĄCE NA UKŁAD NERWOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XA | Gangliozydy i pochodne gangliozydu | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX | Inne leki działające na układ nerwowy | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX01 | tyrylazad | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX02 | ryluzol | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX03 | ksaliproden | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX04 | sodu hydroksymaślan | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX05 | amifamprydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX06 | tetrabenazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX07 | famprydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX08 | tafamidys | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX10 | lakwinimod | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX11 | pitolisant | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX12 | patysyran | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX13 | walbenazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX14 | edarawon | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX15 | inotersen | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX16 | deutetrabenazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX17 | arimoklomol | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX18 | wutrisiran | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX19 | fenylomaślan sodu i ursodoksykoltauryna | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX21 | eplontersen | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX22 | tofersen | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX23 | troriluzol | WHO Anatomical Therapeutic Chemical classification
0‑L | N07XX59 | dekstrometorfan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P | LEKI PRZECIWPASOŻYTNICZE, ŚRODKI OWADOBÓJCZE I REPELENTY | WHO Anatomical Therapeutic Chemical classification
0‑L | P01 | LEKI PRZECIWPIERWOTNIAKOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | P01A | LEKI PRZECIW AMEBOZIE I INNYM CHOROBOM PIERWOTNIAKOWYM | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AA | Pochodne hydroksychinoliny | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AA01 | broksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AA02 | kliochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AA04 | chlorochinaldol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AA05 | tylbrochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AA30 | tylbrochinol i tilichinol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AA52 | kliochinol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB | Pochodne nitroimidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB01 | metronidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB02 | tynidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB03 | ornidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB04 | azanidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB05 | propenidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB06 | nimorazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB07 | seknidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB51 | metronidazol i furazolidon | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AB52 | metronidazol i diloksanid | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AC | Pochodne dichloroacetamidu | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AC01 | diloksanid | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AC02 | klefamid | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AC03 | etofamid | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AC04 | teklozan | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AR | Związki arsenu | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AR01 | arstinol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AR02 | difetarson | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AR03 | glikobiarsol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AR53 | glikobiarsol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX | Inne leki przeciw amebozie i innym chorobom pierwotniakowym | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX01 | chiniofon | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX02 | emetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX04 | fanchinon | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX05 | mepakryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX06 | atowakwon | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX07 | trimetreksat | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX08 | tenonitrozol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX09 | dehydroemetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX10 | fumagilina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX11 | nitazoksanid | WHO Anatomical Therapeutic Chemical classification
0‑L | P01AX52 | emetyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P01B | LEKI PRZECIWMALARYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BA | Pochodne aminochinoliny | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BA01 | chlorochina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BA02 | hydroksychlorochina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BA03 | prymachina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BA06 | amodiachina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BA07 | tafenochina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BB | Biguanidy | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BB01 | proguanil | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BB02 | cykloguanilu embonian | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BB51 | proguanil i atowakwon | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BB52 | chlorokwina i proguanil | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BC | Metanolochinoliny | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BC01 | chinina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BC02 | meflochina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BD | Diaminopirymidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BD01 | pirymetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BD51 | pirymetamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BE | Artemizynina i pochodne, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BE01 | artemizynina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BE02 | artemeter | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BE03 | artezunat | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BE04 | artemotyl | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BE05 | artenimol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF | Artemizynina i pochodne, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF01 | artemeter i lumefantryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF02 | artezunat i meflochina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF03 | artezunat i amodiachina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF04 | artezunat, sulfalen i pirymetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF05 | artenimol i piperachina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF06 | artezunat i pironarydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF07 | artemizynina i piperachina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF08 | artemizynina i naftochina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BF09 | artesunat, sulfadoksyna i pirymetamina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BX | Inne leki przeciwmalaryczne | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BX01 | halofantryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P01BX02 | arterolan i piperachina | WHO Anatomical Therapeutic Chemical classification
0‑L | P01C | LEKI PRZECIW LEISZMANIOZIE I TRYPANOSOMATOZIE | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CA | Pochodne nitroimidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CA02 | benznidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CA03 | feksynidazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CB | Związki antymonu | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CB01 | megluminy antymonian | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CB02 | sodu styboglukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CC | Pochodne nitrofuranu | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CC01 | nifurtymoks | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CC02 | nitrofural | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CD | Związki arsenu | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CD01 | melarsoprol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CD02 | acetarsol | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CX | Inne leki przeciw leiszmaniozie i trypanosomatozom | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CX01 | pentamidyny izetionian | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CX02 | suramina sodowa | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CX03 | eflornityna | WHO Anatomical Therapeutic Chemical classification
0‑L | P01CX04 | miltefosyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P02 | LEKI PRZECIW ROBAKOM | WHO Anatomical Therapeutic Chemical classification
0‑L | P02B | LEKI PRZECIW PŁAZIŃCOM | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BA | Pochodne chinoliny i substancje pokrewne | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BA01 | prazykwantel | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BA02 | oksamnichina | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BA03 | arprazykwantel | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BB | Związki fosforoorganiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BB01 | metryfonat | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BX | Inne leki przeciw płazińcom | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BX01 | bitionol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BX02 | nirydazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BX03 | stybofen | WHO Anatomical Therapeutic Chemical classification
0‑L | P02BX04 | triklabendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02C | LEKI PRZECIW OBLEŃCOM | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA | Pochodne benzimidazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA01 | mebendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA02 | tiabendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA03 | albendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA04 | cyklobendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA05 | flubendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA06 | fenbendazol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CA51 | mebendazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CB | Piperazyna i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CB01 | piperazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CB02 | dietylokarbamazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CC | Pochodne tetrahydropirymidyny | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CC01 | pyrantel | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CC02 | oksantel | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CE | Pochodne imidazotiazolu | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CE01 | lewamizol | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CF | Awermektyny | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CF01 | iwermektyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CX | Inne leki przeciw obleńcom | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CX01 | pirwinium | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CX02 | befenium | WHO Anatomical Therapeutic Chemical classification
0‑L | P02CX03 | moksydektyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P02D | LEKI PRZECIW TASIEMCOM | WHO Anatomical Therapeutic Chemical classification
0‑L | P02DA | Pochodne kwasu salicylowego | WHO Anatomical Therapeutic Chemical classification
0‑L | P02DA01 | niklozamid | WHO Anatomical Therapeutic Chemical classification
0‑L | P02DX | Inne leki przeciw tasiemcom | WHO Anatomical Therapeutic Chemical classification
0‑L | P02DX01 | dezaspidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P02DX02 | dichlorofen | WHO Anatomical Therapeutic Chemical classification
0‑L | P03 | LEKI PRZECIW PASOŻYTOM ZEWNĘTRZNYM, WŁĄCZNIE Z PRZECIWŚWIERZBOWYMI, ŚRODKAMI OWADOBÓJCZYMI I REPELENTAMI | WHO Anatomical Therapeutic Chemical classification
0‑L | P03A | LEKI PRZECIW PASOŻYTOM ZEWNĘTRZNYM, WŁĄCZNIE Z PRZECIWŚWIERZBOWYMI | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AA | Preparaty zawierające siarkę | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AA01 | diksantogen | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AA02 | potasu polisiarczek | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AA03 | mesulfen | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AA04 | disulfiram | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AA05 | tiram | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AA54 | disulfiram, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AB | Preparaty zawierające chlor | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AB01 | klofenotan | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AB02 | lindan | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AB51 | klofenotan, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC | Pyretryny, włącznie ze związkami syntetycznymi | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC01 | pyretrum | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC02 | bioallertyna | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC03 | fenotryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC04 | permetryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC51 | pyretrum, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC52 | bioallertyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC53 | fenotryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AC54 | permetryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX | Inne leki przeciw pasożytom zewnętrznym, włącznie z przeciwświerzbowymi | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX01 | benzylu benzoesan | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX02 | miedzi oleinian | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX03 | malation | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX04 | gorzkla właściwa | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX05 | dimetykon | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX06 | alkohol benzylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | P03AX07 | abametapir | WHO Anatomical Therapeutic Chemical classification
0‑L | P03B | ŚRODKI OWADOBÓJCZE I REPELENTY | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BA | Pyretryny | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BA01 | cyflutryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BA02 | cypermetryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BA03 | dekametryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BA04 | tetrametryna | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BX | Inne środki owadobójcze i repelenty | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BX01 | dietylotoluamid | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BX02 | dimetylu ftalan | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BX03 | dibutylu ftalan | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BX04 | dibutylu bursztynian | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BX05 | dimetylokarban | WHO Anatomical Therapeutic Chemical classification
0‑L | P03BX06 | etoheksadiol | WHO Anatomical Therapeutic Chemical classification
0‑L | R | UKŁAD ODDECHOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | R01 | LEKI DO NOSA | WHO Anatomical Therapeutic Chemical classification
0‑L | R01A | LEKI ZMNIEJSZAJĄCE PRZEKRWIENIE BŁONY ŚLUZOWEJ I INNE LEKI DO NOSA DO STOSOWANIA MIEJSCOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA | Sympatykomimetyki, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA02 | cyklopentamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA03 | efedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA04 | fenylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA05 | oksymetazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA06 | tetryzolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA07 | ksylometazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA08 | nafazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA09 | tramazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA10 | metyzolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA11 | tuaminoheptan | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA12 | fenoksazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA13 | tymazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA14 | epinefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AA15 | indanazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB | Sympatykomimetyki, połączenia z wyłączeniem kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB01 | fenylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB02 | nafazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB03 | tetryzolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB05 | efedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB06 | ksylometazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB07 | oksymetazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AB08 | tuaminoheptan | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC | Leki przeciwalergiczne, z wyłączeniem kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC01 | kwas kromoglika | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC02 | lewokabastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC03 | azelastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC04 | antazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC05 | kwas spaglumowy | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC06 | tonzylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC07 | nedokromil | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC08 | olopatadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AC51 | kwas kromoglika, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD | Kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD01 | beklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD02 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD03 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD04 | flunizolid | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD05 | budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD06 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD07 | tyksokortol | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD08 | flutykazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD09 | mometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD11 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD12 | flutykazonu furoinian | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD13 | cyklezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD52 | prednizolon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD53 | deksametazon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD57 | tyksokortol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD58 | flutykazon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD59 | mometazon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AD60 | hydrokortyzon, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX | Inne leki do nosa | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX01 | wapnia heksaminy tiocyjanian | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX02 | retynol | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX03 | ipratropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX05 | rytiometan | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX06 | mupirocyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX07 | heksamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX08 | framycetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX09 | kwas hialuro | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX10 | różne | WHO Anatomical Therapeutic Chemical classification
0‑L | R01AX30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01B | LEKI ZMNIEJSZAJĄCE PRZEKRWIENIE BŁONY ŚLUZOWEJ NOSA DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | R01BA | Sympatykomimetyki | WHO Anatomical Therapeutic Chemical classification
0‑L | R01BA01 | fenylopropanolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R01BA02 | pseudoefedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01BA03 | fenylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R01BA51 | fenylopropanolamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01BA52 | pseudoefedryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R01BA53 | fenylefryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R02 | LEKI STOSOWANE W CHOROBACH GARDŁA | WHO Anatomical Therapeutic Chemical classification
0‑L | R02A | LEKI STOSOWANE W CHOROBACH GARDŁA | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA | Antyseptyki | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA01 | ambazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA02 | dekwalinium | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA03 | alkohol dichlorobenzylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA05 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA06 | cetylopirydynium | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA09 | benzetonium | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA10 | mirystyl – benzalkonium | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA11 | chlorchinaldol | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA12 | heksylorezorcynol | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA13 | akryflawiniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA14 | oksychinolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA15 | powidon jodowany | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA16 | benzalkonium | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA17 | cetrymonium | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA18 | heksamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA19 | fenol | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA20 | różne | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AA21 | oktenidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AB | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AB01 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AB02 | tyrotrycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AB03 | fusafungina | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AB04 | bacytracyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AB30 | gramicydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AD | Leki znieczulające miejscowo | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AD01 | benzokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AD02 | lidokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AD03 | kokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AD04 | dyklonina | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AD05 | ambroksol | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AX | Inne leki stosowane w chorobach gardła | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AX01 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AX02 | ibuprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | R02AX03 | benzydamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03 | LEKI STOSOWANE W CHOROBACH PRZEBIEGAJĄCYCH ZE SKURCZEM OSKRZELI | WHO Anatomical Therapeutic Chemical classification
0‑L | R03A | LEKI ADRENERGICZNE, WZIEWNE | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AA | Agoniści receptorów alfa- i beta-adrenergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AA01 | epinefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AB | Nieselektywni agoniści receptorów beta-adrenergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AB02 | izoprenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AB03 | orcyprenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC | Selektywni agoniści receptorów beta-2-adrenergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC02 | salbutamol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC03 | terbutalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC04 | fenoterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC05 | rymiterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC06 | heksoprenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC07 | izoetaryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC08 | pirbuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC09 | tretochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC10 | karbuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC11 | tulobuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC12 | salmeterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC13 | formoterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC14 | klenbuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC15 | reproterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC16 | prokaterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC17 | bitolterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC18 | indakaterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AC19 | olodaterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AH | Połączenia leków adrenergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK | Leki adrenergiczne w połączeniu z krortykosteroidami lub innymi lekami, z wyłączeniem leków cholinolitycznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK01 | epinefryna i inne leki stosowane w chorobach przebigających ze skurczem oskrzeli | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK02 | izoprenalina i inne leki stosowane w chorobach przebigających ze skurczem oskrzeli | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK04 | salbutamol i sodu kromoglikan | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK05 | reproterol i sodu kromoglikan | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK06 | salmeterol i flutykazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK07 | formoterol i budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK08 | formoterol i beklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK09 | formoterol i mometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK10 | wilanterol i flutykazonu furoinian | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK11 | formoterol i flutykazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK12 | salmeterol i budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK13 | salbutamol i beklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK14 | indakaterol i mometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AK15 | salbutamol i budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL | Leki adrenergiczne w połączeniu z lekami cholinolitycznymi włącznie z potrójnymi połączeniami z kortykosteroidami | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL01 | fenoterol i ipratropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL02 | salbutamol i ipratropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL03 | wilanterol i umeklidyniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL04 | indakaterol i glikopironiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL05 | formoterol i aklidyniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL06 | olodaterol i tiotropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL07 | formoterol i glikopironiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL08 | wilanterol, umeklidyniowy bromek i flutykazonu furoinian | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL09 | formoterol, glikopironiowy bromek i beklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL10 | formoterol i tiotropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL11 | formoterol, glikopironiowy bromek i budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R03AL12 | indakaterol, glikopironiowy bromek i mometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03B | INNE LEKI STOSOWANE W CHOROBACH PRZEBIEGAJĄCYCH ZE SKURCZEM OSKRZELI, WZIEWNE | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA | Glikokortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA01 | beklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA02 | budezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA03 | flunizolid | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA04 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA05 | flutykazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA06 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA07 | mometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA08 | cyklezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BA09 | flutykazonu furoinian | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB | Leki cholinolityczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB01 | ipratropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB02 | oksytropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB03 | preparaty bielunia dziędzierzawy | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB04 | tiotropiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB05 | aklidyniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB06 | glikopironiowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB07 | umeklidyniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB08 | rewefenacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BB54 | tiotropiowy bromek, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BC | Leki przeciwalergiczne, z wyłączeniem kortykosteroidów | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BC01 | kwas kromoglika | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BC03 | nedokromil | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BX | Inne leki stosowane w chorobach przebiegających ze skurczem oskrzeli, wziewne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03BX01 | fenspiryd | WHO Anatomical Therapeutic Chemical classification
0‑L | R03C | LEKI ADRENERGICZNE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CA | Agoniści receptorów alfa- i beta-adrenergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CA02 | efedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CB | Nieselektywni agoniści receptorów beta-adrenergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CB01 | izoprenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CB02 | metoksyfenamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CB03 | orcyprenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CB51 | izoprenalina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CB53 | orcyprenalina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC | Selektywni agoniści receptorów beta-2-adrenergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC02 | salbutamol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC03 | terbutalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC04 | fenoterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC05 | heksoprenalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC06 | izoetaryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC07 | pirbuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC08 | prokaterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC09 | tretochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC10 | karbuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC11 | tulobuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC12 | bambuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC13 | klenbuterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC14 | reproterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC15 | formoterol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC53 | terbutalina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CC63 | klenbuterol i ambroksol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03CK | Leki adrenergiczne i inne leki stosowane w chorobach przebiegających ze skurczem oskrzeli | WHO Anatomical Therapeutic Chemical classification
0‑L | R03D | INNE LEKI DO STOSOWANIA OGÓLNEGO W CHOROBACH PRZEBIEGAJĄCYCH ZE SKURCZEM OSKRZELI | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA | Ksantyny | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA01 | diprofilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA02 | choliny teofilinian | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA03 | proksyfilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA04 | teofilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA05 | aminofilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA06 | etamifilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA07 | teobromina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA08 | bamifilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA09 | acefilina z piperazyną | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA10 | bufilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA11 | boksofilina | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA12 | mepyraminy teofilinooctan | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA20 | połączenia ksantyn | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA51 | diprofilina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA54 | teofilina, połączenia z wyłączeniem psycholeptyków | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA55 | aminofilina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA57 | teobromina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DA74 | teofilina, połączenia z psycholeptykami | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DB | Ksantyny i leki adrenergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DB01 | diprofilina i leki adrenergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DB02 | choliny teofilinian i leki adrenergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DB03 | proksyfilina i leki adrenergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DB04 | teofilina i leki adrenergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DB05 | aminofilina i leki adrenergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DB06 | etamifilina i leki adrenergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DC | Antagoniści receptora leukotrienowego | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DC01 | zafirlukast | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DC02 | pranlukast | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DC03 | montelukast | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DC04 | ibudilast | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DC53 | montelukast, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX | Inne leki do stosowania ogólnego w chorobach przebiegających ze skurczem oskrzeli | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX01 | amleksanoks | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX02 | eprozynol | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX03 | fenspiryd | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX05 | omalizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX06 | seratrodast | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX07 | roflumilast | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX08 | reslizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX09 | mepolizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX10 | benralizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | R03DX11 | tezepelumab | WHO Anatomical Therapeutic Chemical classification
0‑L | R05 | LEKI STOSOWANE W KASZLU I PRZEZIĘBIENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | R05C | LEKI WYKRZTUŚNE, Z WYŁĄCZENIEM POŁĄCZEŃ Z LEKAMI PRZECIWKASZLOWYMI | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA | Leki wykrztuśne | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA01 | tyloksapol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA02 | potasu jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA03 | gwajafenezyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA04 | ipekakuana | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA05 | altheae radix (korzeń prawoślazu) | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA06 | krzyżownica | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA07 | antymonu pentasiarczek | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA08 | kreozot | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA09 | gwajakolosulfonian | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA11 | lewowerbenon | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA12 | liść bluszczu pospolitego | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CA13 | cyneol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB | Mukolityki | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB01 | acetylocysteina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB02 | bromoheksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB03 | karbocysteina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB04 | eprazynon | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB05 | mesna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB06 | ambroksol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB07 | sobrerol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB08 | domiodol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB09 | letosteina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB10 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB11 | stepronina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB13 | dornaza alfa (dezoksyrybonukleaza) | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB14 | nelteneksyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB15 | erdosteina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05CB16 | mannitol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05D | LEKI PRZECIWKASZLOWE, Z WYŁĄCZENIEM POŁĄCZEŃ Z LEKAMI WYKRZTUŚNYMI | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA | Alkaloidy opium i pochodne | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA01 | etylomorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA03 | hydrokodon | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA04 | kodeina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA05 | alkaloidy opium z morfiną | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA06 | normetadon | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA07 | noskapina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA08 | folkodyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA09 | dekstrometorfan | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA10 | tebakon | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA11 | dimemorfan | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA12 | acetylodihydrokodeina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DA20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB | Inne leki przeciwkaszlowe | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB01 | benzonatat | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB02 | benproperyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB03 | klobutynol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB04 | izoaminil | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB05 | pentoksyweryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB07 | oksolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB09 | okseladyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB10 | klofedanol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB11 | pipazetat | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB12 | bibenzoniowy bromek | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB13 | butamirat | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB14 | fedrylat | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB15 | zipeprol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB16 | dibunat | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB17 | droksypropina | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB18 | prenoksdiazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB19 | dropropizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB20 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB21 | kloperastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB22 | meprotyksol | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB23 | piperydion | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB24 | typepidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB25 | morklofon | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB26 | nepinalon | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB27 | lewodropropizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB28 | dimetoksanat | WHO Anatomical Therapeutic Chemical classification
0‑L | R05DB29 | gefapiksant | WHO Anatomical Therapeutic Chemical classification
0‑L | R05F | LEKI PRZECIWKASZLOWE I WYKRZTUŚNE, POŁĄCZENIA | WHO Anatomical Therapeutic Chemical classification
0‑L | R05FA | Pochodne opium i leki wykrztuśne | WHO Anatomical Therapeutic Chemical classification
0‑L | R05FA01 | pochodne opium i mukolityki | WHO Anatomical Therapeutic Chemical classification
0‑L | R05FA02 | pochodne opium i leki wykrztuśne | WHO Anatomical Therapeutic Chemical classification
0‑L | R05FB | Inne leki przeciwkaszlowe i wykrztuśne | WHO Anatomical Therapeutic Chemical classification
0‑L | R05FB01 | leki przeciwkaszlowe i mukolityki | WHO Anatomical Therapeutic Chemical classification
0‑L | R05FB02 | leki przeciwkaszlowe i wykrztuśne | WHO Anatomical Therapeutic Chemical classification
0‑L | R05X | INNE PREPARATY PRZECIW PRZEZIĘBIENIOM | WHO Anatomical Therapeutic Chemical classification
0‑L | R06 | LEKI PRZECIWHISTAMINOWE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | R06A | LEKI PRZECIWHISTAMINOWE DO STOSOWANIA OGÓLNEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA | Aminoalkilowe etery | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA01 | bromazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA02 | difenhydramina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA04 | klemastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA06 | chlorfenoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA07 | difenylopiralina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA08 | karbinoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA09 | doksylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA10 | trimetobenzamid | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA11 | dimenhydrynat | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA52 | difenhydramina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA54 | klemastyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA56 | chlorfenoksamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA57 | difenylopiralina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA59 | doksylamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AA61 | dimenhydrynat, kombinacje | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB | Alkiloaminy podstawione | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB01 | bromofeniramina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB02 | deksochlorofeniramina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB03 | dimetynden | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB04 | chlorofenamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB05 | feniramina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB06 | deksbromofeniramina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB07 | talastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB51 | bromofeniramina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB52 | dekschlorofeniramina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB54 | chlorofenamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AB56 | deksbromofeniramina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC | Etylenodiaminy podstawione | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC01 | mepiramina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC02 | histapirodyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC03 | chloropiramina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC04 | tripelenamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC05 | metapirylen | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC06 | tonzylamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC52 | histapirodyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AC53 | chlorpiramina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD | Pochodne fenotiazyny | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD01 | alimemazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD02 | prometazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD03 | tietyloperazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD04 | metdylazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD05 | hydroksyetyloprometazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD06 | tiazynam | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD07 | mekwitazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD08 | oksomemazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD09 | izotipendyl | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD52 | prometazyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AD55 | hydroksyetyloprometazyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE | Pochodne piperazyny | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE01 | buklizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE03 | cyklizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE04 | chlorocyklizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE05 | meklozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE06 | oksatomid | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE07 | cetyryzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE09 | lewocetyryzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE51 | buklizyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE53 | cyklizyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AE55 | meklozyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AK | Połączenia leków przeciwhistamich | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX | Inne leki przeciwhistaminowe do stosowania ogólnego | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX01 | bamipina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX02 | cyproheptadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX03 | tenalidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX04 | fenindamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX05 | antazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX07 | triprolidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX08 | pirobutamina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX09 | azatadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX11 | astemizol | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX12 | terfenadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX13 | loratadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX15 | mebhydrolina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX16 | deptropina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX17 | ketotifen | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX18 | akrywastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX19 | azelastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX21 | trytokwalina | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX22 | ebastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX23 | pimetiksen | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX24 | epinastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX25 | mizolastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX26 | feksofenadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX27 | desloratadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX28 | rupatadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX29 | bilastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX31 | chifenadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX32 | sekwifenadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX53 | tenalidyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R06AX58 | pirobutamina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R07 | INNE LEKI STOSOWANE W CHOROBACH UKŁADU ODDECHOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | R07A | INNE LEKI STOSOWANE W CHOROBACH UKŁADU ODDECHOWEGO | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AA | Surfaktanty płucne | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AA01 | kolfoscerylu palmitynian | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AA02 | naturalne fosfolipidy | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AA30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB | Leki pobudzające czynność oddechową | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB01 | doksapram | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB02 | niketamid | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB03 | pentetrazol | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB04 | etamiwan | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB05 | bemegryd | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB06 | pretkamid | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB07 | almitryna | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB08 | dimeflina | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB09 | mepiksanoks | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB52 | niketamid, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AB53 | pentetrazol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AX | Inne leki stosowane w chorobach układu oddechowego | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AX01 | tlenek azotu | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AX02 | iwakaftor | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AX30 | iwakaftor i lumakaftor | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AX31 | iwakaftor i tezakaftor | WHO Anatomical Therapeutic Chemical classification
0‑L | R07AX32 | iwakaftor, tezakaftor i eleksakaftor | WHO Anatomical Therapeutic Chemical classification
0‑L | S | NARZĄDY ZMYSŁÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | S01 | LEKI OFTALMOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01A | LEKI PRZECIWINFEKCYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA | Antybiotyki | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA01 | chloramfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA02 | chlorotetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA03 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA04 | oksytetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA05 | tyrotrycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA07 | framycetyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA09 | tetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA10 | natamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA11 | gentamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA12 | tobramycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA13 | kwas fusydy | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA14 | benzylopenicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA15 | dihydrostreptomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA16 | ryfamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA17 | erytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA18 | polimyksyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA19 | ampicylina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA20 | antybiotyki w połączeniu z innymi lekami | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA21 | amikacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA22 | mikronomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA23 | netylmycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA24 | kanamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA25 | azydamfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA26 | azytromycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA27 | cefuroksym | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA28 | wankomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA29 | dibekacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA30 | połączenia różnych antybiotyków | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA31 | cefmenoksym | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AA32 | bacytracyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AB | Sulfonamidy | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AB01 | sulfametyzol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AB02 | sulfafurazol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AB03 | sulfadikramid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AB04 | sulfacetamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AB05 | sulfafenazol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD | Leki przeciwwirusowe | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD01 | idoksurydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD02 | triflurydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD03 | acyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD05 | interferon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD06 | widarabina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD07 | famcyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD08 | fomiwirsen | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AD09 | gancyklowir | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE | Fluorochinolony | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE01 | ofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE02 | norfloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE03 | cyprofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE04 | lomefloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE05 | lewofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE06 | gatyfloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE07 | moksyfloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE08 | bezyfloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AE09 | tosufloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX | Inne leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX01 | związki rtęci | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX02 | związki srebra | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX03 | związki cynku | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX04 | nitrofural | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX05 | bibrokatol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX06 | rezorcynol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX07 | sodu boran | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX08 | heksamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX09 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX10 | sodu propionian | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX14 | dibromopropamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX15 | propamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX16 | pikloksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX18 | powidon jodowany | WHO Anatomical Therapeutic Chemical classification
0‑L | S01AX24 | poliheksanid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01B | LEKI PRZECIWZAPALNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA | Kortykosteroidy, bez dodatków | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA01 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA02 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA03 | kortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA04 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA05 | triamcynolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA06 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA07 | fluorometolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA08 | medryzon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA09 | klobetazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA10 | alklometazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA11 | dezonid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA12 | formokortal | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA13 | rimeksolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA14 | loteprednol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA15 | fluocynolonu acetonid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BA16 | difluprednat | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BB | Kortykosteroidy i leki rozszerzające źrenice w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BB01 | hydrokortyzon i leki rozszerzające źrenice | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BB02 | prednizolon i leki rozszerzające źrenice | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BB03 | fluorometolon i leki rozszerzające źrenice | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BB04 | betametazon i leki rozszerzające źrenice | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC | Niesteroidowe leki przeciwzapalne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC01 | indometacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC02 | oksyfenbutazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC03 | diklofenak | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC04 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC05 | ketorolak | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC06 | piroksykam | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC07 | bendazak | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC08 | kwas salicylowy | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC09 | pranoprofen | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC10 | nepafenak | WHO Anatomical Therapeutic Chemical classification
0‑L | S01BC11 | bromfenak | WHO Anatomical Therapeutic Chemical classification
0‑L | S01C | LEKI PRZECIWZAPALNE I PRZECIWINFEKCYJNE W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA | Kortykosteroidy i leki przeciwinfekcyjne w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA01 | deksametazon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA02 | prednizolon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA03 | hydrokortyzon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA04 | fluokortolon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA05 | betametazon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA06 | fludrokortyzon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA07 | fluorometolon I leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA08 | metyloprednizolon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA09 | chloroprednizolon leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA10 | fluocynolonu acetonid i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA11 | klobetazon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CA12 | loteprednol i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CB | Kortykosteroidy/ leki przeciwinfekcyjne/ leki rozszerzające źrenice w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CB01 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CB02 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CB03 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CB04 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CB05 | fluorometolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CC | Leki przeciwzapalne, połączenie leków niesteroidowych i przeciwinfekcyjnch | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CC01 | diklofenak i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01CC02 | indometacyna i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01E | LEKI STOSOWANE W JASKRZE I ZWĘŻAJĄCE ŹRENICE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EA | Sympatykomimetyki stosowane w leczeniu jaskry | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EA01 | epinefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EA02 | dipiwefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EA03 | apraklonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EA04 | klonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EA05 | brymonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EA51 | epinefryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB | Parasympatykomimetyki | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB01 | pilokarpina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB02 | karbachol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB03 | ekotiopat | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB04 | demekarium | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB05 | fizostygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB06 | neostygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB07 | fluostygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB08 | aceklidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB09 | acetylocholina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB10 | paraokson | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB51 | pilokarpina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EB58 | aceklidyna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EC | Inhibitory anhydrazy węglanowej | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EC01 | acetazolamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EC02 | diklofenamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EC03 | dorzolamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EC04 | brynzolamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EC05 | metazolamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EC54 | brynzolamid, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED | Beta-adrenolityki | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED01 | tymolol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED02 | betaksolol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED03 | lewobunolol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED04 | metypranolol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED05 | karteolol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED06 | befunolol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED51 | tymolol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED52 | betaksolol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED54 | metypranolol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01ED55 | karteolol, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE | Analogi prostaglandyny | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE01 | latanoprost | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE02 | unoproston | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE03 | bimatoprost | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE04 | trawoprost | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE05 | tafluprost | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE06 | latanoprosten bunod | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EE51 | latanoprost i netarsudyl | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EX | Inne leki stosowane w jaskrze | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EX01 | guanetydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EX02 | dapiprazol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EX05 | netarsudyl | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EX06 | omidenepag | WHO Anatomical Therapeutic Chemical classification
0‑L | S01EX07 | ripasudyl | WHO Anatomical Therapeutic Chemical classification
0‑L | S01F | LEKI ROZSZERZAJĄCE ŹRENICE I PORAŻAJĄCE AKOMODACJE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA | Leki cholinolityczne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA01 | atropina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA02 | skopolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA03 | metyloskopolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA04 | cyklopentolat | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA05 | homatropina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA06 | tropikamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA54 | cyklopentolat, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FA56 | tropikamid, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FB | Sympatykomimetyki, z wyłączeniem leków stosowanych w jaskrze | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FB01 | fenylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FB02 | efedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FB03 | ibopamina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01FB51 | fenylefryna i ketorolak | WHO Anatomical Therapeutic Chemical classification
0‑L | S01G | LEKI ZWĘŻAJĄCE NACZYNIA KRWIONOŚNE I PRZECIWALERGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA | Sympatykomimetyki stosowane jako leki zwężające naczynia krwionośne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA01 | nafazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA02 | tetryzolina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA03 | ksylometazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA04 | oksymetazolina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA05 | fenylefryna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA06 | oksedryna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA07 | brymonidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA51 | nafazolina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA52 | tetryzolina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA53 | ksylometazolina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA55 | fenylefryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GA56 | oksedryna, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX | Inne leki przeciwalergiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX01 | kwas kromoglika | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX02 | lewokabastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX03 | kwas spaglumowy | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX04 | nedokromil | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX05 | lodoksamid | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX06 | emedastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX07 | azelastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX08 | ketotifen | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX09 | olopatadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX10 | epinastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX11 | alkaftadyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX12 | cetyryzyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX13 | bilastyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01GX51 | kwas kromoglika, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01H | LEKI ZNIECZULAJĄCE MIEJSCOWO | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA | Leki znieczulające miejscowo | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA01 | kokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA02 | oksybuprokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA03 | tetrakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA04 | proksymetakaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA05 | prokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA06 | cynchokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA07 | lidokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA08 | chloroprokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01HA30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01J | PREPARATY DIAGNOSTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01JA | Preparaty barwiące | WHO Anatomical Therapeutic Chemical classification
0‑L | S01JA01 | fluoresceina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01JA02 | róż bengalski sodowy | WHO Anatomical Therapeutic Chemical classification
0‑L | S01JA51 | fluoresceina, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01JX | Inne preparaty diagnostyczne oftalmologiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01K | POMOCNICZE ŚRODKI CHIRURGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01KA | Substancje wiskoelastyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01KA01 | kwas hialuro | WHO Anatomical Therapeutic Chemical classification
0‑L | S01KA02 | hypromeloza | WHO Anatomical Therapeutic Chemical classification
0‑L | S01KA51 | kwas hialuro, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S01KX | Inne pomocnicze środki chirurgiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01KX01 | chymotrypsyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01KX02 | błękit trypanowy | WHO Anatomical Therapeutic Chemical classification
0‑L | S01L | LEKI STOSOWANE W CHOROBACH NACZYNIOWYCH OKA | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA | Leki przeciwneowaskularyzacyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA01 | werteporfina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA02 | anekortaw | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA03 | pegaptanib | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA04 | ranibizumab | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA05 | aflibercept | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA06 | brolucyzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA07 | abicipar pegol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA08 | bewacyzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | S01LA09 | farycymab | WHO Anatomical Therapeutic Chemical classification
0‑L | S01X | INNE LEKI OFTALMOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA | Inne leki oftalmologiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA01 | gwajazulen | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA02 | retynol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA03 | sodu chlorek, roztwór hipertoniczny | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA04 | potasu jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA05 | sodu edetynian | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA06 | etylomorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA07 | ałun | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA08 | acetylocysteina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA09 | jodoheparynat | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA10 | inozyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA11 | nandrolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA12 | deksopantenol | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA13 | alteplaza | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA14 | heparyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA15 | kwas askorbowy | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA18 | cyklosporyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA19 | komórki macierzyste rąbka rogówki, autologiczne | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA20 | sztuczne łzy i inne obojętne preparaty | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA21 | markaptamina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA22 | okryplazmina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA23 | sirolimus | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA24 | cenegermin | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA25 | lifitegrast | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA26 | ryboflawina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA27 | Woretygen neparwowek | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA28 | wareniklina | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA29 | sepofarsen | WHO Anatomical Therapeutic Chemical classification
0‑L | S01XA31 | pegketakoplan | WHO Anatomical Therapeutic Chemical classification
0‑L | S02 | LEKI OTOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S02A | LEKI PRZECIWINFEKCYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA | Leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA01 | chloramfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA02 | nitrofural | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA03 | kwas borowy | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA04 | glinu acetowinian | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA05 | kliochinol | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA06 | wodoru nadtlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA07 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA08 | tetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA09 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA10 | kwas octowy | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA11 | polimyksyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA12 | ryfamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA13 | mikonazol | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA14 | gentamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA15 | cyprofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA16 | ofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA17 | fosfomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA18 | cefmenoksym | WHO Anatomical Therapeutic Chemical classification
0‑L | S02AA30 | leki przeciwinfekcyjne, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S02B | KORTYKOSTEROIDY | WHO Anatomical Therapeutic Chemical classification
0‑L | S02BA | Kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | S02BA01 | hydrokortyzon | WHO Anatomical Therapeutic Chemical classification
0‑L | S02BA03 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S02BA06 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S02BA07 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S02BA08 | fluocynolonu acetonid | WHO Anatomical Therapeutic Chemical classification
0‑L | S02C | KORTYKOSTEROIDY I LEKI PRZECIWINFEKCYJNE W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA | Kortykosteroidy i leki przeciwinfekcyjne w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA01 | prednizolon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA02 | flumetazon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA03 | hydrokortyzon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA04 | triamcynolon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA05 | fluocynolonu acetonid i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA06 | deksametazon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02CA07 | fludrokortyzon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S02D | INNE LEKI OTOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S02DA | Leki przeciwbólowe i znieczulające | WHO Anatomical Therapeutic Chemical classification
0‑L | S02DA01 | lidokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S02DA02 | kokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S02DA03 | fenazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S02DA04 | cynchokaina | WHO Anatomical Therapeutic Chemical classification
0‑L | S02DA30 | połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S02DC | Leki obojętne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03 | LEKI OFTALMOLOGICZNE I OTOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S03A | LEKI PRZECIWINFEKCYJNE | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA | Leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA01 | neomycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA02 | tetracyklina | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA03 | polimyksyna B | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA04 | chloroheksydyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA05 | heksamidyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA06 | gentamycyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA07 | cyprofloksacyna | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA08 | chloramfenikol | WHO Anatomical Therapeutic Chemical classification
0‑L | S03AA30 | leki przeciwinfekcyjne, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | S03B | KORTYKOSTEROIDY | WHO Anatomical Therapeutic Chemical classification
0‑L | S03BA | Kortykosteroidy | WHO Anatomical Therapeutic Chemical classification
0‑L | S03BA01 | deksametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S03BA02 | prednizolon | WHO Anatomical Therapeutic Chemical classification
0‑L | S03BA03 | betametazon | WHO Anatomical Therapeutic Chemical classification
0‑L | S03C | KORTYKOSTEROIDY I LEKI PRZECIWINFEKCYJNE W POŁĄCZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | S03CA | Kortykosteroidy i leki przeciwinfekcyjne w połączeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | S03CA01 | deksametazon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03CA02 | prednizolon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03CA04 | hydrokortyzon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03CA05 | fludrokortyzon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03CA06 | betametazon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03CA07 | metyloprednizolon i leki przeciwinfekcyjne | WHO Anatomical Therapeutic Chemical classification
0‑L | S03D | INNE PREPARATY OFTALMOLOGICZNE I OTOLOGICZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V | RÓŻNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V01 | ALERGENY | WHO Anatomical Therapeutic Chemical classification
0‑L | V01A | ALERGENY | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA | Wyciągi alergenów | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA01 | pierze | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA02 | pyłki traw | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA03 | roztocza kurzu domowego | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA04 | grzyby pleśniowe i drożdże | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA05 | pyłki drzew | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA07 | owady | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA08 | pokarm | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA09 | tkaniny | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA10 | kwiaty | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA11 | zwierzęta | WHO Anatomical Therapeutic Chemical classification
0‑L | V01AA20 | różne | WHO Anatomical Therapeutic Chemical classification
0‑L | V03 | WSZYSTKIE INNE PRODUKTY LECZNICZE | WHO Anatomical Therapeutic Chemical classification
0‑L | V03A | WSZYSTKIE INNE PRODUKTY LECZNICZE | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB | Odtrutki | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB01 | ipekakuana | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB02 | nalorfina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB03 | edetyniany | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB04 | pralidoksym | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB05 | prednizolon i prometazyna | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB06 | tiosiarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB08 | sodu azotyn | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB09 | dimerkaprol | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB13 | obidoksym | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB14 | protamina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB15 | nalokson | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB16 | etanol | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB17 | metylotioniniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB18 | potasu nadmanganian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB19 | fizostygmina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB20 | miedzi siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB21 | potasu jodek | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB22 | amylu azotyn | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB23 | acetylocysteina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB24 | przeciwciała przeciw digoksynie | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB25 | flumazenil | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB26 | metionina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB27 | 4-dimetyloaminofenol | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB29 | cholinoesteraza | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB31 | błękit pruski | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB32 | glutation | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB33 | hydroksokobalamina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB34 | fomepizol | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB35 | sugammadeks | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB36 | fentolamina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB37 | idarucyzumab | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB38 | andeksanet alfa | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AB54 | pralidoksym i atropina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AC | Czynniki wiążące żelazo | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AC01 | deferoksamina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AC02 | deferypron | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AC03 | deferazyroks | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE | Leki stosowane w leczeniu hiperkaliemii i hiperfosfatemii | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE01 | polistyrenosulfonian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE02 | sewelamer | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE03 | lantanu węglan | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE04 | wapnia octan i magnezu węglan | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE05 | cukrożelazowy tlenowodorotlenek | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE06 | kolestylan | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE07 | wapnia octan | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE08 | żelaza(III) cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE09 | wapnia patyromer | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AE10 | sodu cyrkonu cyklokrzemian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF | Leki zmniejszające toksyczność leków przeciwnowotworowych | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF01 | mesna | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF02 | deksrazoksan | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF03 | wapnia folinian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF04 | wapnia lewofolinian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF05 | amifostyna | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF06 | sodu folinian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF07 | rasburykaza | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF08 | palifermina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF09 | glukarpidaza | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF10 | sodu lewofolinian | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF11 | arginina i lizyna | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AF12 | trilacyklib | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AG | Leki stosowane w leczeniu hiperkalcemii | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AG01 | sodu fosforan celulozy | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AG05 | fosforan sodu | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AH | Leki stosowane w leczeniu hipoglikemii | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AH01 | diazoksyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AK | Kleje tkankowe | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AM | Leki stosowane do embolizacji | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AN | Gazy medyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AN01 | tlen | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AN02 | dwutlenek węgla | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AN03 | hel | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AN04 | azot | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AN05 | powietrze medyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AX | Inne produkty lecznicze | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AX02 | nalfurafina | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AX03 | kobicystat | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AX04 | difelikefalin | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AZ | Leki hamujące przewodzenie nerwowe | WHO Anatomical Therapeutic Chemical classification
0‑L | V03AZ01 | etanol | WHO Anatomical Therapeutic Chemical classification
0‑L | V04 | PREPARATY DIAGNOSTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V04B | TESTY DO BADANIA MOCZU | WHO Anatomical Therapeutic Chemical classification
0‑L | V04C | INNE PREPARATY DIAGNOSTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CA | Testy stosowane w cukrzycy | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CA01 | tolbutamid | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CA02 | glukoza | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CB | Testy do badania wchłaniania tłuszczów | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CB01 | witaminy A koncentraty | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CC | Testy drożności dróg żółciowych | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CC01 | sorbitol | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CC02 | magnezu siarczan | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CC03 | synkalid | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CC04 | ceruletyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CD | Testy czynności przysadki | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CD01 | metyrapon | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CD03 | sermorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CD04 | kortykorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CD05 | somatorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CD06 | macymorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CE | Testy czynności wątroby | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CE01 | galaktoza | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CE02 | sulfobromoftaleina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CE03 | metacetyna (13C) | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CF | Preparaty stosowane w diagnostyce gruźlicy | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CF01 | tuberkulina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CG | Testy wydzielania żołądkowego | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CG01 | żywice katiomienne | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CG02 | betazol | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CG03 | histaminy fosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CG04 | pentagastryna | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CG05 | metylotioniniowy chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CG30 | kofeina i sodu benzoesan | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CH | Testy czynności nerek i uszkodzeń moczowodów | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CH01 | inulina i inne polifruktozany | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CH02 | indygokarmin | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CH03 | fenolosulfonoftaleina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CH04 | alsaktyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CH30 | kwas aminohipurowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CJ | Testy czynności tarczycy | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CJ01 | tyreotropina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CJ02 | protyrelina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CK | Testy czynności trzustki | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CK01 | sekretyna | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CK02 | pankreozymina (cholecystokinina) | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CK03 | bentyromid | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CL | Testy stosowane w chorobach alergicznych | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CM | Testy stosowane w zaburzeniach płodności | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CM01 | gonadorelina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX | Inne preparaty diagnostyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX01 | zieleń indocyjaniny | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX02 | kwas foliowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX03 | metacholina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX04 | mannitol | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX05 | 13C-mocznik | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX06 | heksaminolewulinat | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX07 | edrofonium | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX08 | tlenek węgla | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX09 | błękit sulfanowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX10 | pafolacianina | WHO Anatomical Therapeutic Chemical classification
0‑L | V04CX11 | chlorek litu | WHO Anatomical Therapeutic Chemical classification
0‑L | V06 | PREPARATY ŻYWIENIOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | V06A | PREPARATY ŻYWIENIOWE STOSOWANE W LECZENIU OTYŁOŚCI | WHO Anatomical Therapeutic Chemical classification
0‑L | V06AA | Preparaty żywieniowe ubogokaloryczne | WHO Anatomical Therapeutic Chemical classification
0‑L | V06B | PREPARATY UZUPEŁNIAJĄCE NIEDOBÓR BIAŁEK | WHO Anatomical Therapeutic Chemical classification
0‑L | V06C | PREPARATY ŻYWIENIOWE DLA NIEMOWLĄT | WHO Anatomical Therapeutic Chemical classification
0‑L | V06CA | Preparaty żywieniowe niezawierające fenyloalaniny | WHO Anatomical Therapeutic Chemical classification
0‑L | V06D | INNE PREPARATY ŻYWIENIOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DA | Węglowodany/białka/związki mineralne/witaminy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DB | Tłuszcze/węglowodany/białka/związki mineralne/witaminy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DC | Węglowodany | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DC01 | glukoza | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DC02 | fruktoza | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DD | Aminokwasy, włącznie z połączeniami z polipeptydami | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DE | Aminokwasy/weglowodany/związki mineralne/witaminy, połączenia | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DF | Preparaty mlekozastępcze | WHO Anatomical Therapeutic Chemical classification
0‑L | V06DX | Inne połączenia substancji odżywczych | WHO Anatomical Therapeutic Chemical classification
0‑L | V07 | WSZYSTKIE INNE PREPARATY NIETERAPEUTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V07A | WSZYSTKIE INNE PREPARATY NIETERAPEUTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AA | Plastry | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AB | Rozpuszczalniki i rozcieńczalniki, włącznie z roztworami do irygacji | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AC | Preparaty pomocnicze do przetaczania krwi | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AD | Preparaty pomocnicze do badania krwi | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AN | Sprzęt stosowany w nietrzymaniu moczu/kału | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AR | Testy wrażliwości, dyski i tabletki | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AS | Zestawy do stomii | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AT | Kosmetyki | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AV | Techniczne preparaty dezynfekujące | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AX | Preparaty do mycia itp. | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AY | Inne nieterapeutyczne preparaty pomocnicze | WHO Anatomical Therapeutic Chemical classification
0‑L | V07AZ | Chemikalia i reagenty do analiz | WHO Anatomical Therapeutic Chemical classification
0‑L | V08 | ŚRODKI KONTRASTOWE | WHO Anatomical Therapeutic Chemical classification
0‑L | V08A | ŚRODKI KONTRASTOWE DO BADANIA RTG, ZAWIERAJĄCE JOD | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA | Rozpuszczalne w wodzie, wydalane przez nerki środki kontrastowe o dużej osmolarności do badania RTG | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA01 | kwas diatryzoi | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA02 | kwas metryzoi | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA03 | jodamid | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA04 | kwas jotalamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA05 | kwas joksytalamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA06 | kwas joglikowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA07 | kwas acetryzoi | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA08 | kwas jokarmowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA09 | metiodal | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AA10 | diodon | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB | Rozpuszczalne w wodzie, wydalane przez nerki środki kontrastowe o małej osmolarności do badania RTG | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB01 | metryzamid | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB02 | joheksol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB03 | kwas joksagly | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB04 | jopamidol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB05 | jopromid | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB06 | jotrolan | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB07 | jowersol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB08 | jopentol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB09 | jodyksanol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB10 | jomeprol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB11 | jobitrydol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AB12 | joksylan | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC | Rozpuszczalne w wodzie, wydalane przez wątrobę, środki kontrastowe do badania RTG | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC01 | kwas jodoksamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC02 | kwas jotroksowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC03 | kwas joglikamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC04 | adypiodon | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC05 | kwas jobenzamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC06 | kwas jopanoi | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC07 | kwas jocetamowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC08 | sodu jopodan | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC09 | kwas tyropa | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AC10 | wapnia jopodan | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AD | Nierozpuszczalne w wodzie środki kontrastowe do badania RTG | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AD01 | estry etylowe jodowanych kwasów tłuszczowych | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AD02 | jopidol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AD03 | propyljodon | WHO Anatomical Therapeutic Chemical classification
0‑L | V08AD04 | jofendylan | WHO Anatomical Therapeutic Chemical classification
0‑L | V08B | ŚRODKI KONTRASTOWE DO BADANIA RTG, NIEZAWIERAJĄCE JODU | WHO Anatomical Therapeutic Chemical classification
0‑L | V08BA | Środki kontrastowe do badania RTG zawierające siarczan baru | WHO Anatomical Therapeutic Chemical classification
0‑L | V08BA01 | baru siarczan z substancjami zawieszającymi | WHO Anatomical Therapeutic Chemical classification
0‑L | V08BA02 | baru siarczan bez substancji zawieszających | WHO Anatomical Therapeutic Chemical classification
0‑L | V08C | ŚRODKI KONTRASTOWE DO MRI | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA | Paramagnetyczne środki kontrastowe | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA01 | kwas gadopentetowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA02 | kwas gadoterowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA03 | gadodiamid | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA04 | gadoterydol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA05 | mangafodypir | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA06 | gadowersetamid | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA07 | żelaza(III)-amonowego cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA08 | kwas gadobe | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA09 | gadobutrol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA10 | kwas gadoksetowy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA11 | gadofosweset | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CA12 | gadopiklenol | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CB | Superparamagnetyczne środki kontrastowe | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CB01 | ferumoksyl | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CB02 | ferysten | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CB03 | żelaza tlenku nanocząstki | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CX | Inne środki kontrastowe do MRI | WHO Anatomical Therapeutic Chemical classification
0‑L | V08CX01 | perflubron | WHO Anatomical Therapeutic Chemical classification
0‑L | V08D | ŚRODKI KONTRASTOWE DO USG | WHO Anatomical Therapeutic Chemical classification
0‑L | V08DA | Środki kontrastowe do USG | WHO Anatomical Therapeutic Chemical classification
0‑L | V08DA01 | perflutren, mikrosfery ludzkiej albuminy | WHO Anatomical Therapeutic Chemical classification
0‑L | V08DA02 | galaktozy mikrocząstki | WHO Anatomical Therapeutic Chemical classification
0‑L | V08DA03 | perflenapent | WHO Anatomical Therapeutic Chemical classification
0‑L | V08DA04 | perflutren, mikrosfery fosfolipidowe | WHO Anatomical Therapeutic Chemical classification
0‑L | V08DA05 | siarki heksafluorek, mikrosfery fosfolipidowe | WHO Anatomical Therapeutic Chemical classification
0‑L | V08DA06 | perflubutan, mikrosfery fosfolipidowe | WHO Anatomical Therapeutic Chemical classification
0‑L | V09 | RADIOFARMACEUTYKI DIAGNOSTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V09A | OŚRODKOWY UKŁAD NERWOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AA | Technetu (99mTc) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AA01 | techneto(99mTc)eksametazym | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AA02 | techneto(99mTc)bicyzynian | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AB | Jodu (123I) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AB01 | jofetamina znakowana 123I | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AB02 | jolopryd znakowany 123I | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AB03 | joflupan znakowany 123I | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AX | Inne radiofarmaceutyki stosowane w diagnostyce ośrodkowego układu nerwowego | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AX01 | kwas pentety z indem (111In) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AX03 | 2beta-karbometoksy-3beta-(4-jodofenylo)-tropan z jodem (124I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AX04 | flutemetamol (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AX05 | florbetapir (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AX06 | florbetaben (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09AX07 | flortaucypir (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09B | UKŁAD SZKIELETOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | V09BA | Technetu (99mTc) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09BA01 | kwas oksydro z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09BA02 | kwas medro z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09BA03 | technetu (99mTc) pirofosforan | WHO Anatomical Therapeutic Chemical classification
0‑L | V09BA04 | kwas butedro z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09C | UKŁAD MOCZOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CA | Technetu (99mTc) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CA01 | kwas pentety z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CA02 | technetu (99mTc) sukcymer | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CA03 | techneto(99mTc)mertiatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CA04 | technetu (99mTc) gluceptan | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CA05 | technetu (99mTc) glukonian | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CA06 | technetu (99mTc) etylenodicysteina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CX | Inne radiofarmaceutyki stosowane w diagnostyce układu moczowego | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CX01 | sodu jodohipuran (123I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CX02 | sodu jodohipuran (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CX03 | sodu jotalamian (125I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09CX04 | chromu (51Cr) edetynian | WHO Anatomical Therapeutic Chemical classification
0‑L | V09D | WĄTROBA I UKŁAD SIATECZKOWO-ŚRÓDBŁONKOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DA | Technetu (99mTc) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DA01 | techneto(99mTc)dizofenina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DA02 | techneto(99mTc)etyfenina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DA03 | techneto(99mTc)lidofenina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DA04 | techneto(99mTc)mebrofenina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DA05 | techneto(99mTc)galtyfenina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB | Technet (99mTc), cząstki i koloidy | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB01 | nanokoloid z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB02 | mikrokoloid z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB03 | milimikrosfery z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB04 | cyna koloidalna z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB05 | siarka koloidalna z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB06 | renu siarczek koloidalny z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DB07 | technetu (99mTc) fitynian | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DX | Inne radiofarmaceutyki stosowane w diagnostyce wątroby i układu siateczkowo-śróbłonkowego | WHO Anatomical Therapeutic Chemical classification
0‑L | V09DX01 | kwas tauroselcholowy z selenem (75Se) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09E | UKŁAD ODDECHOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EA | Wziewne preparaty zawierające technet (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EA01 | kwas pentety z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EA02 | technetu (99mTc) technegaz | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EA03 | nanokoloid z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EB | Technet (99mTc), cząstki do wstrzyknięć | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EB01 | makrosalb z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EB02 | mikrosfery z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EX | Inne radiofarmaceutyki stosowane w diagnostyce układu oddechowego | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EX01 | krypton (81mKr) gaz | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EX02 | ksenon (127Xe) gaz | WHO Anatomical Therapeutic Chemical classification
0‑L | V09EX03 | ksenon (133Xe) gaz | WHO Anatomical Therapeutic Chemical classification
0‑L | V09F | TARCZYCA | WHO Anatomical Therapeutic Chemical classification
0‑L | V09FX | Różne radiofarmaceutyki stosowane w diagnostyce tarczycy | WHO Anatomical Therapeutic Chemical classification
0‑L | V09FX01 | sodu nadtechnecjan (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09FX02 | sodu jodek (123I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09FX03 | sodu jodek (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09FX04 | sodu jodek (124I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09G | UKŁAD SERCOWO-NACZYNIOWY | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA | Technetu (99mTc) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA01 | techneto(99mTc)sestamibi | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA02 | techneto(99mTc)tetrofosmina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA03 | techneto(99mTc)teboroksym | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA04 | albumina ludzka z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA05 | techneto(99mTc)furyfosmina | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA06 | komórki znakowane technetu (99mTc) koloidem cynawym | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GA07 | techneto(99mTc)apcytyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GB | Jodu (125I) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GB01 | fibrynogen z jodem (125I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GB02 | albumina ludzka z jodem (125I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GX | Inne radiofarmaceutyki stosowane w diagnostyce układu sercowo-naczyniowego | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GX01 | talu (201Tl) chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GX02 | imcyromab z indem (111In) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GX03 | komórki znakowane chromianem (51Cr) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GX04 | rubidu (82Rb) chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | V09GX05 | amoniak (13N) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09H | WYKRYWANIE STANÓW ZAPALNYCH I ZAKAŻEŃ | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HA | Technetu (99mTc) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HA01 | immunoglobulina ludzka z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HA02 | komórki znakowane techneto(99mTc)eksametazymem | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HA03 | przeciwciało przeciw granulocytom znakowane technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HA04 | sulesomab z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HB | Indu (111In) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HB01 | komórki znakowane indu (111In) oksynianem | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HB02 | komórki znakowane indu (111In) tropolonianem | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HX | Inne radiofarmaceutyki stosowane w celu wykrycia stanów zapalnych i zakażeń | WHO Anatomical Therapeutic Chemical classification
0‑L | V09HX01 | galu (67Ga) cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | V09I | DIAGNOSTYKA NOWOTWORÓW | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA | Technetu (99mTc) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA01 | przeciwciało przeciw CEA znakowane technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA02 | przeciwciało przeciw komórkom czerniaka znakowane technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA03 | technetu (99mTc) sukcymer pięciowalentny | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA04 | wotumumab z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA05 | techneto(99mTc)depreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA06 | arcytumomab z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA07 | techneto(99mTc)tektrotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA08 | techneto(99mTc)etarfolatyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA09 | tylmanocept z technetem (99mTc) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IA10 | technet (99mTc)chlorek trofolastatu | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IB | Indu (111In) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IB01 | indu (111In) pentetreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IB02 | pendetydosatumomab z indem (111In) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IB03 | przeciwciało przeciw komórkom raka jajnika znakowane indem (111In) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IB04 | pendetydokapromab z indem (111In) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX | Inne radiofarmaceutyki stosowane w diagnostyce nowotworów | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX01 | Jobenguan (123I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX02 | Jobenguan (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX03 | przeciwciało monoklonalne CC49 znakowane jodem (125I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX04 | fludeoksyglukoza (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX05 | fluorodopa (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX06 | sodu fluorek (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX07 | fluorocholina (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX08 | fluoroetylocholina (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX09 | galu (68Ga) edotreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX10 | fluoroetylo-L- tyrozyna (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX11 | fluoroestradiol (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX12 | flucyklowina (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX13 | metionina (11C) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX14 | gozetotyd galu (68Ga) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX15 | dotatat miedzi (64Cu) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX16 | piflufolastat (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09IX17 | PSMA-1007 (18F) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09X | INNE RADIOFARMACEUTYKI DIAGNOSTYCZNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XA | Jodu (131I) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XA01 | norcholesterol z jodem (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XA02 | jodocholesterol (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XA03 | albumina ludzka z jodem (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XX | Różne radiofarmaceutyki diagnostyczne | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XX01 | cyjanokobalamina (57Co) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XX02 | cyjanokobalamina (58Co) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XX03 | norcholesterol z selenem (75Se) | WHO Anatomical Therapeutic Chemical classification
0‑L | V09XX04 | żelaza(III) (59Fe) cytrynian | WHO Anatomical Therapeutic Chemical classification
0‑L | V10 | RADIOFARMACEUTYKI STOSOWANE W LECZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | V10A | LEKI PRZECIWZAPALNE | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AA | Itru (90Y) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AA01 | itru (90Y) cytrynian koloidalny | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AA02 | itr (Y90) z żelaza wodorotlenkiem koloidalnym | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AA03 | itru (90Y) krzemian koloidalny | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AX | Inne przeciwzapalne radiofarmaceutyki | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AX01 | chromu fosforan (32P) koloidalny | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AX02 | hydroksyapatyt koloidalny z samarem (153Sm) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AX03 | dysproz (165Dy) koloidalny | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AX04 | erbu (169Er) cytrynian koloidalny | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AX05 | renu (186Re) siarczek koloidalny | WHO Anatomical Therapeutic Chemical classification
0‑L | V10AX06 | złoto (198Au) koloidalne | WHO Anatomical Therapeutic Chemical classification
0‑L | V10B | ŁAGODZENIE DOLEGLIWOŚCI BÓLOWYCH (LEKI GROMADZĄCE SIĘ W KOŚCIACH) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10BX | Różne radiofarmaceutyki stosowane w łagodzeniu bólu | WHO Anatomical Therapeutic Chemical classification
0‑L | V10BX01 | strontu (89Sr) chlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | V10BX02 | samaru (153Sm) leksydronam | WHO Anatomical Therapeutic Chemical classification
0‑L | V10BX03 | kwas etydro z renem (186Re) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10X | INNE RADIOFARMACEUTYKI STOSOWANE W LECZENIU | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XA | Jodu (131I) związki | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XA01 | sodu jodek (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XA02 | jobenguan (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XA03 | jod (131I) omburtamab | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XA53 | tozytumomab/tozytumomab z jodem (131I) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XX | Różne radiofarmaceutyki stosowane w leczeniu | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XX01 | sodu fosforan (32P) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XX02 | ibrytumomab tiuksetan (90Y) | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XX03 | radu (223Ra) dichlorek | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XX04 | lutetu (117Lu) oksodotreotyd | WHO Anatomical Therapeutic Chemical classification
0‑L | V10XX05 | tetraksetan wipiwotydu lutetu (177Lu) | WHO Anatomical Therapeutic Chemical classification
0‑L | V20 | OPATRUNKI CHIRURGICZNE | WHO Anatomical Therapeutic Chemical classification
Legenda: Typ L=liść, S=specjalizowalny, A=abstrakcyjny, D=odrzucony. NullFlavour powinien występować w atrybucie @nullFlavour, a nie w @code.